CUMULATIVE
SUPPLEMENT 10
JAN'92-OCT'92

APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

12TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION

Prepared By
Division of Drug Information Resources
Office of Management
Center for Drug Evaluation and Research, FDA

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

12TH EDITION

Cumulative Supplement 10

October 1992

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

12TH EDITION

CUMULATIVE SUPPLEMENT 10

OCTOBER 1992

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 12th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item. A newly approved product is also identified by a lozenge (◆) to the right of its strength which remains throughout all Cumulative Supplements for this edition.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >DLT> (DELETE) to the left of the line containing overstruck print. The >DLT> symbol is dropped in subsequent Cumulative Supplements for that item. The overstruck print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the overstruck print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the " ∋ " symbol to designate their non-marketed status. All products having a " ∋ " symbol in the 12th Cumulative Supplement of the 12th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 13th Edition.

1.2 CEFADROXIL/CEFADROXIL HEMIHYDRATE ACTIVE INGREDIENT HEADING

The active ingredient heading Cefadroxil/Cefadroxil Hemihydrate replaces the active ingredient heading Cefadroxil which is currently listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, 12th Edition. All products which are listed under Cefadroxil (which is understood to be the monohydrate form) in the 12th Edition will now be listed along with the newly approved duplicate drug products under the new active ingredient, Cefadroxil/Cefadroxil Hemihydrate.

1.3 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 7, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;oral)	SEP 7, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 5, 1985 (50 FR 27688)
Tranylcypromine Sulfate	MAR 22, 1984 (49 FR 10708)

1.4 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant; or when an applicant changes its name; or when an applicant name is changed to meet internal publication standards. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the Cumulative Supplement.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
BARNES HIND PHARMACEUTICALS INC (BARNES HIND)	SOLA BARNES HIND (SOLA BARNES HIND)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
MERCK SHARP AND DOHME RESEARCH LABS DIV MERCK AND CO INC (MSD)	MERCK RESEARCH LABORATORIES DIV MERCK AND CO INC (MERCK)
NORWICH EATON PHARMS INC SUB PROCTOR & GAMBLE CO (NORWICH EATON)	PROCTER & GAMBLE PHARMACEUTICALS INC (P&G)
OFFICE SURGEON GENERAL DEPT ARMY (DEPT ARMY)	OFFICE SURGEON GENERAL DEPT ARMY (US ARMY)
RECKITT AND COLMAN PHARMACEUTICALS INC (R & C)	RECKITT AND COLMAN PHARMACEUTICALS INC (RECKITT AND COLMAN)
SCHWARZ PHARMACEUTICALS INC (SCHWARZ)	SCHWARZ PHARMACEUTICALS INC (SCHWARZ PHARMA)
SOLOPAK LABORATORIES (SOLOPAK)	SMITH AND NEPHEW SOLOPAK DIVISION OF SMITH AND NEPHEW (SMITH NEPHEW SOLOPAK)
VICKS HEALTH CARE DIV RICHARDSON VICKS INC (VICKS HLTH CARE)	VICKS HEALTH CARE DIV RICHARDSON VICKS INC (VICKS HEALTH CARE)
WHITBY PHARMACEUTICALS INC (WHITBY PHARMS)	WHITBY PHARMACEUTICALS INC (WHITBY)
US CHEMICAL MARKETING GROUP INC (US CHEM MKTG)	US CHEMICAL MARKETING GROUP INC (US CHEM)

1.5 USP MONOGRAPH TITLE ADDITIONS OR CHANGES

The U.S. Pharmacopeia (USP) periodically makes additions to or changes in monograph titles. Some of these additions or changes may affect dosage form terms listed in *Approved Drug Products with Therapeutic Equivalence Evaluations* (ADP). Instead of making the change in each affected product, the Cumulative Supplement (CS) will list applicable monograph title and dosage form additions or changes in this section. These will appear as soon as the modified USP monograph title is official. It is possible for these additions or changes to be listed in this section before all applicant holders have made labeling modifications.

The monograph title additions or changes shown below will remain in this section in each succeeding supplement of this edition. Once the next edition of the ADP is published, the products affected by the title additions or changes will be displayed with the new dosage form in the appropriate drug list. As notification to the reader, these monograph title additions or changes will also be listed in a special section of the ADP.

USP MONOGRAPH TITLE ADDITIONS OR CHANGES

FORMER USP MONOGRAPH TITLE (FORMER ADP DOSAGE FORM; ROUTE)	NEW USP MONOGRAPH TITLE (NEW ADP DOSAGE FORM; ROUTE)
LACTULOSE SYRUP (SYRUP; ORAL)	LACTULOSE SOLUTION (SOLUTION; ORAL)
LACTULOSE SYRUP (SYRUP; ORAL, RECTAL)	LACTULOSE SOLUTION (SOLUTION; ORAL, RECTAL)
NONE (SYRUP; ORAL)	METOCLOPRAMIDE ORAL SOLUTION (SOLUTION; ORAL)

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1991) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1991	MAR 1992	JUN 1992	SEP 1992
DRUG PRODUCTS LISTED	9584	9473	9476	9501
SINGLE SOURCE	2187 (22.8%)	2222 (23.4%)	2227 (23.5%)	2227 (23.4%)
MULTISOURCE	7397 (77.2%)	7251 (76.6%)	7249 (76.5%)	7274 (76.6%)
THERAPEUTICALLY EQUIVALENT	6580 (68.7%)	6510 (68.7%)	6494 (68.5%)	6518 (68.6%)
NOT THERAPEUTICALLY EQUIVALENT	664 (6.9%)	592 (6.3%)	595 (6.3%)	590 (6.2%)
EXCEPTIONS[1]	153 (1.6%)	149 (1.6%)	160 (1.7%)	166 (1.8%)
NEW MOLECULAR ENTITIES APPROVED	--	4	2	8
NUMBER OF APPLICANTS	430	437	455	471

[1]Amino acid-containing products of varying composition (see Introduction, page xvi of the List).

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

> ADD >		BUTAPAP			
> ADD >	AB	MIKART	325MG;50MG¤	N89987 001	OCT 26, 1992
> ADD >					
> ADD >	AB		650MG;50MG¤	N89988 001	OCT 26, 1992
> ADD >					
		SEDAPAP			
> ADD >	AB	+ MAYRAND	650MG;50MG	N88944 001	OCT 17, 1985
> ADD >					

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

	FIORICET W/ CODEINE			
	+ SANDOZ	325MG;50MG;40MG;30MG¤	N20232 001	JUL 30, 1992

ACETAMINOPHEN; CODEINE PHOSPHATE

ELIXIR; ORAL

	ACETAMINOPHEN AND CODEINE PHOSPHATE			
> ADD >	AA MIKART	120MG/5ML;12MG/5ML¤	N89450 001	OCT 27, 1992
> ADD >				
	ACETAMINOPHEN AND CODEINE PHOSPHATE			
	AA PHARM BASICS	120MG/5ML;12MG/5ML	N87006 001	
	/ACETAMINOPHEN AND CODEINE/			
	/AA/ /PHARM/BASICS/	/120MG/5ML;12MG/5ML/	/N87006/001/	

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE			
∂ EON LABS	300MG;15MG	N87433 001	
∂	300MG;30MG	N85917 001	
∂	300MG;60MG	N87423 001	
AA GENEVA	300MG;30MG¤	N81250 001	JUL 16, 1992
AA	300MG;60MG¤	N81249 001	JUL 16, 1992
∂ PARKE DAVIS	300MG;15MG	N85992 001	
∂	300MG;30MG	N85218 002	
/∂/VITARINE/	/300MG;15MG/	/N87433/001/	
/∂/	/300MG;30MG/	/N85917/001/	
/∂/	/300MG;60MG/	/N87423/001/	

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

	ACETAMINOPHEN W/ CODEINE PHOSPHATE			
/AA/	/CHELSEA/	/300MG;15MG/	/N87277/001/	/MAY/26,/1982/
/AA/		/300MG;30MG/	/N87276/001/	/MAY/26,/1982/
/AA/		/300MG;60MG/	/N87275/001/	/MAY/26,/1982/
	∂ CHELSEA	300MG;15MG	N87277 001	MAY 26, 1982
	∂	300MG;30MG	N87276 001	MAY 26, 1982
	∂	300MG;60MG	N87275 001	MAY 26, 1982
/AA/	/PARKE/DAVIS/	/300MG;15MG/	/N85992/001/	
/AA/		/300MG;30MG/	/N85218/002/	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

ELIXIR; ORAL

	HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
> ADD >	MIKART	500MG/15ML;5MG/15ML¤	N81226 001	OCT 27, 1992
> ADD >		500MG/15ML;5MG/15ML¤	N89557 001	APR 29, 1992
		500MG/15ML;7.5MG/15ML¤	N81051 001	AUG 28, 1992

TABLET; ORAL

	HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
AA	MIKART	500MG;5MG¤	N89697 001	JAN 28, 1992
		650MG;10MG¤	N81223 001	MAY 29, 1992
/B*/	/PHARM/BASICS/	/500MG;5MG/	/N89291/001/	/MAY/29,/1987/
	∂ PHARM BASICS	500MG;5MG	N89291 001	MAY 29, 1987

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

	PROPOXYPHENE HCL AND ACETAMINOPHEN			
AA	MYLAN	650MG;65MG	N83978 001	
	∂	325MG;32MG	N83689 001	
	/PROPOXYPHENE HCL W/ APAP/			
/AA/	/MYLAN/	/650MG;65MG/	/N83978/001/	
		/325MG;32MG/	/N83689/001/	

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

	BOROFAIR			
AT	PHARMAFAIR	2%	N88606 001	AUG 21, 1985

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

	BOROFAIR			
AT	PHARMAFAIR	2%;0.79%	N88606 001	AUG 21, 1985
	DOMEBORO			
AT	MILES	2%;0.79%	N84476 001	

ACETOHEXAMIDE

TABLET; ORAL

	ACETOHEXAMIDE			
B*	PHARM BASICS	250MG	N70753 001	NOV 03, 1986
B*	PHARM BASICS	500MG	N70754 001	NOV 03, 1986

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

	ACETYLCYSTEINE			
AN	CETUS BEN VENUE	10%¤	N72323 001	APR 30, 1992
AN		20%¤	N72324 001	APR 30, 1992
AN	ROXANE	10%¤	N72621 001	SEP 30, 1992
AN		20%¤	N72622 001	SEP 30, 1992
	MUCOMYST			
> ADD > AN	APOTHECON	10%	N13601 002	
> ADD > AN		20%	N13601 001	
> DLT > AN	MEAD JOHNSON	10%	N13601 002	
> DLT > AN		20%	N13601 001	

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

	MUCOSIL-10			
AN	DEY	10%	N70575 001	OCT 14, 1986
	MUCOSIL-20			
AN	DEY	20%	N70576 001	OCT 14, 1986

ALBUTEROL SULFATE

SOLUTION; INHALATION

	ALBUTEROL SULFATE			
AN	DEY	EQ 0.083% BASE¤	N72652 001	FEB 21, 1992
	PROVENTIL			
AN	SCHERING	EQ 0.083% BASE	N19243 002	JAN 14, 1987
	VENTOLIN			
AN	GLAXO	EQ 0.083% BASE¤	N19773 001	APR 23, 1992

SYRUP; ORAL

	ALBUTEROL SULFATE			
AA	LEMMON	EQ 2MG BASE/5ML¤	N73419 001	MAR 30, 1992

TABLET; ORAL

	ALBUTEROL SULFATE			
AB	MD PHARM	EQ 2MG BASE¤	N73120 001	SEP 29, 1992
AB		EQ 4MG BASE¤	N73121 001	SEP 29, 1992

ALGLUCERASE

INJECTABLE; INJECTION

	CEREDASE			
	GENZYME	10 UNITS/ML¤	N20057 004	MAY 08, 1992

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

/AB/	/BOLAR/	/100MG/	/N18241/001/ /NOV/16,/1984/	
	ə BOLAR	100MG	N18241 001 NOV 16, 1984	

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN

AP	ELKINS SINN	EQ 50MG BASE/ML*	N63274 001 MAY 18, 1992	
AP		EQ 250MG BASE/ML*	N63275 001 MAY 18, 1992	
	AMIKIN			
AP	BRISTOL	EQ 50MG BASE/ML	N50495 001	
AP		EQ 50MG BASE/ML	N62562 001 SEP 20, 1984	
AP		EQ 250MG BASE/ML	N50495 002	
AP		EQ 250MG BASE/ML	N62562 002 SEP 20, 1984	

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

>DLT>	/AMINOSYN/4.25%/W/DEXTROSE/25%/IN/PLASTIC/CONTAINER/		
>DLT>	/ABBOTT/	/4.25%;25GM/100ML/	/N19119/001/ /OCT/11,/1984/
>DLT>	ə ABBOTT	4.25%;25GM/100ML	N19119 001 OCT 11, 1984

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

/INJECTABLE;/INJECTION/ /AMINOSYN/3.5%/M/		
/ABBOTT/	/3.5%;21MG/100ML;128MG/100ML;/ /234MG/100ML/	/N17789/001/
ə ABBOTT	3.5%;21MG/100ML;128MG/100ML; 234MG/100ML	N17789 001

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

/AMITRIL/

/AB/	/WARNER/CHILCOTT/	/10MG/	/N83939/001/
/AB/		/25MG/	/N83937/001/
/AB/		/50MG/	/N83938/002/
/AB/		/75MG/	/N84957/001/
/AB/		/100MG/	/N85093/001/
/AB/		/150MG/	/N86295/001/
	ə WARNER CHILCOTT	10MG	N83939 001
	ə	25MG	N83937 001
	ə	50MG	N83938 002
	ə	75MG	N84957 001
	ə	100MG	N85093 001
	ə	150MG	N86295 001

AMITRIPTYLINE HCL

/BP/	/PAR/	/10MG/	/N88697/001/ /SEP/25,/1984/
/BP/		/25MG/	/N88698/001/ /SEP/25,/1984/
/BP/		/50MG/	/N88699/001/ /SEP/25,/1984/
/BP/		/75MG/	/N88700/001/ /SEP/25,/1984/
/BP/		/100MG/	/N88701/001/ /SEP/25,/1984/
/BP/		/150MG/	/N88702/001/ /SEP/25,/1984/
	ə PAR	10MG	N88697 001 SEP 25, 1984
	ə	25MG	N88698 001 SEP 25, 1984
	ə	50MG	N88699 001 SEP 25, 1984
	ə	75MG	N88700 001 SEP 25, 1984
	ə	100MG	N88701 001 SEP 25, 1984
	ə	150MG	N88702 001 SEP 25, 1984

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL

/B*/	/PHARM BASICS/	/EQ 12.5MG BASE;5MG/	/N70477 001/ /JAN 12, 1988/
/B*/		/EQ 25MG BASE;10MG/	/N70478 001/ /JAN 12, 1988/
	ə PHARM BASICS	EQ 12.5MG BASE;5MG	N70477 001 JAN 12, 1988
	ə	EQ 25MG BASE;10MG	N70478 001 JAN 12, 1988

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL
PERPHENAZINE AND AMITRIPTYLINE HCL

/S/	/CHELSEA/	/50MG;4MG/	/N71558 001/ /MAR 02, 1987/

AMLODIPINE BESYLATE

TABLET; ORAL
NORVASC

+	PFIZER	EQ 10MG BASE¤	N19787 003 JUL 31, 1992
		EQ 2.5MG BASE¤	N19787 001 JUL 31, 1992
		EQ 5MG BASE¤	N19787 002 JUL 31, 1992

AMOXAPINE

TABLET; ORAL
AMOXAPINE

AB	DANBURY	25MG¤	N72688 001 AUG 28, 1992
AB		50MG¤	N72689 001 AUG 28, 1992
AB		100MG¤	N72690 001 AUG 28, 1992
AB		150MG¤	N72691 001 AUG 28, 1992

AMOXICILLIN

CAPSULE; ORAL
POLYMOX

AB	BRISTOL MYERS	250MG¤	N63099 001 MAR 20, 1992
AB		500MG¤	N63099 002 MAR 20, 1992

UTIMOX;

/AB/	/PARKE/DAVIS/	/250MG/	/N62107 001/
/AB/		/500MG/	/N62107 002/
	ə PARKE DAVIS	250MG	N62107 001
	ə	500MG	N62107 002

POWDER FOR RECONSTITUTION; ORAL
AMOXICILLIN

/AB/	/CLONMEL/	/125MG/5ML/	/N62927 001/ /NOV 25, 1988/
/AB/		/250MG/5ML/	/N62927 002/ /NOV 25, 1988/
BX	CLONMEL	125MG/5ML	N62927 001 NOV 25, 1988
BX		250MG/5ML	N62927 002 NOV 25, 1988

UTIMOX

/AB/	/PARKE/DAVIS/	/125MG/5ML/	/N62127 001/
/AB/		/250MG/5ML/	/N62127 002/
	ə PARKE DAVIS	125MG/5ML	N62127 001
	ə	250MG/5ML	N62127 002

AMPHOTERICIN B

INJECTABLE; INJECTION
AMPHOTERICIN B

AP	PHARMA TEK	50MG/VIAL¤	N63206 001 APR 29, 1992

AMPICILLIN SODIUM

INJECTABLE; INJECTION

POLYCILLIN-N

/AP/	/BRISTOL/	/EQ 125MG BASE/VIAL/	/N50309/001/
/AP/		/EQ 250MG BASE/VIAL/	/N50309/002/
/AP/		/EQ 500MG BASE/VIAL/	/N50309/003/
/AP/		/EQ 1GM BASE/VIAL/	/N50309/004/
/AP/		/EQ 2GM BASE/VIAL/	/N50309/005/
	∂ BRISTOL	EQ 125MG BASE/VIAL	N50309 001
	∂	EQ 250MG BASE/VIAL	N50309 002
	∂	EQ 500MG BASE/VIAL	N50309 003
	∂	EQ 1GM BASE/VIAL	N50309 004
	∂	EQ 2GM BASE/VIAL	N50309 005

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

/AMCILL/

/AB/	/PARKE/DAVIS/	/EQ 250MG BASE/	/N62041/001/
/AB/		/EQ 500MG BASE/	/N62041/002/
	∂ PARKE DAVIS	EQ 250MG BASE	N62041 001
	∂	EQ 500MG BASE	N62041 002

POLYCILLIN

/AB//+//BRISTOL/		/EQ 250MG BASE/	/N50310/001/
/AB/		/EQ 250MG BASE/	/N61392/001/
AB	+ BRISTOL	EQ 250MG BASE	N61392 001
/AB/		/EQ 500MG BASE/	/N50310/002/
	∂	EQ 250MG BASE	N50310 001
	∂	EQ 500MG BASE	N50310 002

POWDER FOR RECONSTITUTION; ORAL

/AMCILL/

/AB/	/PARKE/DAVIS/	/EQ 125MG BASE/5ML/	/N62030/001/
/AB/		/EQ 250MG BASE/5ML/	/N62030/002/
	∂ PARKE DAVIS	EQ 125MG BASE/5ML	N62030 001
	∂	EQ 250MG BASE/5ML	N62030 002

POLYCILLIN

/AB/	/BRISTOL/	/EQ 100MG BASE/ML/	/N50308/004/
/AB/		/EQ 100MG BASE/ML/	/N61394/001/
	∂ BRISTOL	EQ 100MG BASE/ML	N50308 004
		EQ 100MG BASE/ML	N61394 001

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

POWDER FOR RECONSTITUTION; ORAL

POLYCILLIN-PRB

/AB//+//BRISTOL/		/EQ 3.5GM BASE/BOT; 1GM/BOT/	/N50457/001/
/AB/		/EQ 3.5GM BASE/BOT; 1GM/BOT/	/N61898/001/
AB	+ BRISTOL	EQ 3.5GM BASE/BOT; 1GM/BOT	N61898 001
	∂	EQ 3.5GM BASE/BOT; 1GM/BOT	N50457 001

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

/BUTALBITAL; ASPIRIN AND CAFFEINE/

/AB/	/CHELSEA/	/325MG;50MG;40MG/	/N86231/002/ /FEB/12,/1985/
	∂ CHELSEA	325MG;50MG;40MG	N86231 002 FEB 12, 1985

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENADRINE COMPOUND		
∂ EON LABS	385MG;30MG;25MG	N71564 001 JUN 23, 1988
/∂/VITARINE/	/385MG;30MG;25MG/	/N71564/001/ /JUN/23,/1988/
ORPHENADRINE COMPOUND DOUBLE STRENGTH		
∂ EON LABS	770MG;60MG;50MG	N71565 001 JUN 23, 1988
/∂/VITARINE/	/770MG;60MG;50MG/	/N71565/001/ /JUN/23,/1988/

ASPIRIN; MEPROBAMATE

TABLET; ORAL

MEPRO-ASPIRIN		
∂ EON LABS	325MG;200MG	N89127 001 MAR 02, 1987
/∂/VITARINE/	/325MG;200MG/	/N89127/001/ /MAR/02,/1987/

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	APOTHECON	50MG¤	N73317 001	MAR 20, 1992
AB		100MG¤	N73318 001	MAR 20, 1992
AB	GENEVA	25MG¤	N74052 001	MAY 01, 1992
AB	IPR	25MG¤	N73646 001	JUL 31, 1992
AB	LEDERLE	25MG¤	N74099 001	APR 28, 1992
AB	MYLAN	50MG¤	N73456 001	JAN 24, 1992
AB		100MG¤	N73457 001	JAN 24, 1992
> ADD > AB	SCHIAPPARELLI SEARLE	50MG¤	N73676 001	OCT 30, 1992
> ADD > AB		100MG¤	N73676 002	OCT 30, 1992

TENORMIN

AB	ICI	25MG	N18240 004	APR 09, 1990

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

AB	DANBURY	50MG;25MG¤	N73665 001	JUL 02, 1992
AB		100MG;25MG¤	N73665 002	JUL 02, 1992

TENORETIC 100

AB	+ ICI	100MG;25MG	N18760 001	JUN 08, 1984
/AB/	/+//STUART/	/100MG;25MG/	/N18760/001/	/JUN/08,/1984/

TENORETIC 50

AB	ICI	50MG;25MG	N18760 002	JUN 08, 1984
/AB/	/STUART/	/50MG;25MG/	/N18760/002/	/JUN/08,/1984/

ATROPINE SULFATE

> DLT >	/AEROSOL;/METERED;/INHALATION/			
> DLT >	/ATROPINE/SULFATE/			
> DLT >	/US/ARMY/	/EQ/0.36MG/BASE/INH/	/N20056/001/	/SEP/19,/1990/
> ADD >	∂ US ARMY	EQ 0.36MG BASE/INH	N20056 001	SEP 19, 1990

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

LOMANATE

/AA/	/BARRE/	/0.025MG/5ML;2.5MG/5ML/	/N85746/001/	
	∂ BARRE	0.025MG/5ML;2.5MG/5ML	N85746 001	

TABLET; ORAL

DIPHENOXYLATE HCL AND ATROPINE SULFATE

/AA/	/CHELSEA/	/0.025MG;2.5MG/	/N85876/001/	
	∂ CHELSEA	0.025MG;2.5MG	N85876 001	
	DIPHENOXYLATE HCL W/ ATROPINE SULFATE			
	∂ EON LABS	0.025MG;2.5MG	N86173 001	
	/∂/VITARINE/	/0.025MG;2.5MG/	/N86173/001/	

/AZITHROMYCIN/

/CAPSULE;/ORAL/

/ZITHROMAX/

/+//PFIZER/	/250MG/	/N50670/001/	/NOV/01,/1991/

AZITHROMYCIN DIHYDRATE

CAPSULE; ORAL

ZITHROMAX

+ PFIZER	EQ 250MG BASE	N50670 001	NOV 01, 1991

BACLOFEN

INJECTABLE; INJECTION

LIORESAL

MEDTRONIC	0.5MG/ML¤	N20075 001	JUN 17, 1992
	2MG/ML¤	N20075 002	JUN 17, 1992

BACLOFEN

TABLET; ORAL
BACLOFEN

AB	BIOCRAFT	10MG¤	N73043 001 FEB 27, 1992
AB		20MG¤	N73044 001 FEB 27, 1992
	ə EON LABS	10MG	N71901 001 APR 13, 1988
	ə	20MG	N71902 001 APR 13, 1988
/B*/	/PHARM/BASICS/	/10MG/	/N71260/001/ /MAY/06,/1988/
/B*/		/20MG/	/N71261/001/ /MAY/06,/1988/
	ə PHARM BASICS	10MG	N71260 001 MAY 06, 1988
	ə	20MG	N71261 001 MAY 06, 1988
	/ə/VITARINE/	/10MG/	/N71901/001/ /APR/13,/1988/
	/ə/	/20MG/	/N71902/001/ /APR/13,/1988/

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
LOTENSIN HCT

+	CIBA	20MG;25MG¤	N20033 003 MAY 19, 1992
		5MG;6.25MG¤	N20033 001 MAY 19, 1992
		10MG;12.5MG¤	N20033 002 MAY 19, 1992
		20MG;12.5MG¤	N20033 004 MAY 19, 1992

BENZTROPINE MESYLATE

TABLET; ORAL
BENZTROPINE MESYLATE

AA	MUTUAL PHARM	1MG¤	N81264 001 JAN 23, 1992
AA		2MG¤	N81265 001 JAN 23, 1992

BENZTROPINE MESYLATE

TABLET; ORAL
BENZTROPINE MESYLATE

/B*/	/PHARM/BASICS/	/0.5MG/	/N89211/001/ /JUN/14,/1988/
/B*/		/1MG/	/N89212/001/ /JUN/14,/1988/
/B*/		/2MG/	/N89213/001/ /JUN/14,/1988/
	ə PHARM BASICS	0.5MG	N89211 001 JUN 14, 1988
	ə	1MG	N89212 001 JUN 14, 1988
	ə	2MG	N89213 001 JUN 14, 1988

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL
BETAMETHASONE DIPROPIONATE

/AB/	/CLAY/PARK/	/EQ 0.05% BASE/	/N72536/001/ /JAN/31,/1990/
B*	CLAY PARK	EQ 0.05% BASE	N72536 001 JAN 31, 1990
AB	TARO	EQ 0.05% BASE¤	N73552 001 APR 30, 1992

OINTMENT; TOPICAL
BETAMETHASONE DIPROPIONATE

/AB/	/CLAY/PARK/	/EQ 0.05% BASE/	/N72526/001/ /JAN/31,/1990/
B*	CLAY PARK	EQ 0.05% BASE	N72526 001 JAN 31, 1990

BETAMETHASONE VALERATE

CREAM; TOPICAL
BETAMETHASONE VALERATE

/AB/	/PHARMAFAIR/	/EQ 0.1% BASE/	/N70485/001/ /MAY/29,/1987/
	ə PHARMAFAIR	EQ 0.1% BASE	N70485 001 MAY 29, 1987

BETAMETHASONE VALERATE

OINTMENT; TOPICAL
BETAMETHASONE VALERATE

/AB/	/CLAY/PARK/	/EQ 0.1% BASE/	/N71478/001/ /DEC/23,/1987/	
B*	CLAY PARK	EQ 0.1% BASE	N71478 001 DEC 23, 1987	
/AB/	/PHARMAFAIR/	/EQ 0.1% BASE/	/N70486/001/ /MAY/29,/1987/	
	∂ PHARMAFAIR	EQ 0.1% BASE	N70486 001 MAY 29, 1987	

BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

> ADD > TABLET; ORAL
> ADD > KERLEDEX

> ADD >	+ LOREX	10MG;12.5MG¤	N19807 002 OCT 30, 1992
> ADD >		5MG;12.5MG¤	N19807 001 OCT 30, 1992

BETHANECHOL CHLORIDE

TABLET; ORAL
BETHANECHOL CHLORIDE

> ADD >	∂ EON LABS	10MG	N84378 001
> ADD >	∂	25MG	N84384 001
/AA/	/VITARINE/	/5MG/	/N84353/001/
/AA/		/10MG/	/N84379/001/
/AA/		/25MG/	/N84383/001/
	∂ VITARINE	5MG	N84353 001
> DLT >	/∂/	/10MG/	/N84378/001/
	∂	10MG	N84379 001
	∂	25MG	N84383 001
> DLT >	/∂/	/25MG/	/N84384/001/

BISOPROLOL FUMARATE

TABLET; ORAL
ZEBETA

	+ LEDERLE	10MG¤	N19982 001 JUL 31, 1992
		5MG¤	N19982 002 JUL 31, 1992

BITOLTEROL MESYLATE

SOLUTION; INHALATION
TORNALATE

> DLT >	/STERLING/	/0.2%/	/N19548/001/ /FEB/19,/1992/	
> DLT >				
> ADD >	STERLING WINTHROP	0.2%¤	N19548 001 FEB 19, 1992	
> ADD >				

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
BRETYLIUM TOSYLATE

/AP/	/LYPHOMED/	/50MG/ML/	/N70134/001/ /FEB/12,/1986/	
	∂ LYPHOMED	50MG/ML	N70134 001 FEB 12, 1986	

BROMPHENIRAMINE MALEATE

TABLET; ORAL
BROMPHENIRAMINE MALEATE

/AA/	/PIONEER/PHARMS/	/4MG/	/N88604/001/ /JUL/13,/1984/	
	∂ PIONEER PHARMS	4MG	N88604 001 JUL 13, 1984	

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
BUPIVACAINE HCL KIT

	ABBOTT	0.075%¤	N19978 001 SEP 03, 1992
		0.114%¤	N19978 002 SEP 03, 1992
		0.23%¤	N19978 003 SEP 03, 1992

BUTABARBITAL SODIUM

TABLET; ORAL
BUTABARBITAL SODIUM

	∂ EON LABS	15MG	N85938 001
	∂	30MG	N85934 001
	/∂/VITARINE/	/15MG/	/N85938/001/
	/∂/	/30MG/	/N85934/001/

BUTABARBITAL SODIUM

TABLET; ORAL
SODIUM BUTABARBITAL

/AA/	/WEST/WARD/	/15MG/	/N85418/001/	
/AA/		/30MG/	/N85432/001/	
	∂ WEST WARD	15MG	N85418 001	
	∂	30MG	N85432 001	

BUTORPHANOL TARTRATE

SPRAY, METERED; NASAL
STADOL

+	BRISTOL MYERS SQUIBB 1MG/INH		N19890 001
			DEC 12, 1991
		/1MG/INH/	/N19890/001/
			/DEC/12,/1991/

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

	DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER		
	FRESENIUS	18.4MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML¤	N20171 001
			AUG 19, 1992
	DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER		
	FRESENIUS	18.4MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML¤	N20171 002
			AUG 19, 1992
	DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER		
	FRESENIUS	18.4MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML¤	N20171 003
			AUG 19, 1992

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

AP	MCGAW	33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML¤	N20000 001	
			APR 17, 1992	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
RINGER'S IN PLASTIC CONTAINER

AP	MCGAW	33MG/100ML;30MG/100ML; 860MG/100ML¤	N20002 001
			APR 17, 1992

CARBAMAZEPINE

TABLET; ORAL
CARBAMAZEPINE

/AB/	/PARKE/DAVIS/	/200MG/	/N70429/001/	
			/JAN/02,/1987/	
/B*/	/PHARM/BASICS/	/200MG/	/N70300/001/	
			/MAY/15,/1986/	
	∂ PHARM BASICS	200MG	N70300 001	
			MAY 15, 1986	
	∂ WARNER CHILCOTT	200MG	N70429 001	
			JAN 02, 1987	

TABLET, CHEWABLE; ORAL
EPITOL

AB	LEMMON	100MG¤	N73524 001
			JUL 29, 1992

CARBIDOPA; LEVODOPA

TABLET; ORAL
CARBIDOPA AND LEVODOPA

AB	LEMMON	10MG;100MG¤	N73618 001
			AUG 28, 1992
AB		25MG;100MG¤	N73589 001
			AUG 28, 1992
AB		25MG;250MG¤	N73607 001
			AUG 28, 1992
	SINEMET		
AB	MSD	10MG;100MG	N17555 001
AB		25MG;100MG	N17555 003
AB	+	25MG;250MG	N17555 002

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

>DLT>	/B*/	/EON/LABS/	/350MG/	/N89566/001/
>DLT>				/AUG/30,/1988/
>ADD>		∂ EON LABS	350MG	N89566 001
>ADD>				AUG 30, 1988

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

	CEFADROXIL			
AB	ZENITH	EQ 500MG BASE	N62766 001	MAR 03, 1987
	/S/	/EQ/500MG/BASE/	/N62766/001/	/MAR/03,/1987/

TABLET; ORAL

	CEFADROXIL			
AB	ZENITH	EQ 1GM BASE	N62774 001	APR 08, 1987
	/S/	/EQ/1GM/BASE/	/N62774/001/	/APR/08,/1987/

CEFPODOXIME PROXETIL

GRANULE, FOR RECONSTITUTION; ORAL

	BANAN			
AB	SANKYO	EQ 50MG BASE/5ML¤	N50688 002	AUG 07, 1992
AB		EQ 100MG BASE/5ML¤	N50688 001	AUG 07, 1992
	VANTIN			
AB	UPJOHN	EQ 50MG BASE/5ML¤	N50675 001	AUG 07, 1992
AB	+	EQ 100MG BASE/5ML¤	N50675 002	AUG 07, 1992

TABLET; ORAL

	BANAN			
AB	SANKYO	EQ 100MG BASE¤	N50687 001	AUG 07, 1992
AB		EQ 200MG BASE¤	N50687 002	AUG 07, 1992
	VANTIN			
AB	UPJOHN	EQ 100MG BASE¤	N50674 001	AUG 07, 1992
AB	+	EQ 200MG BASE¤	N50674 002	AUG 07, 1992

CEFPROZIL

POWDER FOR RECONSTITUTION; ORAL

	CEFZIL			
	+ BRISTOL MYERS SQUIBB	250MG/5ML	N50665 002	DEC 23, 1991
		/250MG/5ML/	/N50665/002/	/DEC/23,/1991/

TABLET; ORAL

	CEFZIL			
	+ BRISTOL MYERS SQUIBB	500MG	N50664 002	DEC 23, 1991
		/500MG/	/N50664/002/	/DEC/23,/1991/

CEFTAZIDIME

INJECTABLE; INJECTION

/CEPTAZ/			
/GLAXO/	/500MG/VIAL/	/N50646/001/	/SEP/27,/1990/
	/1GM/VIAL/	/N50646/002/	/SEP/27,/1990/
	/2GM/VIAL/	/N50646/003/	/SEP/27,/1990/
	/10GM/VIAL/	/N50646/004/	/SEP/27,/1990/

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION

	CEPTAZ			
AP	GLAXO	1GM/VIAL	N50646 002	SEP 27, 1990
AP		2GM/VIAL	N50646 003	SEP 27, 1990
AP		10GM/VIAL	N50646 004	SEP 27, 1990
		500MG/VIAL	N50646 001	SEP 27, 1990
	PENTACEF			
AP	SMITHKLINE BEECHAM	1GM/VIAL¤	N64006 001	MAR 31, 1992
AP		2GM/VIAL¤	N64006 002	MAR 31, 1992
AP		10GM/VIAL¤	N64008 002	MAR 31, 1992
		6GM/VIAL¤	N64008 001	MAR 31, 1992

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

ROCEPHIN			
/ROCHE/	/EQ/250MG/BASE/VIAL/	/N62510/001/	
		/MAR/12,/1985/	
ə ROCHE	EQ 250MG BASE/VIAL	N62510 001	
		MAR 12, 1985	
	/EQ/500MG/BASE/VIAL/	/N62510/002/	
		/MAR/12,/1985/	
ə	EQ 500MG BASE/VIAL	N62510 002	
		MAR 12, 1985	
	/EQ/1GM/BASE/VIAL/	/N62510/003/	
		/MAR/12,/1985/	
ə	EQ 1GM BASE/VIAL	N62510 003	
		MAR 12, 1985	

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEFADYL			
> DLT >/AP/ /BRISTOL/	/EQ 20GM BASE/VIAL/	/N50446/004/	
> ADD > BRISTOL	EQ 20GM BASE/VIAL	N50446 004	
CEPHAPIRIN SODIUM			
> DLT >/AP/ /ELKINS/SINN/	/EQ 500MG BASE/VIAL/	/N62720/001/	
		/JUL/02,/1987/	
> DLT >			
> DLT >/AP/	/EQ 1GM BASE/VIAL/	/N62720/002/	
		/JUL/02,/1987/	
> DLT >			
> DLT >/AP/	/EQ 2GM BASE/VIAL/	/N62720/003/	
		/JUL/02,/1987/	
> DLT >			
> DLT >/AP/	/EQ 20GM BASE/VIAL/	/N62720/004/	
		/JUL/02,/1987/	
> DLT >			
> ADD > ə ELKINS SINN	EQ 500MG BASE/VIAL	N62720 001	
		JUL 02, 1987	
> ADD >			
> ADD > ə	EQ 1GM BASE/VIAL	N62720 002	
		JUL 02, 1987	
> ADD >			
> ADD > ə	EQ 2GM BASE/VIAL	N62720 003	
		JUL 02, 1987	
> ADD >			
> ADD > ə	EQ 20GM BASE/VIAL	N62720 004	
		JUL 02, 1987	
> ADD >			

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HCL			
/AB/ /PARKE/DAVIS/	/5MG/		/N85163/001/
/AB/	/10MG/		/N84598/001/
/AB/	/25MG/		/N85164/001/
ə PARKE DAVIS	5MG		N85163 001
ə	10MG		N84598 001
ə	25MG		N85164 001
/AB/ /VITARINE/	/5MG/		/N84919/001/
/AB/	/10MG/		/N84920/001/
/AB/	/25MG/		/N84823/001/
/AB/ /WEST/WARD/	/5MG/		/N85014/001/
/AB/	/10MG/		/N85000/001/
/AB/	/25MG/		/N85294/001/
ə WEST WARD	5MG		N85014 001
ə	10MG		N85000 001
ə	25MG		N85294 001

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HCL		
ə EON LABS	5MG	N84919 001
ə	10MG	N84920 001
ə	25MG	N84823 001

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE			
/AA/ /WEST/WARD/	/EQ 150MG BASE/		/N83082/001/
ə WEST WARD	EQ 150MG BASE		N83082 001

CHLOROTHIAZIDE

TABLET; ORAL

CHLOROTHIAZIDE		
ə EON LABS	250MG	N85485 001
/S/VITARINE/	/250MG/	/N85485/001/

CHLORPHENIRAMINE MALEATE

TABLET; ORAL

CHLORPHENIRAMINE MALEATE			
/AA/ /PIONEER/PHARMS/	/4MG/		/N88556/001/
			/JUL/13,/1984/
ə PIONEER PHARMS	4MG		N88556 001
			JUL 13, 1984

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE		
ə EON LABS	250MG	N84669 001

CHLORPROPAMIDE

TABLET; ORAL
CHLORPROPAMIDE

/B*/	/PHARM/BASICS/	/100MG/	/N88708/001/ /AUG/30,/1984/
/B*/		/250MG/	/N88709/001/ /AUG/30,/1984/
	∂ PHARM BASICS	100MG	N88708 001 AUG 30, 1984
	∂	250MG	N88709 001 AUG 30, 1984
	/S/VITARINE/	/250MG/	/N84669/001/

CHLORTHALIDONE

TABLET; ORAL
CHLORTHALIDONE

AB	EON LABS	50MG	N87118 001
/AB/	/VITARINE/	/50MG/	/N87118/001/
/AB/	/WARNER/CHILCOTT/	/25MG/	/N87515/001/ /JAN/24,/1983/
/AB/		/50MG/	/N87516/001/ /FEB/09,/1983/
	∂ WARNER CHILCOTT	25MG	N87515 001 JAN 24, 1983
	∂	50MG	N87516 001 FEB 09, 1983

THALITONE

/AB/	/BOEHRINGER/INGELHEIM/	/25MG/	/N88051/001/ /NOV/12,/1982/
		/15MG/	/N19574/001/ /DEC/20,/1988/
BX	HORUS	25MG	N88051 001 NOV 12, 1982
		15MG	N19574 001 DEC 20, 1988

CHYMOTRYPSIN

POWDER FOR RECONSTITUTION; OPHTHALMIC
/ALPHA CHYMAR/

/AT/	/BARNES/HIND/	/750 UNITS/VIAL/	/N11837/001/
	∂ SOLA BARNES HIND	750 UNITS/VIAL	N11837 001

ZOLYSE

/AT/	/ALCON/	/750 UNITS/VIAL/	/N11903/001/
	ALCON	750 UNITS/VIAL	N11903 001

CINOXACIN

CAPSULE; ORAL
CINOBAC

AB	LILLY	250MG	N18067 001
AB	+	500MG	N18067 002

CINOXACIN

AB	BIOCRAFT	250MG¤	N73005 001 FEB 28, 1992
AB		500MG¤	N73006 001 FEB 28, 1992

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION; IRRIGATION
RENACIDIN

	/GUARDIAN/LABS/	/6.602GM/100ML;0.198GM/100ML;/ /3.177GM/100ML/	/N19481/001/ /OCT/02,/1990/
	GUARDIAN LABS	6.602GM/100ML;198MG/100ML; 3.177GM/100ML	N19481 001 OCT 02, 1990

CLEMASTINE FUMARATE

SYRUP; ORAL
CLEMASTINE FUMARATE

AA	COPLEY	EQ 0.5MG BASE/5ML¤	N73095 001 APR 21, 1992

TAVIST

/AA/	/DORSEY/	/EQ 0.5MG BASE/5ML/	/N16675/001/ /JUN/28,/1985/
AA	SANDOZ	EQ 0.5MG BASE/5ML	N18675 001 JUN 28, 1985

TABLET; ORAL
CLEMASTINE FUMARATE

/AB/	/LEMMON/	/1.34MG¤/	/N73282/001/ /JAN/31,/1992/
AB	LEMMON	2.68MG¤	N73283 001 JAN 31, 1992
		1.34MG¤	N73282 001 JAN 31, 1992

TAVIST

AB	+ SANDOZ	2.68MG	N17661 001

TAVIST-1

/AB/	/DORSEY/	/1.34MG/	/N17661/002/
	∂ SANDOZ	1.34MG	N17661 002

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

/TABLET;/EXTENDED/RELEASE;/ORAL/
/TAVIST/D/
/*//SANDOZ/ /EQ/1MG/BASE;75MG/ /N18298/001/
/DEC/15,/1982/

ə SANDOZ EQ 1MG BASE;75MG N18298 001
DEC 15, 1982

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLINDAMYCIN HCL
ə EON LABS EQ 75MG BASE N62910 001
JUL 05, 1988

ə EQ 150MG BASE N62910 002
JUL 05, 1988

/ə/VITARINE/ /EQ/75MG/BASE/ /N62910/001/
/JUL/05,/1988/

/ə/ /EQ/150MG/BASE/ /N62910/002/
/JUL/05,/1988/

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL
CLEOCIN
+ UPJOHN EQ 2% BASE¤ N50680 001
AUG 11, 1992

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE
AP GENSIA EQ 150MG BASE/ML¤ N63282 001
MAY 29, 1992

SOLUTION; TOPICAL
CLINDA-DERM
AT PADDOCK EQ 1% BASE¤ N63329 001
SEP 30, 1992

CLIOQUINOL; HYDROCORTISONE

/CREAM;/TOPICAL/
/VIOFORM-HYDROCORTISONE/
/CIBA/ /3%;0.5%/ /N16412/002/
/3%;1%/ /N16412/001/

CLIOQUINOL; HYDROCORTISONE

/OINTMENT;/TOPICAL/
/VIOFORM-HYDROCORTISONE/
/ə/CIBA/ /3%;0.5%/ /N16412/004/
/3%;1%/ /N16412/003/

CLIOQUINOL; NYSTATIN

/OINTMENT;/TOPICAL/
/NYSTAFORM/
/MILES/ /10MG/GM;/
/100,000/UNITS/GM/ /N50235/001/

ə MILES 10MG/GM;
100,000 UNITS/GM N50235 001

CLOFIBRATE

CAPSULE; ORAL
CLOFIBRATE
AB PHARMACAPS 500MG¤ N73396 001
MAR 20, 1992

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM
/B*/ /PHARM/BASICS/ /3.75MG/ /N71242/001/
/MAY/20,/1987/
/B*/ /7.5MG/ /N71243/001/
/MAY/20,/1987/
/B*/ /15MG/ /N71244/001/
/MAY/20,/1987/

ə PHARM BASICS 3.75MG N71242 001
MAY 20, 1987

ə 7.5MG N71243 001
MAY 20, 1987

ə 15MG N71244 001
MAY 20, 1987

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

/AB/	/WARNER/CHILCOTT/	/3.75MG/	/N71828/001/ /MAR/03,/1988/
/AB/		/7.5MG/	/N71829/001/ /MAR/03,/1988/
/AB/		/15MG/	/N71830/001/ /MAR/03,/1988/
	ə WARNER CHILCOTT	3.75MG	N71828 001 MAR 03, 1988
	ə	7.5MG	N71829 001 MAR 03, 1988
	ə	15MG	N71830 001 MAR 03, 1988

CLOTRIMAZOLE

CREAM; TOPICAL

LOTRIMIN

/AT/+/SCHERING/		/1%/	/N17619/001/
BX +	SCHERING	1%	N17619 001

MYCELEX

/AT/	/MILES/	/1%/	/N18183/001/
BX	MILES	1%	N18183 001

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

HISTAFED C

/AA/	/CENCI/	/10MG/5ML;30MG/5ML;/ /1.25MG/5ML/	/N89018/001/ /JUL/23,/1986/
	TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE		
AA	CENCI	10MG/5ML;30MG/5ML; 1.25MG/5ML	N89018 001 JUL 23, 1986

COLCHICINE; PROBENECID

TABLET; ORAL

PROBEN-C

/BP/	/CHELSEA/	/0.5MG;500MG/	/N85552/001/
	ə CHELSEA	0.5MG;500MG	N85552 001

PROBENECID AND COLCHICINE

/BP/	/EON/LABS/	/0.5MG;500MG/	/N86130/001/
	ə EON LABS	0.5MG;500MG	N86130 001

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

/AP/	/LUITPOLD/	/0.03MG/ML/	/N80668/001/
	ə LUITPOLD	0.03MG/ML	N80668 001

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYCLOPENTOLATE HCL

/AT/	/BARNES/HIND/	/1%/	/N84863/001/
	ə SOLA BARNES HIND	1%	N84863 001

DACARBAZINE

INJECTABLE; INJECTION

/DACARBAZINE/

/AP/	/LYPHOMED/	/100MG/VIAL/	/N70962/001/ /AUG/28,/1986/
/AP/		/200MG/VIAL/	/N70990/001/ /AUG/28,/1986/
	ə LYPHOMED	100MG/VIAL	N70962 001 AUG 28, 1986
	ə	200MG/VIAL	N70990 001 AUG 28, 1986

DTIC-DOME

/AP/	/MILES/	/100MG/VIAL/	/N17575/001/
/AP/		/200MG/VIAL/	/N17575/002/
	MILES	100MG/VIAL	N17575 001
		200MG/VIAL	N17575 002

DESFLURANE

LIQUID; INHALATION

SUPRANE

+	ANAQUEST	99.9%w	N20118 001 SEP 18, 1992

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HCL

AB	EON LABS	25MG	N71601 001	JUN 05, 1987
AB		50MG	N71588 001	JUN 05, 1987
AB		75MG	N71602 001	OCT 05, 1987
AB		100MG	N71766 001	OCT 05, 1987
	ə	10MG	N72167 001	FEB 03, 1988
	ə	150MG	N72254 001	FEB 03, 1988
/B*/	/PHARM/BASICS/	/25MG/	/N71864/001/	/SEP/09,/1987/
/B*/		/50MG/	/N71865/001/	/SEP/09,/1987/
/B*/		/75MG/	/N71866/001/	/SEP/09,/1987/
/B*/		/100MG/	/N71867/001/	/SEP/09,/1987/
	ə PHARM BASICS	25MG	N71864 001	SEP 09, 1987
	ə	50MG	N71865 001	SEP 09, 1987
	ə	75MG	N71866 001	SEP 09, 1987
	ə	100MG	N71867 001	SEP 09, 1987
/AB/	/VITARINE/	/25MG/	/N71601/001/	/JUN/05,/1987/
/AB/		/50MG/	/N71588/001/	/JUN/05,/1987/
/AB/		/75MG/	/N71602/001/	/OCT/05,/1987/
/AB/		/100MG/	/N71766/001/	/OCT/05,/1987/
	/ə/	/10MG/	/N72167/001/	/FEB/03,/1988/
	/ə/	/150MG/	/N72254/001/	/FEB/03,/1988/

DESONIDE

CREAM; TOPICAL

DESONIDE

AB	COPLEY	0.05%¤	N74027 001	SEP 28, 1992

DESONIDE

CREAM; TOPICAL

DESONIDE

AB	TARO	0.05%¤	N73548 001	JUN 30, 1992

LOTION; TOPICAL

DESOWEN

OWEN GALDERMA	0.05%¤	N72354 001	JAN 24, 1992

DEXAMETHASONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC

DEXAIR

/BAUSCH/AND/LOMB/	/EQ/0.1%/PHOSPHATE/	/N88433/001/	/DEC/15,/1983/
PHARMAFAIR	EQ 0.1% PHOSPHATE	N88433 001	DEC 15, 1983

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

MCGAW	3.3GM/100ML;75MG/100ML; 300MG/100ML¤	N19630 049	MAY 07, 1992

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

MCGAW	3.3GM/100ML;110MG/100ML; 300MG/100ML¤	N19630 050	MAY 07, 1992

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

MCGAW	3.3GM/100ML;150MG/100ML; 300MG/100ML¤	N19630 051	MAY 07, 1992

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

MCGAW	3.3GM/100ML;220MG/100ML; 300MG/100ML¤	N19630 052	MAY 07, 1992

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

MCGAW	3.3GM/100ML;300MG/100ML; 300MG/100ML¤	N19630 053	MAY 07, 1992

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

/AB/	/PARKE/DAVIS/	/5MG/ML/	/N71614/001/ /OCT/22,/1987/
/AP/		/5MG/ML/	/N71613/001/ /OCT/22,/1987/
	∂ PARKE DAVIS	5MG/ML	N71613 001 OCT 22, 1987
	∂	5MG/ML	N71614 001 OCT 22, 1987

TABLET; ORAL

DIAZEPAM

/AB/	/PARKE/DAVIS/	/2MG/	/N70209/001/ /SEP/04,/1985/
/AB/		/5MG/	/N70210/001/ /SEP/04,/1985/
/AB/		/10MG/	/N70222/001/ /SEP/04,/1985/
/AB/	/PIONEER/PHARMS/	/2MG/	/N70787/001/ /AUG/02,/1988/
/AB/		/5MG/	/N70788/001/ /AUG/02,/1988/
/AB/		/10MG/	/N70776/001/ /AUG/02,/1988/
	∂ PIONEER PHARMS	2MG	N70787 001 AUG 02, 1988
	∂	5MG	N70788 001 AUG 02, 1988
	∂	10MG	N70776 001 AUG 02, 1988
	∂ WARNER CHILCOTT	2MG	N70209 001 SEP 04, 1985
	∂	5MG	N70210 001 SEP 04, 1985
	∂	10MG	N70222 001 SEP 04, 1985

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

VOLTAREN

+	GEIGY	25MG	N19201 001 JUL 28, 1988
+		50MG	N19201 002 JUL 28, 1988
		/25MG/	/N19201/001/ /JUL/28,/1988/
		/50MG/	/N19201/002/ /JUL/28,/1988/

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HCL

	∂ EON LABS	25MG	N85916 001
	/∂/VITARINE/	/25MG/	/N85916/001/

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

AB	LEMMON	250MG¤	N73679 001 JUL 31, 1992
AB		500MG¤	N73673 001 JUL 31, 1992

DOLOBID

AB	MSD	250MG	N18445 001 APR 19, 1982
AB +		500MG	N18445 002 APR 19, 1982

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM CD

BC +	MARION MERRELL DOW	180MG	N20062 002 DEC 27, 1991
BC +		240MG	N20062 003 DEC 27, 1991
+		120MG¤	N20062 001 AUG 10, 1992
+		300MG	N20062 004 DEC 27, 1991
		/300MG/	/N20062/004/ /DEC/27,/1991/

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM SR

+	MARION MERRELL DOW	60MG	N19471 001	JAN 23, 1989
+		90MG	N19471 002	JAN 23, 1989
		/60MG/	/N19471/001/	/JAN/23,/1989/
		/90MG/	/N19471/002/	/JAN/23,/1989/

DILACOR XR

BC	RHONE POULENC RORER	180MG¤	N20092 002	MAY 29, 1992
BC		240MG¤	N20092 003	MAY 29, 1992
∂		120MG¤	N20092 001	MAY 29, 1992

INJECTABLE; INJECTION

CARDIZEM

	MARION MERRELL DOW	5MG/ML	N20027 001	OCT 24, 1991
		/25MG/VIAL/	/N20027/001/	/OCT/24,/1991/
		/50MG/VIAL/	/N20027/002/	/OCT/24,/1991/

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HCL

AA	EON LABS	25MG	N80845 002	
AA		50MG	N80845 001	
/AA/	/PIONEER/PHARMS/	/25MG/	/N89101/001/	/DEC/20,/1985/
/AA/		/50MG/	/N88880/001/	/DEC/20,/1985/
∂	PIONEER PHARMS	25MG	N89101 001	DEC 20, 1985
∂		50MG	N88880 001	DEC 20, 1985
/AA/	/VITARINE/	/25MG/	/N80845/002/	
/AA/		/50MG/	/N80845/001/	

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

AB	GENEVA	50MG¤	N87562 001	FEB 25, 1992
AB		75MG¤	N87561 001	FEB 25, 1992

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

/B*/	/CHELSEA/	/EQ/100MG/BASE/	/N71026/001/	/DEC/01,/1986/
/B*/		/EQ/150MG/BASE/	/N71021/001/	/DEC/01,/1986/
/B*/	/INTERPHARM/	/EQ/100MG/BASE/	/N71190/001/	/JAN/15,/1987/
/B*/		/EQ/150MG/BASE/	/N71191/001/	/JAN/15,/1987/
∂	INTERPHARM	EQ 100MG BASE	N71190 001	JAN 15, 1987
∂		EQ 150MG BASE	N71191 001	JAN 15, 1987

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HCL

/AP/	/LYPHOMED/	/40MG/ML/	/N70058/001/	/MAR/20,/1985/
/AP/		/80MG/ML/	/N70059/001/	/MAR/20,/1985/
/AP/		/160MG/ML/	/N70364/001/	/DEC/04,/1985/
∂	LYPHOMED	40MG/ML	N70058 001	MAR 20, 1985
∂		80MG/ML	N70059 001	MAR 20, 1985
∂		160MG/ML	N70364 001	DEC 04, 1985

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOPRAM

AP	ROBINS	20MG/ML	N14879 001

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION
DOXAPRAM HCL

AP	STERIS	20MG/ML¤	N73529 001 JAN 30, 1992

DOXYCYCLINE HYCLATE

CAPSULE; ORAL
DOXYCYCLINE HYCLATE

	∂ EON LABS	EQ 50MG BASE	N62780 001 APR 12, 1988
	∂	EQ 100MG BASE	N62227 001
/B*/	/INTERPHARM/	/EQ/50MG/BASE/	/N62763/001/ /SEP/02,/1988/
/B*/		/EQ/100MG/BASE/	/N62763/002/ /SEP/02,/1988/
	∂ INTERPHARM	EQ 50MG BASE	N62763 001 SEP 02, 1988
	∂	EQ 100MG BASE	N62763 002 SEP 02, 1988
/AB/	/PARKE/DAVIS/	/EQ 50MG BASE/	/N62594/001/ /DEC/05,/1985/
/AB/		/EQ 100MG BASE/	/N62594/002/ /DEC/05,/1985/
	/∂/VITARINE/	/EQ/50MG/BASE/	/N62780/001/ /APR/12,/1988/
	/∂/	/EQ/100MG/BASE/	/N62227/001/
	∂ WARNER CHILCOTT	EQ 50MG BASE	N62594 001 DEC 05, 1985
	∂	EQ 100MG BASE	N62594 002 DEC 05, 1985

CAPSULE, COATED PELLETS; ORAL
DOXYCYCLINE HYCLATE

AB	SIDMAK	EQ 100MG BASE¤	N63187 001 JUN 30, 1992

TABLET; ORAL
DOXYCYCLINE HYCLATE

/B*/	/INTERPHARM/	/EQ/100MG/BASE/	/N62764/001/ /SEP/02,/1988/
	∂ INTERPHARM	EQ 100MG BASE	N62764 001 SEP 02, 1988
/AB/	/PARKE/DAVIS/	/EQ 100MG BASE/	/N62593/001/ /AUG/28,/1985/
	∂ WARNER CHILCOTT	EQ 100MG BASE	N62593 001 AUG 28, 1985

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL

/AP/	/LYPHOMED/	/2.5MG/ML/	/N70992/001/ /NOV/17,/1986/
/AP/		/2.5MG/ML/	/N70993/001/ /NOV/17,/1986/
	∂ LYPHOMED	2.5MG/ML	N70992 001 NOV 17, 1986
	∂	2.5MG/ML	N70993 001 NOV 17, 1986
/AP/	/SOLOPAK/	/2.5MG/ML/	/N71750/001/ /SEP/06,/1988/
	∂ SOLOPAK	2.5MG/ML	N71750 001 SEP 06, 1988

ENOXACIN

TABLET; ORAL
PENETREX

+	PARKE DAVIS	400MG	N19616 005 DEC 31, 1991
		/400MG/	/N19616/005/ /DEC/31,/1991/

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL AND EPINEPHRINE

>ADD>	AP	GRAHAM CHEM	0.01MG/ML;2%	N80504 004 OCT 19, 1983
>ADD>				
>ADD>	AP		0.02MG/ML;2%	N80504 005 OCT 19, 1983
>ADD>				

LIDOCAINE HCL W/ EPINEPHRINE

>DLT>/AP/		/GRAHAM/CHEM/	/0.01MG/ML;2%/	/N80504/004/ /OCT/19,/1983/
>DLT>				
>DLT>/AP/			/0.02MG/ML;2%/	/N80504/005/ /OCT/19,/1983/
>DLT>				

ERGOLOID MESYLATES

TABLET; SUBLINGUAL
ALKERGOT

∂ EON LABS	0.5MG	N85153 001
∂	1MG	N87417 001
/∂/VITARINE/	/0.5MG/	/N85153/001/
/∂/	/1MG/	/N87417/001/

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

/AA/	/ERGOMAR/ FISONS/	/2MG/	/N87693/001/ FEB/24,/1983/	
	ə FISONS	2MG	N87693 001 FEB 24, 1983	

ERYTHROMYCIN

SOLUTION; TOPICAL

/AT/	/C-SOLVE-2/ SYOSSET/	/2%/	/N62468/001/ JUL/03,/1985/	
AT	**C-SOLVE-2** SYOSSET	2%	N62468 001 JUL 03, 1985	
AT	**ERYTHROMYCIN** PHARM BASICS	2%	N62825 001 OCT 23, 1987	
/AT/	/MYTHROMYCIN/ PHARM/BASICS/	/2%/	/N62825/001/ OCT/23,/1987/	
AT	**SANSAC** OWEN GALDERMA	2%	N62522 001 JAN 24, 1985	
/AT/	/SANSACNE/ OWEN/GALDERMA/	/2%/	/N62522/001/ JAN/24,/1985/	

TABLET, COATED PARTICLES; ORAL

	PCE ABBOTT	500MG	N50611 002 AUG 22, 1990

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL

> DLT >	/E-MYCIN-E/			
> DLT >/AB/	/UPJOHN/	/EQ 200MG BASE/5ML/	/N62198/001/	
> DLT >/AB/		/EQ 400MG BASE/5ML/	/N62198/002/	
> ADD >	ə UPJOHN	EQ 200MG BASE/5ML	N62198 001	
> ADD >	ə	EQ 400MG BASE/5ML	N62198 002	
/AB/	**ERYTHROMYCIN ETHYLSUCCINATE** /PARKE/DAVIS/	/EQ 200MG BASE/5ML/	/N62231/001/	
/AB/		/EQ 400MG BASE/5ML/	/N62231/002/	
	ə PARKE DAVIS	EQ 200MG BASE/5ML	N62231 001	
	ə	EQ 400MG BASE/5ML	N62231 002	

ESTROPIPATE

TABLET; ORAL

/AB/ /AB/+/	/OGEN/ /ABBOTT/	/0.75MG/ /1.5MG/ /3MG/ /6MG/	/N83220/001/ /N83220/002/ /N83220/003/ /N83220/004/	
AB	**OGEN .625** ABBOTT	0.75MG	N83220 001	
AB +	**OGEN 1.25** ABBOTT	1.5MG	N83220 002	
	OGEN 2.5 ABBOTT	3MG	N83220 003	
	OGEN 5 ABBOTT	6MG	N83220 004	

ETHINYL ESTRADIOL

TABLET; ORAL

	ESTINYL			
/BP/	/SCHERING/	/0.05MG/	/N05292/002/	
	SCHERING	0.05MG	N05292 002	
/BP/	/FEMINONE/ /UPJOHN/	/0.05MG/	/N16649/001/	
	ə UPJOHN	0.05MG	N16649 001	

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

AB	**GENCEPT 0.5/35-21** GENCON	0.035MG;0.5MG¤	N72692 001 FEB 28, 1992	
AB	**GENCEPT 1/35-21** GENCON	0.035MG;1MG¤	N72693 001 FEB 28, 1992	
AB	**GENCEPT 10/11-21** GENCON	0.035MG;0.5MG AND 1MG¤	N72694 001 FEB 28, 1992	
/AB/	/N.E.E.1/35-21/ /METRONED/	/0.035MG;1MG/	/N71541/001/ /DEC/14,/1987/	
	ə LPI	0.035MG;1MG	N71541 001 DEC 14, 1987	

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

GENCEPT 0.5/35-28

AB	GENCON	0.035MG;0.5MG¤	N72695 001 FEB 28, 1992

GENCEPT 1/35-28

AB	GENCON	0.035MG;1MG¤	N72696 001 FEB 28, 1992

GENCEPT 10/11-28

AB	GENCON	0.035MG;0.5MG AND 1MG¤	N72697 001 FEB 28, 1992

/N.E.E. 1/35 28;/

/AB/	/METROMED/	/0.035MG;1MG/	/N71542/001/ /DEC/14,/1987/
	∂ LPI	0.035MG;1MG	N71542 001 DEC 14, 1987

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-21

ORTHO TRI-CYCLEN

+	JOHNSON RW	0.035MG; 0.18MG,0.215MG,0.25MG¤	N19697 002 JUL 03, 1992

TABLET; ORAL-28

ORTHO TRI-CYCLEN

	JOHNSON RW	0.035MG; 0.18MG,0.215MG,0.25MG¤	N19697 001 JUL 03, 1992

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

PLENDIL

/MERCK/	/5MG/		/N19834/001/ /JUL/25,/1991/
MERCK	5MG		N19834 001 JUL 25, 1991
	/10MG/		/N19834/002/ /JUL/25,/1991/
	10MG		N19834 002 JUL 25, 1991

FENOPROFEN CALCIUM

CAPSULE; ORAL

FENOPROFEN CALCIUM

/AB/	/HALSEY/	/EQ 200MG BASE/	/N72355/001/ /JUL/05,/1988/
/AB/		/EQ 300MG BASE/	/N72356/001/ /JUL/05,/1988/
	∂ HALSEY	EQ 200MG BASE	N72355 001 JUL 05, 1988
	∂	EQ 300MG BASE	N72356 001 JUL 05, 1988

TABLET; ORAL

FENOPROFEN CALCIUM

/AB/	/HALSEY/	/EQ 600MG BASE/	/N72357/001/ /JUL/05,/1988/
	∂ HALSEY	EQ 600MG BASE	N72357 001 JUL 05, 1988

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

AP	STERIS	EQ 0.05MG BASE/ML¤	N73488 001 JUN 30, 1992

FINASTERIDE

TABLET; ORAL

PROSCAR

+	MSD	5MG¤	N20180 001 JUN 19, 1992

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUONID

AT	ALLERGAN HERBERT	0.025%	N87156 002 SEP 06, 1984
/AT/	/HERBERT/	/0.025%/	/N87156/002/ /SEP/06,/1984/

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE

/AB/	/CLAY/PARK/	/0.05%/	/N71790/001/ /APR/25,/1988/
B*	CLAY PARK	0.05%	N71790 001 APR 25, 1988
AB	NMC	0.05%¤	N73085 001 FEB 14, 1992

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL

/AP/	/LYPHOMED/	/50MG/ML/	/N89152/001/ /MAR/21,/1986/
/AP/		/50MG/ML/	/N89428/001/ /JAN/12,/1987/
/AP/		/50MG/ML/	/N89519/001/ /MAR/12,/1987/
	ə LYPHOMED	50MG/ML	N89152 001 MAR 21, 1986
	ə	50MG/ML	N89428 001 JAN 12, 1987
	ə	50MG/ML	N89519 001 MAR 12, 1987

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL
FLURAZEPAM HCL

/B*/	/PHARM/BASICS/	/15MG/	/N70562/001/ /JUL/09,/1987/
/B*/		/30MG/	/N70563/001/ /JUL/09,/1987/
	ə PHARM BASICS	15MG	N70562 001 JUL 09, 1987
	ə	30MG	N70563 001 JUL 09, 1987

FOLIC ACID

TABLET; ORAL
FOLIC ACID

	ə EON LABS	1MG	N84472 001
/AA/	/LILLY/	/1MG/	/N06135/003/
	ə LILLY	1MG	N06135 003
	/ə/VITARINE/	/1MG/	/N84472/001/

FURAZOLIDONE

SUSPENSION; ORAL
FUROXONE

+	ROBERTS	50MG/15ML /50MG/15ML/	N11323 002 /N11323/002/

TABLET; ORAL
FUROXONE

+	ROBERTS	100MG /100MG/	N11270 002 /N11270/002/

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

/AP/	/LYPHOMED/	/10MG/ML/	/N18507/001/ /JUL/30,/1982/
	ə LYPHOMED	10MG/ML	N18507 001 JUL 30, 1982

TABLET; ORAL
FUROSEMIDE

/AB/	/CHELSEA/	/20MG/	/N18369/001/ /MAY/14,/1982/
/AB/		/40MG/	/N18369/002/ /MAY/14,/1982/
	ə CHELSEA	20MG	N18369 001 MAY 14, 1982
	ə	40MG	N18369 002 MAY 14, 1982
	ə EON LABS	40MG	N18750 002 JUL 30, 1984
	/ə/VITARINE/	/40MG/	/N18750/002/ /JUL/30,/1984/

GALLIUM CITRATE, GA-67

INJECTABLE; INJECTION
GALLIUM CITRATE GA 67

/BS/	/DUPONT/	/2MCI/ML/	/N17478/001/
BS	DUPONT MERCK	2MCI/ML	N17478 001

GLYBURIDE

TABLET; ORAL

	GLUBATE			
BX	HOECHST ROUSSEL	1.5MG¤	N20055 001 APR 17, 1992	
BX		3MG¤	N20055 002 APR 17, 1992	
	GLYNASE			
BX	UPJOHN	1.5MG	N20051 001 MAR 04, 1992	
BX +		3MG	N20051 002 MAR 04, 1992	

GONADORELIN ACETATE

INJECTABLE; INJECTION

	LUTREPULSE PUMP KIT		
	FERRING	0.8MG/VIAL	N19687 001 OCT 10, 1989
		3.2MG/VIAL	N19687 002 OCT 10, 1989
/JOHNSON/RW/		/0.8MG/VIAL/	/N19687/001/ /OCT/10,/1989/
		/3.2MG/VIAL/	/N19687/002/ /OCT/10,/1989/

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

	ULTRAGRIS-165			
AB	SIDMAK	165MG¤	N62645 001 JUN 30, 1992	
	ULTRAGRIS-330			
AB	SIDMAK	330MG¤	N62646 001 JUN 30, 1992	

HALOFANTRINE HYDROCHLORIDE

TABLET; ORAL

	HALFAN		
+	SMITHKLINE BEECHAM	250MG¤	N20250 001 JUL 24, 1992

HALOPERIDOL

TABLET; ORAL

	HALOPERIDOL				
/AB/	/ROYCE/	/0.5MG/	/N71722/001/ /DEC/24,/1987/		
/AB/		/1MG/	/N71723/001/ /DEC/24,/1987/		
/AB/		/2MG/	/N71724/001/ /DEC/24,/1987/		
/AB/		/5MG/	/N71725/001/ /DEC/24,/1987/		
/AB/		/10MG/	/N72121/001/ /DEC/24,/1987/		
/AB/		/20MG/	/N72122/001/ /DEC/24,/1987/		
	ə ROYCE	0.5MG	N71722 001 DEC 24, 1987		
	ə	1MG	N71723 001 DEC 24, 1987		
	ə	2MG	N71724 001 DEC 24, 1987		
	ə	5MG	N71725 001 DEC 24, 1987		
	ə	10MG	N72121 001 DEC 24, 1987		
	ə	20MG	N72122 001 DEC 24, 1987		

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

	HALOPERIDOL				
/AP/	/LYPHOMED/	/EQ 5MG BASE/ML/	/N71187/001/ /JAN/20,/1987/		
	ə LYPHOMED	EQ 5MG BASE/ML	N71187 001 JAN 20, 1987		

HEPARIN SODIUM

INJECTABLE; INJECTION

	HEPARIN LOCK FLUSH				
/AP/	/LUITPOLD/	/10 UNITS/ML/	/N89063/001/ /OCT/09,/1985/		
/AP/		/100 UNITS/ML/	/N89064/001/ /OCT/09,/1985/		
	ə LUITPOLD	10 UNITS/ML	N89063 001 OCT 09, 1985		
	ə	100 UNITS/ML	N89064 001 OCT 09, 1985		

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH PRESERVATIVE FREE

/AP/	/LYPHOMED/	/10 UNITS/ML/	/N17029/011/ /SEP/22,/1987/
/AP/		/100 UNITS/ML/	/N17029/012/ /SEP/22,/1987/
	@ LYPHOMED	10 UNITS/ML	N17029 011 SEP 22, 1987
	@	100 UNITS/ML	N17029 012 SEP 22, 1987

HEPARIN LOCK FLUSH PRESERVATIVE FREE IN PLASTIC CONTAINER;

/AP/	/LYPHOMED/	/10 UNITS/ML/	/N17029/008/ /SEP/22,/1987/
/AP/		/100 UNITS/ML/	/N17029/009/ /SEP/22,/1987/
	@ LYPHOMED	10 UNITS/ML	N17029 008 SEP 22, 1987
	@	100 UNITS/ML	N17029 009 SEP 22, 1987

HEPARIN SODIUM

/AP/	/LUITPOLD/	/1,000 UNITS/ML/	/N87452/001/ /OCT/31,/1983/
	@ LUITPOLD	1,000 UNITS/ML	N87452 001 OCT 31, 1983

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%

/$/	/ABBOTT/	/10,000 UNITS/100ML/	/N18911/006/ /JAN/30,/1985/
AP	ABBOTT	10,000 UNITS/100ML	N18911 006 JAN 30, 1985

HEPARIN SODIUM 1000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	MCGAW	200 UNITS/100ML¤	N19953 001 JUL 20, 1992

HEPARIN SODIUM 12500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	MCGAW	5,000 UNITS/100ML¤	N19802 001 JUL 20, 1992

HEPARIN SODIUM 20000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	4,000 UNITS/100ML¤	N19952 001 JUL 20, 1992

HEPARIN SODIUM 25000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	5,000 UNITS/100ML¤	N19952 004 JUL 20, 1992
AP		10,000 UNITS/100ML¤	N19952 005 JUL 20, 1992

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 25000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	MCGAW	5,000 UNITS/100ML¤	N19802 005 JUL 20, 1992
AP		10,000 UNITS/100ML¤	N19802 002 JUL 20, 1992

HEPARIN SODIUM 25000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	MCGAW	5,000 UNITS/100ML¤	N19802 003 JUL 20, 1992

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

APRESOLINE

/AP/	/CIBA/	/20MG/ML/	/N08303/003/
	CIBA	20MG/ML	N08303 003

HYDRALAZINE HCL

/AP/	/LYPHOMED/	/20MG/ML/	/N89532/001/ /AUG/11,/1987/
	@ LYPHOMED	20MG/ML	N89532 001 AUG 11, 1987

TABLET; ORAL

HYDRALAZINE HCL

	@ EON LABS	50MG	N85088 001
/AA/	/VANGARD/	/25MG/	/N87712/001/
	@ VANGARD	25MG	N87712 001
	/$/VITARINE/	/50MG/	/N85088/001/

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDRAL/

/AB/	/SOLVAY/	/25MG;25MG/	/N87608/001/ /FEB/08,/1982/
/AB/		/50MG;50MG/	/N87213/001/ /FEB/08,/1982/
/AB/		/100MG;50MG/	/N87609/001/ /FEB/08,/1982/

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

AB	SOLVAY	25MG;25MG	N87608 001	FEB 08, 1982
AB		50MG;50MG	N87213 001	FEB 08, 1982
	@	100MG;50MG	N87609 001	FEB 08, 1982

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
HYDRAP-ES

	@ EON LABS	25MG;15MG;0.1MG	N84876 001	
	/@/VITARINE/	/25MG;15MG;0.1MG/	/N84876/001/	
>DLT>	/RESERPINE/HYDRALAZINE/HCL/HYDROCHLOROTHIAZIDE/			
>DLT>	/BP/ /DANBURY/	/25MG;15MG;0.1MG/	/N85549/001/	
>DLT>	/BP/	/25MG;15MG;0.1MG/	/N87556/001/	

RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

>ADD>	BP DANBURY	25MG;15MG;0.1MG	N85549 001	
>ADD>	BP	25MG;15MG;0.1MG	N87556 001	

HYDRALAZINE HYDROCHLORIDE; RESERPINE

TABLET; ORAL
DRALSERP

	@ EON LABS	25MG;0.1MG	N84617 001	
	/@/VITARINE/	/25MG;0.1MG/	/N84617/001/	

SERPASIL-APRESOLINE

/BP/	/CIBA/	/25MG;0.1MG/	/N09296/004/	
	CIBA	25MG;0.1MG	N09296 004	

HYDROCHLOROTHIAZIDE

TABLET; ORAL
HYDROCHLOROTHIAZIDE

AB	DANBURY	25MG	N81189 001	JAN 24, 1992
AB		100MG	N81190 001	JAN 24, 1992
>DLT> /AB/	/EON/LABS/	/25MG/	/N83899/001/	
AB	EON LABS	50MG	N85219 001	
>ADD>	@	25MG	N83899 001	
/AB/	/HEATHER/	/50MG/	/N84135/001/	
	@ HEATHER	50MG	N84135 001	
/AB/	/VITARINE/	/50MG/	/N85219/001/	

HYDROCHLOROTHIAZIDE

TABLET; ORAL
HYDROCHLOROTHIAZIDE

/AB/	/WARNER/CHILCOTT/	/25MG/	/N87586/001/	/MAY/03,/1982/
/AB/		/50MG/	/N87587/001/	/MAY/03,/1982/
	@ WARNER CHILCOTT	25MG	N87586 001	MAY 03, 1982
	@	50MG	N87587 001	MAY 03, 1982

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
HYDRO-SERP 25

	@ EON LABS	25MG;0.125MG	N84827 001	
	/@/VITARINE/	/25MG;0.125MG#/	/N84827/001/	

HYDRO-SERP 50

	@ EON LABS	50MG;0.125MG	N85213 001	
	/@/VITARINE/	/50MG;0.125MG#/	/N85213/001/	

/SERPASIL-ESIDRIX/#1/

/BP/	/CIBA/	/25MG;0.1MG/	/N11878/003/	
	@ CIBA	25MG;0.1MG	N11878 003	

/SERPASIL-ESIDRIX/#2/

/BP/+/	/CIBA/	/50MG;0.1MG/	/N11878/005/	
	@ CIBA	50MG;0.1MG	N11878 005	

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL
MAXZIDE-25

AB	MYLAN	25MG;37.5MG	N19129 003	MAY 13, 1988

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

>DLT> /B*/	/EON/LABS/	/50MG;75MG/	/N71360/001/	/DEC/08,/1987/
>DLT>				
>ADD>	@ EON LABS	50MG;75MG	N71360 001	DEC 08, 1987
>ADD>				
AB	GENEVA	25MG;37.5MG	N73281 001	APR 30, 1992

HYDROCORTISONE

CREAM; TOPICAL
HYDROCORTISONE

/AT/	/BAUSCH/AND/LOMB/	/1%/	/N87838/001/	/JUL/28,/1982/

HYDROCORTISONE

CREAM; TOPICAL

	HYDROCORTISONE			
AT	PHARMAFAIR	1%	N87838 001	JUL 28, 1982

LOTION; TOPICAL

	/CORT-DOME/			
/AT/	/MILES/	/0.5%/	/N09895/003/	
/AT/		/1%/	/N09895/001/	
	ə MILES	0.5%	N09895 003	
	ə	1%	N09895 001	

OINTMENT; TOPICAL

	HYDROCORTISONE			
AT	NMC	1%	N87796 001	OCT 13, 1982
	/HYMAC/			
/AT/	/NMC/	/1%/	/N87796/001/	/OCT/13,/1982/

SOLUTION; TOPICAL

	TEXACORT			
	GENDERM	2.5%¤	N81271 001	APR 17, 1992

TABLET; ORAL

	/HYCORTOLE/			
	/ə/VITARINE/	/20MG/	/N80642/002/	
	HYDROCORTISONE			
	ə EON LABS	20MG	N80642 002	

HYDROCORTISONE ACETATE

CREAM; TOPICAL

	HEMSOL-HC			
AT	ABLE	1%¤	N81274 001	JUN 19, 1992

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

SUSPENSION/DROPS; OPHTHALMIC

	COR-OTICIN			
>DLT >/AT/	/AKORN/	/1.5%;EQ 3.5MG BASE/ML/	/N60188/001/	
>ADD >	AKORN	1.5%;EQ 3.5MG BASE/ML	N60188 001	

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

SUSPENSION/DROPS; OPHTHALMIC

>DLT >	/NEO-CORTEF/			
>DLT >/AT/	/UPJOHN/	/0.5%;EQ 3.5MG BASE/ML/	/N60612/002/	
>DLT >/AT/		/1.5%;EQ 3.5MG BASE/ML/	/N60612/001/	
>ADD >	ə UPJOHN	0.5%;EQ 3.5MG BASE/ML	N60612 002	
>ADD >	ə	1.5%;EQ 3.5MG BASE/ML	N60612 001	

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

	/HYDROCORTISONE ACETATE/			
/AT/	/THAMES/	/1%;10%/	/N89472/001/	/JUN/13,/1988/
	U-CORT			
AT	THAMES	1%;10%	N89472 001	JUN 13, 1988

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

	HYDROCORTISONE SODIUM SUCCINATE			
>DLT >/AP/	/ELKINS/SINN/	/EQ 100MG BASE/VIAL/	/N86619/001/	
>DLT >/AP/		/EQ 250MG BASE/VIAL/	/N87567/001/	
>DLT >/AP/		/EQ 500MG BASE/VIAL/	/N87568/001/	
>ADD >	ə ELKINS SINN	EQ 100MG BASE/VIAL	N86619 001	
>ADD >	ə	EQ 250MG BASE/VIAL	N87567 001	
>ADD >	ə	EQ 500MG BASE/VIAL	N87568 001	

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

	/HYDROFLUMETHIAZIDE/AND/RESERPINE/			
/B*/	/PHARM/BASICS/	/50MG;0.125MG/	/N88195/001/	/OCT/26,/1983/
	ə PHARM BASICS	50MG;0.125MG	N88195 001	OCT 26, 1983

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

	PAREMYD			
	ALLERGAN	1%;0.25%¤	N19261 001	JAN 30, 1992

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL
HYDROXYZINE HCL

/AB/	/EON/LABS/	/10MG/	/N87246/001/	
/AB/		/25MG/	/N85247/001/	
/AB/		/50MG/	/N87245/001/	
	∂ EON LABS	10MG	N87246 002	
	∂	25MG	N85247 001	
	∂	50MG	N87245 001	
/B*/	/PHARM/BASICS/	/10MG/	/N89121/001/	
/B*/		/25MG/	/MAR/20,/1986/	
/B*/		/50MG/	/N89122/001/	
	∂ PHARM BASICS	10MG	/MAR/20,/1986/	
	∂	25MG	/N89123/001/	
	∂	50MG	/MAR/20,/1986/	
			N89121 001	
			MAR 20, 1986	
			N89122 001	
			MAR 20, 1986	
			N89123 001	
			MAR 20, 1986	

HYDROXYZINE PAMOATE

CAPSULE; ORAL
HY-PAM

AB	EON LABS	EQ 25MG HCL	N87479 001	
/AB/	/VITARINE/	/EQ 25MG HCL/	/N87479/001/	

HYDROXYZINE PAMOATE

AB	EON LABS	EQ 50MG HCL	N86183 001	
/AB/	/VITARINE/	/EQ 50MG HCL/	/N86183/001/	

IBUPROFEN

TABLET; ORAL
IBUPROFEN

/AB/	/BOOTS/	/600MG/	/N70556/001/	
	∂ BOOTS	600MG	/JUN/14,/1985/	
AB	LEMMON	400MG¤	N70556 001	
AB		600MG¤	JUN 14, 1985	
AB		800MG¤	N73343 001	
/AB/	/SUPERPHARM/	/600MG/	JUN 30, 1992	
	∂ SUPERPHARM	600MG	N73344 001	
			JUN 30, 1992	
			N73345 001	
			JUN 30, 1992	
			/N70709/001/	
			/APR/25,/1986/	
			N70709 001	
			APR 25, 1986	

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL
IMIPRAMINE HCL

AB	EON LABS	10MG	N85200 001
AB		25MG	N84869 002
AB		50MG	N85133 001
AB	/VITARINE/	/25MG/	/N84869/002/
/AB/		/50MG/	/N85133/001/
/AB/		/10MG/	/N85200/001/
/∂/			

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN

∂ EON LABS	25MG	N71711 001	
		JUL 05, 1988	
∂	50MG	N71712 001	
		JUL 05, 1988	
/∂/VITARINE/	/25MG/	/N71711/001/	
		/JUL/05,/1988/	
/∂/	/50MG/	/N71712/001/	
		/JUL/05,/1988/	

CAPSULE, EXTENDED RELEASE; ORAL
INDOMETHACIN

/B*/	/EON/LABS/	/75MG/	/N71531/001/	
			/JUL/21,/1987/	
	∂ EON LABS	75MG	N71531 001	
			JUL 21, 1987	

SUPPOSITORY; RECTAL
INDOCIN

AB	+ MERCK	50MG	N17814 001
			AUG 13, 1984

INDOMETHEGAN

AB	G AND W	50MG¤	N73314 001
			AUG 31, 1992

IOFETAMINE HYDROCHLORIDE I-123

INJECTABLE; INJECTION
SPECTAMINE

IMP	1 MCI/ML	N19432 001
		DEC 24, 1987
/MEDI/PHYSICS/	/1/MCI/ML/	/N19432/001/
		/DEC/24,/1987/

IOPAMIDOL

INJECTABLE; INJECTION
ISOVUE-250
SQUIBB 51% N18735 007 JUL 06, 1992

IOPHENDYLATE

/INJECTABLE;/INJECTION/
/PANTOPAQUE/
/LAFAYETTE/ /100%/ /N05319/001/

ə ALCON 100% N05319 001

IOVERSOL

INJECTABLE; INJECTION
OPTIRAY 300
MALLINCKRODT 64% N19710 004 JAN 22, 1992

OPTIRAY 350
MALLINCKRODT 74% N19710 005 JAN 22, 1992

IRON DEXTRAN

INJECTABLE; INJECTION
/IMFERON/
/AP/ /FISONS/ /EQ 50MG IRON/ML/ /N10787/002/
ə FISONS EQ 50MG IRON/ML N10787 002

IRON DEXTRAN
/AP/ /STERIS/ /EQ 50MG IRON/ML/ /N17441/001/
STERIS EQ 50MG IRON/ML N17441 001

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL
/AN/ /ARMOUR/ /0.125%/ /N87938/001/ /NOV/15,/1982/
/AN/ /0.167%/ /N88470/001/ /MAR/14,/1984/
/AN/ /0.2%/ /N88471/001/ /MAR/14,/1984/
/AN/ /0.25%/ /N88472/001/ /MAR/14,/1984/
/AN/ /0.062%/ /N87937/001/ /NOV/15,/1982/
AN ASTRA 0.125% N87938 001 NOV 15, 1982
0.062% N87937 001 NOV 15, 1982
ə 0.167% N88470 001 MAR 14, 1984
ə 0.2% N88471 001 MAR 14, 1984
ə 0.25% N88472 001 MAR 14, 1984
/AN/ /DEY/ /0.08%/ /N88187/001/ /DEC/03,/1982/
/AN/ /0.1%/ /N87389/001/
/AN/ /0.17%/ /N87390/001/
/AN/ /0.25%/ /N88188/001/ /DEC/03,/1982/
/AN/ /1%/ /N86763/001/
ə DEY 0.08% N88187 001 DEC 03, 1982
ə 0.1% N87389 001
ə 0.17% N87390 001
ə 0.25% N88188 001 DEC 03, 1982
ə 1% N86763 001

ISOETHARINE HCL S/F
AN DEY 0.17% N89819 001 NOV 22, 1988
/0.17%/ /N89819/001/ /NOV/22,/1988/

ISONIAZID

TABLET; ORAL
>DLT< /INH/
>DLT</AA/ /CIBA/ /300MG/ /N80935/001/
>ADD< ə CIBA 300MG N80935 001

ISONIAZID

TABLET; ORAL

	ISONIAZID			
AA	EON LABS	100MG	N08678 002	
AA		300MG	N08678 003	
/AA/	/LILLY/	/100MG/	/N08499/002/	
/AA/		/300MG/	/N08499/003/	
	@ LILLY	100MG	N08499 002	
	@	300MG	N08499 003	
/AA/	/VITARINE/	/100MG/	/N08678/002/	
/AA/		/300MG/	/N08678/003/	

ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION

	ISOPROTERENOL HCL			
/AN/	/DEY/	/0.5%/	/N86764/001/ /JAN/04/1982/	
	@ DEY	0.5%	N86764 001 JAN 04, 1982	

ISOSORBIDE MONONITRATE

TABLET; ORAL

	ISMO			
+	WYETH	20MG	N19091 001 DEC 30, 1991	
		/20MG/	/N19091/001/ /DEC/30/1991/	

ITRACONAZOLE

CAPSULE; ORAL

	SPORANOX			
+	JANSSEN	100MG¤	N20083 001 SEP 11, 1992	

KANAMYCIN SULFATE

INJECTABLE; INJECTION

	KANAMYCIN SULFATE			
AP	LOCH	EQ 75MG BASE/2ML¤	N63021 001 JUL 31, 1992	
AP		EQ 500MG BASE/2ML¤	N63022 001 JUL 31, 1992	
AP		EQ 1GM BASE/3ML¤	N63025 001 JUL 31, 1992	

KETOROLAC TROMETHAMINE

TABLET; ORAL

	TORADOL			
+	SYNTEX	10MG	N19645 001 DEC 20, 1991	
		/10MG/	/N19645/001/ /DEC/20/1991/	

LACTULOSE

SYRUP; ORAL

	LACTULOSE			
AA	PACO	10GM/15ML¤	N73160 001 AUG 25, 1992	
AA	ROXANE	10GM/15ML¤	N73591 001 MAY 29, 1992	
AA	UDL	10GM/15ML¤	N74138 001 SEP 30, 1992	

SYRUP; ORAL, RECTAL

	LACTULOSE			
AA	PACO	10GM/15ML¤	N72029 001 AUG 25, 1992	
AA	ROXANE	10GM/15ML¤	N73590 001 MAY 29, 1992	

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

	LEUCOVORIN CALCIUM			
/AP/	/LYPHOMED/	/EQ 50MG BASE/VIAL/	/N88939/001/ /DEC/01/1986/	
	@ LYPHOMED	EQ 50MG BASE/VIAL	N88939 001 DEC 01, 1986	

LEVOCARNITINE

SOLUTION; ORAL

	CARNITOR			
AA	SIGMA TAU	1GM/10ML	N19257 001 APR 10, 1986	
/AA/	/VITACARN/ /MCGAW/	/1GM/10ML/	/N19257/001/ /APR/10/1986/	

LEVODOPA

CAPSULE; ORAL
DOPAR
/+///P/AND/$/ /500MG/ /N16913/002/
/100MG/ /N16913/003/
/250MG/ /N16913/001/
+ ROBERTS 500MG N16913 002
100MG N16913 003
250MG N16913 001

LEVORPHANOL TARTRATE

TABLET; ORAL
LEVO-DROMORAN
+ ROCHE 2MG N08720 001
DEC 19, 1991
/2MG/ /N08720/001/
/DEC/19,/1991/

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL
/INTL/MEDICATION/ /1GM/VIAL/ /N18543/001/
@ INTL MEDICATION 1GM/VIAL N18543 001
/2GM/VIAL/ /N18543/002/
@ 2GM/VIAL N18543 002
LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER
AP MCGAW 200MG/100ML¤ N19830 002
APR 08, 1992
LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER
AP MCGAW 400MG/100ML¤ N19830 003
APR 08, 1992
LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER
AP MCGAW 800MG/100ML¤ N19830 004
APR 08, 1992

LITHIUM CARBONATE

CAPSULE; ORAL
LITHIUM CARBONATE
/B*/ /PHARM/BASICS/ /300MG/ /N72542/001/
/FEB/01,/1989/
@ PHARM BASICS 300MG N72542 001
FEB 01, 1989

LOMEFLOXACIN HYDROCHLORIDE

TABLET; ORAL
MAXAQUIN
+ SEARLE EQ 400MG BASE¤ N20013 001
FEB 21, 1992

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL
LOPERAMIDE HCL
AB GENEVA 2MG¤ N72993 001
AUG 28, 1992
AB LEMMON 2MG¤ N73192 001
APR 30, 1992

LORACARBEF

CAPSULE; ORAL
LORABID
+ LILLY 200MG N50668 001
DEC 31, 1991
/200MG/ /N50668/001/
/DEC/31,/1991/

POWDER FOR RECONSTITUTION; ORAL
LORABID
+ LILLY 200MG/5ML N50667 002
DEC 31, 1991
/200MG/5ML/ /N50667/002/
/DEC/31,/1991/

LORAZEPAM

TABLET; ORAL
LORAZEPAM
/B*/ /PHARM/BASICS/ /1MG/ /N70539/001/
/DEC/22,/1986/
/B*/ /2MG/ /N70540/001/
/DEC/22,/1986/
@ PHARM BASICS 1MG N70539 001
DEC 22, 1986
@ 2MG N70540 001
DEC 22, 1986

MANNITOL

INJECTABLE; INJECTION
MANNITOL 25%

/AP/	/LYPHOMED/	/12.5GM/50ML/	/N86754/001/	
	ə LYPHOMED	12.5GM/50ML	N86754 001	

MASOPROCOL

CREAM; TOPICAL
ACTINEX

	+ CHEMEX	10%¤	N19940 001	SEP 04, 1992

MECLOFENAMATE SODIUM

CAPSULE; ORAL
MECLOFENAMATE SODIUM

/B*/	/PHARM/BASICS/	/EQ/50MG/BASE/	/N71007/001/	/MAR/25/1988/
/B*/		/EQ/100MG/BASE/	/N71008/001/	/MAR/25/1988/
	ə PHARM BASICS	EQ 50MG BASE	N71007 001	MAR 25, 1988
	ə	EQ 100MG BASE	N71008 001	MAR 25, 1988

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION
DEPO-PROVERA

>ADD>	UPJOHN	150MG/ML¤	N20246 001	
>ADD>			OCT 29, 1992	

TABLET; ORAL
GYCRIN

>ADD> AB	WYETH AYERST	2.5MG¤	N81239 001	
>ADD>			OCT 30, 1992	
>ADD> AB		5MG¤	N81240 001	
>ADD>			OCT 30, 1992	
	PROVERA			
>ADD> AB	UPJOHN	2.5MG	N11839 001	
>ADD> AB		5MG	N11839 003	

MEFENAMIC ACID

CAPSULE; ORAL
MEFENAMIC ACID

ə EON LABS	250MG	N72179 001	APR 21, 1988
/S/VITARINE/	/250MG/	/N72179/001/	/APR/21/1988/

MEGESTROL ACETATE

TABLET; ORAL
MEGESTROL ACETATE

/B*/	/PHARM/BASICS/	/20MG/	/N70646/001/	/OCT/02/1987/
/B*/		/40MG/	/N70647/001/	/OCT/02/1987/
	ə PHARM BASICS	20MG	N70646 001	OCT 02, 1987
	ə	40MG	N70647 001	OCT 02, 1987

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPERIDINE HCL

AP	ABBOTT	10MG/ML	N88432 001	AUG 16, 1984
/AP/	/PARKE/DAVIS/	/50MG/ML/	/N80364/002/	
/AP/		/75MG/ML/	/N80364/003/	
/AP/		/100MG/ML/	/N80364/001/	
	ə PARKE DAVIS	50MG/ML	N80364 002	
	ə	75MG/ML	N80364 003	
	ə	100MG/ML	N80364 001	
AP	STERIS	10MG/ML¤	N73443 001	MAR 17, 1992
AP		50MG/ML¤	N73444 001	MAR 17, 1992
AP		100MG/ML¤	N73445 001	MAR 17, 1992

MEPIVACAINE HYDROCHLORIDE

METAPROTERENOL SULFATE

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	/PDL/DOCAINE/			
/AP/	/ASTRA/	/1%/	/N89406/001/	/DEC/01,/1986/
/AP/		/1.5%/	/N89408/001/	/DEC/01,/1986/
/AP/		/2%/	/N89409/001/	/DEC/01,/1986/
	POLOCAINE-MPF			
AP	ASTRA	1%	N89406 001	DEC 01, 1986
AP		1.5%	N89408 001	DEC 01, 1986
AP		2%	N89409 001	DEC 01, 1986

MEPROBAMATE

TABLET; ORAL

	MEPROBAMATE			
	ə ELKINS SINN	200MG	N15426 002	
	ə	400MG	N15426 001	
AA	EON LABS	200MG	N14547 002	
AA		400MG	N14547 001	
/AA/	/HEATHER/	/600MG/	/N84329/001/	
	ə HEATHER	600MG	N84329 001	
/AA/	/ICN/	/200MG/	/N15139/006/	
/AA/		/400MG/	/N15139/005/	
	ə ICN	200MG	N15139 006	
	ə	400MG	N15139 005	
/AA/	/PARKE/DAVIS/	/200MG/	/N84744/001/	
/AA/		/400MG/	/N84744/002/	
	ə PARKE DAVIS	200MG	N84744 001	
	ə	400MG	N84744 002	
	/ə/QUANTUM/PHARMICS/	/200MG/	/N15426/002/	
	/ə/	/400MG/	/N15426/001/	
/AA/	/VITARINE/	/200MG/	/N14547/002/	
/AA/		/400MG/	/N14547/001/	
>DLT>/AA/	/ZENITH/	/200MG/	/N15438/001/	
>DLT>/AA/		/400MG/	/N15438/002/	
>ADD>	ə ZENITH	200MG	N15438 001	
>ADD>	ə	400MG	N15438 002	

MESALAMINE

TABLET, DELAYED RELEASE; ORAL

	ASACOL			
	+ P AND G	400MG¤	N19651 001	JAN 31, 1992

METAPROTERENOL SULFATE

SOLUTION; INHALATION

	METAPROTERENOL SULFATE			
/AN/	/ARMOUR/	/0.4%/	/N71275/001/	/JUL/27,/1988/
/AN/		/0.6%/	/N71018/001/	/JUL/27,/1988/
AN	ASTRA	0.4%	N71275 001	JUL 27, 1988
AN		0.6%	N71018 001	JUL 27, 1988
	/DEY/	/0.33%/	/N71806/001/	/AUG/05,/1988/
	ə DEY	0.33%	N71806 001	AUG 05, 1988
	PROMETA			
AN	MURO	5%¤	N73340 001	MAR 30, 1992

SYRUP; ORAL

	METAPROTERENOL SULFATE			
AA	BIOCRAFT	10MG/5ML¤	N72761 001	FEB 27, 1992
AA	SILARX	10MG/5ML¤	N73632 001	JUL 22, 1992

TABLET; ORAL

	METAPROTERENOL SULFATE			
/B*/	/PHARM/BASICS/	/10MG/	/N71013/001/	/JAN/25,/1988/
/B*/		/20MG/	/N71014/001/	/JAN/25,/1988/
	ə PHARM BASICS	10MG	N71013 001	JAN 25, 1988
	ə	20MG	N71014 001	JAN 25, 1988

METHADONE HYDROCHLORIDE

TABLET, DISPERSIBLE; ORAL

	WESTADONE		
	ə EON LABS	2.5MG	N17108 001
	ə	5MG	N17108 002
	ə	10MG	N17108 003
	ə	40MG	N17108 004
	/ə/VITARINE/	/2.5MG/	/N17108/001/
	/ə/	/5MG/	/N17108/002/
	/ə/	/10MG/	/N17108/003/
	/ə/	/40MG/	/N17108/004/

METHOCARBAMOL

TABLET; ORAL
METHOCARBAMOL

AA	EON LABS	500MG	N87283 001	
AA		750MG	N87282 001	
/AA/	/HEATHER/	/500MG/	/N84675/001/	
/AA/		/750MG/	/N84924/001/	
	∂ HEATHER	500MG	N84675 001	
	∂	750MG	N84924 001	
/AA/	/VITARINE/	/500MG/	/N87283/001/	
/AA/		/750MG/	/N87282/001/	

METHOTREXATE SODIUM

TABLET; ORAL
METHOTREXATE

AB	MYLAN	EQ 2.5MG BASE¤	N81235 001 MAY 15, 1992

METHOXYFLURANE

LIQUID; INHALATION
PENTHRANE

ABBOTT	99.9%	N13056 001
/ABBOTT/	/99.9%/	/N13056/001/

METHYCLOTHIAZIDE

TABLET; ORAL
METHYCLOTHIAZIDE

/B*/	/PHARM/BASICS/	/5MG/	/N88745/001/ /MAR/21,/1985/
	∂ PHARM BASICS	5MG	N88745 001 MAR 21, 1985

METHYLDOPA

TABLET; ORAL
METHYLDOPA

/AB/	/PARKE/DAVIS/	/125MG/	/N70331/001/ /APR/15,/1986/
/AB/		/250MG/	/N70332/001/ /APR/15,/1986/
/AB/		/500MG/	/N70333/001/ /APR/15,/1986/
	∂ PARKE DAVIS	125MG	N70331 001 APR 15, 1986
	∂	250MG	N70332 001 APR 15, 1986
	∂	500MG	N70333 001 APR 15, 1986

METHYLPREDNISOLONE

TABLET; ORAL
METHYLPREDNISOLONE

	∂ EON LABS	4MG	N87341 001
/∂/	/VITARINE/	/4MG/	/N87341/001/

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE

>DLT >/AP/	/ELKINS/SINN/	/EQ 125MG BASE/VIAL/	/N86906/002/
>DLT >/AP/		/EQ 500MG BASE/VIAL/	/N86906/003/
>DLT >/AP/		/EQ 1GM BASE/VIAL/	/N86906/004/
>ADD >	∂ ELKINS SINN	EQ 125MG BASE/VIAL	N86906 002
>ADD >	∂	EQ 500MG BASE/VIAL	N86906 003
>ADD >	∂	EQ 1GM BASE/VIAL	N86906 004

METHYLPREDNISOLONE SODIUM SUCCINATE

>DLT >/AP/	/ELKINS/SINN/	/EQ 40MG BASE/VIAL/	/N86906/001/
>ADD >	∂ ELKINS SINN	EQ 40MG BASE/VIAL	N86906 001

METOCLOPRAMIDE HYDROCHLORIDE

CONCENTRATE; ORAL
METOCLOPRAMIDE INTENSOL

ROXANE	EQ 10MG BASE/ML¤	N72995 001 JAN 30, 1992

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

AP	CETUS BEN VENUE	EQ 10MG BASE/2ML¤	N72155 001	MAR 30, 1992
AP		EQ 10MG BASE/2ML¤	N72244 001	MAR 30, 1992
AP		EQ 10MG BASE/2ML¤	N72247 001	MAY 18, 1992

SOLUTION; ORAL
METOCLOPRAMIDE HCL

>ADD> AA	SILARX	EQ 5MG BASE/5ML¤	N73680 001	OCT 27, 1992

TABLET; ORAL
METOCLOPRAMIDE HCL

/B*/	/INTERPHARM/	/EQ 10MG BASE/	/N71213 001/	/SEP 24, 1986/
	∂ INTERPHARM	EQ 10MG BASE	N71213 001	SEP 24, 1986
/B*/	/PHARM BASICS/	/EQ 10MG BASE/	/N70339 001/	/JUL 29, 1985/
	∂ PHARM BASICS	EQ 10MG BASE	N70339 001	JUL 29, 1985

METOLAZONE

TABLET; ORAL
/DIULO/

/AB/	/SCHIAPPARELLI/SEARLE/	2.5MG	/N18535 001/	
/AB/		5MG	/N18535 002/	
/AB/		10MG	/N18535 003/	
	∂ SCHIAPPARELLI SEARLE	2.5MG	N18535 001	
	∂	5MG	N18535 002	
	∂	10MG	N18535 003	

ZAROXOLYN

/AB/	/FISONS/	2.5MG	/N17386 001/	
/AB/		5MG	/N17386 002/	
/AB/		10MG	/N17386 003/	
	+ FISONS	10MG	N17386 003	
		2.5MG	N17386 001	
		5MG	N17386 002	

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL
TOPROL XL

+	HASSLE	EQ 50MG TARTRATE¤	N19962 001	JAN 10, 1992
+		EQ 100MG TARTRATE¤	N19962 002	JAN 10, 1992
+		EQ 200MG TARTRATE¤	N19962 003	JAN 10, 1992

METRONIDAZOLE

GEL; VAGINAL
METROGEL

+	CURATEK	0.75%¤	N20208 001	AUG 17, 1992

INJECTABLE; INJECTION
METRONIDAZOLE

/AP/	/LYPHOMED/	/500MG/100ML/	/N70071 001/	/DEC 03, 1984/
	∂ LYPHOMED	500MG/100ML	N70071 001	DEC 03, 1984

TABLET; ORAL
METRONIDAZOLE

AB	EON LABS	250MG	N18620 001	MAR 04, 1982
AB		500MG	N18620 002	JUN 02, 1983
/AB/	/VITARINE/	/250MG/	/N18620 001/	/MAR 04, 1982/
/AB/		/500MG/	/N18620 002/	/JUN 02, 1983/

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION
FLAGYL I.V.

/AP/	/SCHIAPPARELLI/SEARLE/	EQ 500MG BASE/VIAL/	/N18353 001/	
	SCHIAPPARELLI SEARLE	EQ 500MG BASE/VIAL	N18353 001	

/METRONIDAZOLE HCL/

/AP/	/LYPHOMED/	/EQ 500MG BASE/VIAL/	/N70295 001/	/OCT 15, 1985/
	∂ LYPHOMED	EQ 500MG BASE/VIAL	N70295 001	OCT 15, 1985

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCYCLINE HCL

AB	BIOCRAFT	EQ 50MG BASE¤	N63011 001 MAR 02, 1992
AB		EQ 100MG BASE¤	N63009 001 MAR 02, 1992

SUSPENSION; ORAL
MINOCIN
+ LEDERLE — EQ 50MG BASE/5ML — N50445 001

/SYRUP;/ORAL/
/MINOCIN/
/+//LEDERLE/ — /EQ/50MG/BASE/5ML/ — /N50445/001/

MINOXIDIL

TABLET; ORAL
MINOXIDIL

/B*/	/PHARM/BASICS/	/2.5MG/	/N71537/001/ /DEC/16,/1988/
	∂ PHARM BASICS	2.5MG	N71537 001 DEC 16, 1988
/AB/	/ROYCE/	/2.5MG/	/N71799/001/ /NOV/10,/1987/
/AB/		/10MG/	/N71796/001/ /NOV/10,/1987/
	∂ ROYCE	2.5MG	N71799 001 NOV 10, 1987
	∂	10MG	N71796 001 NOV 10, 1987

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION
MIVACRON
BURROUGHS WELLCOME — EQ 2MG BASE/ML¤ — N20098 001
JAN 22, 1992

MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER
BURROUGHS WELLCOME — EQ 0.5MG BASE/ML¤ — N20098 002
JAN 22, 1992
EQ 50MG BASE/100ML¤ — N20098 003
JAN 22, 1992

MONOBENZONE

CREAM; TOPICAL
BENOQUIN

/ELDER/	/20%/	/N08173/003/
ICN	20%	N08173 003

MORPHINE SULFATE

INJECTABLE; INJECTION
MORPHINE SULFATE

	ABBOTT	0.5MG/ML¤	N19917 001 OCT 30, 1992
>ADD> AP		0.5MG/ML¤	N73509 001 SEP 30, 1992
>ADD> AP		1MG/ML¤	N19916 001 OCT 30, 1992
>ADD> AP		1MG/ML¤	N73510 001 SEP 30, 1992

NABUMETONE

TABLET; ORAL
RELAFEN

+ SMITHKLINE BEECHAM	750MG	N19583 002 DEC 24, 1991
	/750MG/	/N19583/002/ /DEC/24,/1991/

NAFARELIN ACETATE

SPRAY, METERED; NASAL
SYNAREL
SYNTEX — EQ 0.2MG BASE/INH¤ — N20109 001
FEB 26, 1992

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
/NALBUPHINE/

/AP/	/LYPHOMED/	/10MG/ML/	/N70751/001/ /JUL/02,/1986/
/AP/		/20MG/ML/	/N70752/001/ /JUL/02,/1986/
	∂ LYPHOMED	10MG/ML	N70751 001 JUL 02, 1986
	∂	20MG/ML	N70752 001 JUL 02, 1986

NAPROXEN

TABLET; ORAL
NAPROSYN
> ADD > AB SYNTEX 250MG N17581 002
> ADD > AB 375MG N17581 003
> ADD > AB 500MG N17581 004
> ADD > APR 15, 1982
> ADD > NAPROXEN
> ADD > AB HAMILTON 250MG¤ N74110 001
> ADD > OCT 30, 1992
> ADD > AB 375MG¤ N74110 002
> ADD > OCT 30, 1992
> ADD > AB 500MG¤ N74110 003
> ADD > OCT 30, 1992

NEOMYCIN SULFATE

TABLET; ORAL
NEOMYCIN SULFATE
AA EON LABS EQ 350MG BASE N61586 001
/AA/ /VITARINE/ /EQ 350MG BASE/ /N61586/001/

NEOMYCIN SULFATE; PREDNISOLONE ACETATE

> DLT > /SUSPENSION/DROPS;/OPHTHALMIC/
> DLT > /NEO-DELTA-CORTEF/
> DLT > /UPJOHN/ /EQ/3.5MG/BASE/ML;0.25%/ /N61037/001/

> ADD > @ UPJOHN EQ 3.5MG BASE/ML;0.25% N61037 001

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE

/OINTMENT;/OPHTHALMIC/
/NEO-HYDELTRASOL/
/MSD/ /EQ/3.5MG/BASE/GM;/
/EQ/0.25%/PHOSPHATE/ /N50378/001/

@ MSD EQ 3.5MG BASE/GM;
EQ 0.25% PHOSPHATE N50378 001

NIACIN

TABLET; ORAL
NIACIN
AA WOCKHARDT 500MG¤ N81134 001
APR 28, 1992

NICARDIPINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARDENE SR
+ SYNTEX 30MG¤ N20005 001
FEB 21, 1992
+ 45MG¤ N20005 002
FEB 21, 1992
+ 60MG¤ N20005 003
FEB 21, 1992

INJECTABLE; INJECTION
CARDENE
DUPONT MERCK 2.5MG/ML¤ N19734 001
JAN 30, 1992

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
NICODERM
/BC/ /MARION/MERRELL/DOW/ /7MG/24HR/ /N20165/001/
/NOV/07/1991/
BC + MARION MERRELL DOW 7MG/24HR N20165 001
NOV 07, 1991
/BC/ /14MG/24HR/ /N20165/002/
/NOV/07/1991/
BC + 14MG/24HR N20165 002
NOV 07, 1991
/BC/ /21MG/24HR/ /N20165/003/
/NOV/07/1991/
BC + 21MG/24HR N20165 003
NOV 07, 1991

NICOTROL
+ KABI 5MG/16HR¤ N20150 001
APR 22, 1992
+ 10MG/16HR¤ N20150 002
APR 22, 1992
+ 15MG/16HR¤ N20150 003
APR 22, 1992

PROSTEP
+ ELAN 11MG/24HR¤ N19983 001
JAN 28, 1992
+ 22MG/24HR¤ N19983 002
JAN 28, 1992

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL
NICORETTE

	MERRELL DOW	EQ 2MG BASE	N18612 001 JAN 13, 1984
	NICORETTE DS		
+	MERRELL DOW	EQ 4MG BASE¤	N20066 001 JUN 08, 1992

NIFEDIPINE

CAPSULE; ORAL
NIFEDIPINE

AB	NOVOPHARM	10MG¤	N72651 001 FEB 19, 1992
AB	SCHERER	20MG¤	N74045 001 APR 30, 1992

NITROFURANTOIN

TABLET; ORAL
NITROFURANTOIN

	∂ EON LABS	50MG	N80043 001
	∂	100MG	N80043 002

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE, EXTENDED RELEASE; ORAL
MACROBID

+	P AND G	75MG;25MG	N20064 001 DEC 24, 1991

NITROFURAZONE

DRESSING; TOPICAL
FURACIN

AT	ROBERTS	0.2%	N05795 001

NITROFURAZONE

AT	THAMES	0.2%	N86156 001

OINTMENT; TOPICAL
FURACIN

AT	ROBERTS	0.2%	N05795 001

NITROFURAZONE

AT	THAMES	0.2%	N86156 001

NITROGLYCERIN

INJECTABLE; INJECTION
NITROGLYCERIN

	∂ LUITPOLD	5MG/ML	N71492 001 MAY 24, 1988

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
NORTRIPTYLINE HCL

AB	DANBURY	EQ 10MG BASE¤	N73553 001 MAR 30, 1992
AB		EQ 25MG BASE¤	N73554 001 MAR 30, 1992
AB		EQ 50MG BASE¤	N73555 001 MAR 30, 1992
AB		EQ 75MG BASE¤	N73556 001 MAR 30, 1992
	PAMELOR		
AB	SANDOZ	EQ 10MG BASE	N18013 001
AB		EQ 25MG BASE	N18013 002
AB		EQ 50MG BASE	N18013 004
AB	+	EQ 75MG BASE	N18013 003

NYSTATIN

/SUPPOSITORY;/VAGINAL/
/NYSERT/
/P/AND/S/ /100,000/UNITS/ /N50478/001/

∂ P AND G 100,000 UNITS N50478 001

TABLET; ORAL
NYSTATIN
/AA/ /CHELSEA/ /500,000 UNITS/ /N62402/001/
/DEC/16,/1982/

∂ CHELSEA 500,000 UNITS N62402 001
DEC 16, 1982

AA EON LABS 500,000 UNITS N62065 001
/AA/ /VITARINE/ /500,000 UNITS/ /N62065/001/

TABLET; VAGINAL
NYSTATIN
∂ EON LABS 100,000 UNITS N61965 001
/∂/VITARINE/ /100,000/UNITS/ /N61965/001/

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
NYSTATIN AND TRIAMCINOLONE ACETONIDE
/AT/ /CLAY/PARK/ /100,000 UNITS/GM;0.1%/ /N62186/002/
/JUN/06,/1985/

B* CLAY PARK 100,000 UNITS/GM;0.1% N62186 002
JUN 06, 1985

OFLOXACIN

INJECTABLE; INJECTION
FLOXIN
JOHNSON RW 20MG/ML¤ N20087 002
MAR 31, 1992
40MG/ML¤ N20087 003
MAR 31, 1992

FLOXIN IN DEXTROSE 5%
JOHNSON RW 400MG/100ML¤ N20087 001
MAR 31, 1992

FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER
JOHNSON RW 4MG/ML¤ N20087 004
MAR 31, 1992
400MG/100ML¤ N20087 005
MAR 31, 1992

>ADD> OXAPROZIN

>ADD> TABLET; ORAL
>ADD> DAYPRO
>ADD> + SEARLE 600MG¤ N18841 004
>ADD> OCT 29, 1992

OXAZEPAM

CAPSULE; ORAL
OXAZEPAM
/B*/ /CHELSEA/ /10MG/ /N71661/001/
/MAR/02,/1988/
/B*/ /15MG/ /N71662/001/
/MAR/02,/1988/
/B*/ /30MG/ /N71663/001/
/MAR/02,/1988/

OXICONAZOLE NITRATE

LOTION; TOPICAL
OXISTAT
+ GLAXO EQ 1% BASE¤ N20209 001
SEP 30, 1992

OXYBUTYNIN CHLORIDE

TABLET; ORAL
OXYBUTYNIN CHLORIDE
/B*/ /PHARM/BASICS/ /5MG/ /N70746/001/
/MAR/10,/1988/

∂ PHARM BASICS 5MG N70746 001
MAR 10, 1988

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION
PENICILLIN G POTASSIUM
/AP/ /PARKE/DAVIS/ /1,000,000 UNITS/VIAL/ /N62003/001/
/AP/ /5,000,000 UNITS/VIAL/ /N62003/002/

∂ PARKE DAVIS 1,000,000 UNITS/VIAL N62003 001
∂ 5,000,000 UNITS/VIAL N62003 002

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

	/PENAPAR-VK/			
/AA/	/PARKE/DAVIS/	/EQ 125MG BASE/5ML/	/N62002/001/	
/AA/		/EQ 250MG BASE/5ML/	/N62002/002/	
	ə PARKE DAVIS	EQ 125MG BASE/5ML	N62002 001	
	ə	EQ 250MG BASE/5ML	N62002 002	

TABLET; ORAL

	/PENAPAR-VK/			
/AB/	/PARKE/DAVIS/	/EQ 250MG BASE/	/N62001/001/	
/AB/		/EQ 500MG BASE/	/N62001/002/	
	ə PARKE DAVIS	EQ 250MG BASE	N62001 001	
	ə	EQ 500MG BASE	N62001 002	

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION

	PENTAM 300			
AP	FUJISAWA	300MG/VIAL	N19264 001	OCT 16, 1984
	PENTAMIDINE ISETHIONATE			
AP	ABBOTT	300MG/VIAL¤	N73479 001	JUN 30, 1992

PERPHENAZINE

TABLET; ORAL

	PERPHENAZINE			
/B*/	/CHELSEA/	/8MG/	/N89700/001/	/DEC/23,/1987/

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL

	PHENDIMETRAZINE TARTRATE			
AA	EON LABS	35MG	N85633 001	
AA		35MG	N85694 001	
AA		35MG	N85695 001	
AA		35MG	N85702 001	
/AA/	/VITARINE/	/35MG/	/N85633/001/	
/AA/		/35MG/	/N85694/001/	
/AA/		/35MG/	/N85695/001/	
/AA/		/35MG/	/N85702/001/	

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

	PHENDIMETRAZINE TARTRATE			
BC	EON LABS	105MG	N18074 001	
/BC/	/VITARINE/	/105MG/	/N18074/001/	

TABLET; ORAL

	ALPHAZINE			
	ə EON LABS	35MG	N85034 001	
	/ə/VITARINE/	/35MG/	/N85034/001/	
	/OBEZINE/			
/AA/	/PHARM/BASICS/	/35MG/	/N83805/001/	
/AA/		/35MG/	/N84398/001/	
/AA/		/35MG/	/N84399/001/	
	PHENDIMETRAZINE TARTRATE			
AA	EON LABS	35MG	N85402 001	
> ADD > AA		35MG	N85497 001	
> ADD > AA		35MG	N85588 001	
AA		35MG	N85830 001	
/ə/		/35MG/	/N85830/001/	
	PHENDIMETRAZINE TARTRATE			
AA	PHARM BASICS	35MG	N84399 001	
	ə	35MG	N83805 001	
	ə	35MG	N84398 001	
	PHENDIMETRAZINE TARTRATE			
/AA/	/VITARINE/	/35MG/	/N85402/001/	
> DLT >/AA/		/35MG/	/N85497/001/	
> DLT >/AA/		/35MG/	/N85588/001/	

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

	PHENTERMINE HCL			
AA	EON LABS	15MG	N87301 001	
> ADD > AA		30MG	N86945 001	
> ADD >				JUL 20, 1983
AA		30MG	N87190 001	
AA		30MG	N87208 001	
AA		30MG	N87223 001	
/AA/	/VITARINE/	/15MG/	/N87301/001/	
> DLT >/AA/		/30MG/	/N86945/001/	
> DLT >			/JUL/20,/1983/	
/AA/		/30MG/	/N87190/001/	
/AA/		/30MG/	/N87208/001/	
/AA/		/30MG/	/N87223/001/	

PHENTERMINE HYDROCHLORIDE

TABLET; ORAL
PHENTERMINE HCL

	ə EON LABS	8MG	N85671 001
	ə	8MG	N85689 001
/ə/	/VITARINE/	/8MG/	/N85671/001/
/ə/		/8MG/	/N85689/001/

PHENYLBUTAZONE

CAPSULE; ORAL
/AZOLID/

/AB/	/RHONE/POULENC/RORER//100MG/		/N87260/001/
	ə RHONE POULENC RORER	100MG	N87260 001

TABLET; ORAL
/AZOLID/

/AB/	/RHONE/POULENC/RORER//100MG/		/N87091/001/
	ə RHONE POULENC RORER	100MG	N87091 001

PHENYTOIN

SUSPENSION; ORAL
DILANTIN-125

AB	+	PARKE DAVIS	125MG/5ML	N08762 001

PHENYTOIN

AB		BARRE	125MG/5ML¤	N89892 001 SEP 25, 1992

PHENYTOIN SODIUM, PROMPT

CAPSULE; ORAL
/PHENYTOIN/SODIUM/

/BX/		/CHELSEA/	/100MG/	/N85894/001/
		ə CHELSEA	100MG	N85894 001

PINDOLOL

TABLET; ORAL
PINDOLOL

AB		GENPHARM	5MG¤	N74013 001 SEP 24, 1992
AB			10MG¤	N74018 001 SEP 24, 1992

PINDOLOL

TABLET; ORAL
PINDOLOL

AB		MYLAN	5MG¤	N74019 001 SEP 03, 1992
AB			10MG¤	N74019 002 SEP 03, 1992

VISKEN

AB		SANDOZ	5MG	N18285 001 SEP 03, 1982
AB	+		10MG	N18285 002 SEP 03, 1982

PIROXICAM

CAPSULE; ORAL
FELDENE

AB		PFIZER	10MG	N18147 002 APR 06, 1982
AB	+		20MG	N18147 003 APR 06, 1982

PIROXICAM

AB		COPLEY	10MG¤	N74103 001 AUG 28, 1992
AB			20MG¤	N74103 002 AUG 28, 1992
AB		GENPHARM	10MG¤	N74043 001 SEP 22, 1992
AB			20MG¤	N74043 002 SEP 22, 1992
AB		MYLAN	10MG¤	N74102 001 JUL 31, 1992
AB			20MG¤	N74102 002 JUL 31, 1992
AB		SCHIAPPARELLI SEARLE	10MG¤	N74036 001 MAY 29, 1992
AB			20MG¤	N74036 002 MAY 29, 1992

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL
CO-LAV

AA		COPLEY	240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT¤	N73428 001 JAN 28, 1992

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL

GO-EVAC

AA	COPLEY	236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT¤	N73433 001 APR 28, 1992

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

K-LEASE

AB	ADRIA	8MEQ¤	N73398 001 JAN 28, 1992

MICRO-K

AB	ROBINS	8MEQ	N18238 001

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON

AB	UPSHER SMITH	8MEQ	N19123 001 APR 17, 1986
/BC/		/8MEQ/	/N19123/001/ /APR/17,/1986/

KLOTRIX

BC	APOTHECON	10MEQ	N17850 001
/BC/	/MEAD/JOHNSON/	/10MEQ/	/N17850/001/

PRAZEPAM

CAPSULE; ORAL

CENTRAX

/AB/	/PARKE/DAVIS/	/5MG/	/N18144/001/
/AB/+/		/10MG/	/N18144/002/
	+ PARKE DAVIS	10MG	N18144 002
		5MG	N18144 001

/PRAZEPAM/

/B*/	/PHARM/BASICS/	/5MG/	/N70427/001/ /NOV/06,/1987/
/B*/		/10MG/	/N70428/001/ /NOV/06,/1987/
	∂ PHARM BASICS	5MG	N70427 001 NOV 06, 1987
	∂	10MG	N70428 001 NOV 06, 1987

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

MINIPRESS

/AB/	/PFIZER/	/EQ 2MG BASE/	/N17442/003/
AB	+ PFIZER	EQ 2MG BASE	N17442 003
/AB/+/		/EQ 5MG BASE/	/N17442/001/
AB		EQ 5MG BASE	N17442 001

TABLET, EXTENDED RELEASE; ORAL

MINIPRESS XL

	+ PFIZER	2.5MG¤	N19775 001 JAN 29, 1992
	+	5MG¤	N19775 002 JAN 29, 1992

PREDNISOLONE

TABLET; ORAL

/DELTA-CORTEF/

/BX/+/	/UPJOHN/	/5MG/	/N09987/004/
	∂ UPJOHN	5MG	N09987 004

PREDNISOLONE

	∂ EON LABS	5MG	N84773 001
/BX/	/HEATHER/	/5MG/	/N80326/001/
	∂ HEATHER	5MG	N80326 001
	/∂/VITARINE/	/5MG/	/N84773/001/

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

SUSPENSION/DROPS; OPHTHALMIC

BLEPHAMIDE

/AT/	/ALLERGAN/	/0.22;10%/	/N12813/002/
	ALLERGAN	0.2%;10%	N12813 002

/PREDSULFAIR II/

/AT/	/PHARMAFAIR/	/0.22;10%/	/N88837/001/ /DEC/24,/1985/
	∂ PHARMAFAIR	0.2%;10%	N88837 001 DEC 24, 1985

PREDNISONE

TABLET; ORAL

/FERNISONE/

/BX/	/FERNDALE/	/5MG/	/N83364/001/
	∂ FERNDALE	5MG	N83364 001

PREDNISONE

TABLET; ORAL
PREDNISONE
∂ EON LABS 5MG N84774 001
AB RICHLYN 5MG N80782 001
/BX/ /5MG/ /N80782/001/
/∂/VITARINE/ /5MG/ /N84774/001/

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PROCAINAMIDE HCL
/AB/ /BOLAR/ /250MG/ /N88533/001/ /DEC/03,/1984/
/AB/ /500MG/ /N88534/001/ /DEC/03,/1984/
/AB/ /750MG/ /N88535/001/ /NOV/03,/1984/
∂ BOLAR 250MG N88533 001 DEC 03, 1984
∂ 500MG N88534 001 DEC 03, 1984
∂ 750MG N88535 001 NOV 03, 1984

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION
ACHROMYCIN
AP LEDERLE 40MG/VIAL;100MG/VIAL N50267 002
AP 40MG/VIAL;100MG/VIAL N50276 001
AP 40MG/VIAL;250MG/VIAL N50267 003
TETRACYN
AP PFIZER 40MG/VIAL;250MG/VIAL N60285 003
∂ 40MG/VIAL;100MG/VIAL N60285 002

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE
>DLT >/AP/ /ELKINS/SINN/ /EQ 5MG BASE/ML/ /N89523/001/ /MAY/03,/1988/
>DLT >
>ADD > ∂ ELKINS SINN EQ 5MG BASE/ML N89523 001 MAY 03, 1988
>ADD >

PROCHLORPERAZINE MALEATE

TABLET; ORAL
COMPAZINE
/AB/ /SKF/ /EQ 5MG BASE/ /N10571/001/
/AB/ /EQ 10MG BASE/ /N10571/002/
/AB//+/ /EQ 25MG BASE/ /N10571/003/
+ SKF EQ 25MG BASE N10571 003
EQ 5MG BASE N10571 001
EQ 10MG BASE N10571 002

/PROCHLORPERAZINE/MALEATE;/
/B*/ /DURAMED/ /EQ/5MG/BASE/ /N89484/001/ /JAN/20,/1987/
/B*/ /EQ/10MG/BASE/ /N89485/001/ /JAN/20,/1987/
/B*/ /EQ/25MG/BASE/ /N89486/001/ /JAN/20,/1987/
∂ DURAMED EQ 5MG BASE N89484 001 JAN 20, 1987
∂ EQ 10MG BASE N89485 001 JAN 20, 1987
∂ EQ 25MG BASE N89486 001 JAN 20, 1987

PROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMAZINE HCL
>DLT >/AP/ /STERIS/ /25MG/ML/ /N84510/001/
>ADD > STERIS 25MG/ML N84510 001
SPARINE
>DLT >/AP/ /WYETH/AYERST/ /25MG/ML/ /N10349/008/
>ADD > ∂ WYETH AYERST 25MG/ML N10349 008

PROMETHAZINE HYDROCHLORIDE

TABLET; ORAL
PROMETHAZINE HCL
∂ EON LABS 25MG N85146 001
∂ 50MG N85146 002
/∂/VITARINE/ /25MG/ /N85146/001/
/∂/ /50MG/ /N85146/002/

PROPANTHELINE BROMIDE

TABLET; ORAL
PROPANTHELINE BROMIDE
/AA/ /HEATHER/ /15MG/ /N85780/001/
∂ HEATHER 15MG N85780 001

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	OPHTHAINE			
/AT/	/SQUIBB/	/5MG/ML/	/N08883/001/
AT	SQUIBB	0.5%	N08883 001

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

	PROPOXYPHENE HCL			
>ADD>	∂ EON LABS	32MG	N84014 001
	∂	65MG	N83870 002
	∂	65MG	N86495 001
/AA/	/VITARINE/	/65MG/	/N83688/001/
>DLT>	/∂/	/32MG/	/N84014/001/
	∂ VITARINE	65MG	N83688 001
	/∂/	/65MG/	/N83870/002/
	/∂/	/65MG/	/N86495/001/
	/PROPOXYPHENE HCL 65/		
/AA/	/PARKE/DAVIS/	/65MG/	/N83786/001/
	∂ WARNER CHILCOTT	65MG	N83786 001

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

	PROPRANOLOL HCL		
/AB/	/SUPERPHARM/	/10MG/	/N71515/001/ JUN/08,/1988/
/AB/		/20MG/	/N71516/001/ JUN/08,/1988/
	∂ SUPERPHARM	10MG	N71515 001 JUN 08, 1988
	∂	20MG	N71516 001 JUN 08, 1988

PROTIRELIN

INJECTABLE; INJECTION

	RELEFACT TRH		
AP	FERRING	0.5MG/ML	N18087 001
/AP/	/HOECHST/ROUSSEL/	/0.5MG/ML/	/N18087/001/

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL

	PSEUDOEPHEDRINE HCL AND TRIPROLIDINE HCL		
AA	EON LABS	60MG;2.5MG	N88193 001 MAY 17, 1983
/AA/	/VITARINE/	/60MG;2.5MG/	/N88193/001/ /MAY/17,/1983/

PYRAZINAMIDE

TABLET; ORAL

	PYRAZINAMIDE		
AB	+ LEDERLE	500MG	N80157 001
AB	MIKART	500MG	N81319 001 JUN 30, 1992

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

	PYRIDOXINE HCL		
/AP/	/LUITPOLD/	/100MG/ML/	/N80669/001/
	∂ LUITPOLD	100MG/ML	N80669 001

QUINETHAZONE; RESERPINE

	/TABLET;/ORAL/		
	/HYDROMOX/R/		
	/LEDERLE/	/50MG;0.125MG/	/N13927/001/
	∂ LEDERLE	50MG;0.125MG	N13927 001

QUINIDINE SULFATE

TABLET; ORAL

	QUINIDINE SULFATE		
	∂ ELKINS SINN	200MG	N83622 001
AB	EON LABS	200MG	N84631 001
AB		300MG	N88072 001 SEP 26, 1983
	/∂/QUANTUM/PHARMICS/	/200MG/	/N83622/001/
/AB/	/VITARINE/	/200MG/	/N84631/001/
/AB/		/300MG/	/N88072/001/ /SEP/26,/1983/

RAUWOLFIA SERPENTINA

TABLET; ORAL

/BP/	/RAUVERID/ /FOREST/PHARMS/	/50MG/	/N09255/008/	
	WOLFINA			
	ə FOREST PHARMS	50MG	N09255 008	

RESERPINE

TABLET; ORAL

	RESERPINE			
BP	EON LABS	0.1MG	N09838 001	
BP		0.25MG	N09838 002	
/BP/	/VITARINE/	/0.1MG/	/N09838/001/	
/BP/		/0.25MG/	/N09838/002/	
	/SERPATE/			
/BP/	/VALE/	/0.1MG/	/N09453/001/	
/BP/		/0.25MG/	/N09453/002/	
	ə VALE	0.1MG	N09453 001	
	ə	0.25MG	N09453 002	

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

	RITODRINE HCL			
/AP/	/LYPHOMED/	/10MG/ML/	/N71188/001/ /JUL/23,/1987/	
/AP/		/15MG/ML/	/N71189/001/ /JUL/23,/1987/	
	ə LYPHOMED	10MG/ML	N71188 001 JUL 23, 1987	
	ə	15MG/ML	N71189 001 JUL 23, 1987	

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS			
/E/Z/EM/	/460MG/GM;420MG/GM/	/N18509/001/ /AUG/07,/1985/	
LAFAYETTE	460MG/GM;420MG/GM	N18509 001 AUG 07, 1985	

SODIUM CHLORIDE

INJECTABLE; INJECTION

/SODIUM/CHLORIDE/23.4%/IN/PLASTIC/CONTAINER/				
	/LYPHOMED/	/234MG/ML/	/N19329/001/ /APR/22,/1987/	
	ə LYPHOMED	234MG/ML	N19329 001 APR 22, 1987	

SODIUM LACTATE

INJECTABLE; INJECTION

	SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER			
AP	MCGAW	1.87GM/100ML¤	N20004 001 APR 21, 1992	

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

	NITROPRESS			
AP	ABBOTT	25MG/ML	N71961 001 AUG 01, 1988	
	SODIUM NITROPRUSSIDE			
AP	GENSIA	25MG/ML¤	N73465 001 MAR 30, 1992	

SODIUM POLYSTYRENE SULFONATE

SUSPENSION; ORAL, RECTAL

	SODIUM POLYSTYRENE SULFONATE			
/AA/	/ROXANE/	/15GM/60ML/	/N88453/001/ /NOV/17,/1983/	
	ə ROXANE	15GM/60ML	N88453 001 NOV 17, 1983	

SODIUM THIOSULFATE

INJECTABLE; INJECTION

	SODIUM THIOSULFATE			
	US ARMY	250MG/ML¤	N20166 001 FEB 14, 1992	

>ADD> SOTALOL HYDROCHLORIDE

>ADD> TABLET; ORAL
>ADD> BETAPACE
>ADD> + BERLEX 240MG N19865 003 OCT 30, 1992
>ADD> 80MG N19865 001 OCT 30, 1992
>ADD> 160MG N19865 002 OCT 30, 1992
>ADD> ∂ 320MG N19865 004 OCT 30, 1992

SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE
/AB/ /PARKE/DAVIS/ /25MG/ /N87952/001/ /NOV/18,/1982/
∂ WARNER CHILCOTT 25MG N87952 001 NOV 18, 1982

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
SUCCINYLCHOLINE CHLORIDE
/INTL/MEDICATION/ /100MG/VIAL/ /N85400/001/ /FEB/04,/1982/
∂ INTL MEDICATION 100MG/VIAL N85400 001 FEB 04, 1982

/SULFABENZAMIDE;/SULFACETAMIDE;/SULFATHIAZOLE/

/CREAM;/VAGINAL/
/SULTRIN/
/JOHNSON/RW/ /3.72;2.862;3.422/ /N05794/001/

/TABLET;/VAGINAL/
/SULTRIN/
/JOHNSON/RW/ /184MG;143.75MG;172.5MG/ /N05794/002/
/TRIPLE/SULFA/
/∂/FOUGERA/ /184MG;143.75MG;172.5MG/ /N88463/001/ /JAN/03,/1985/
/∂/PHARMADERM/ /184MG;143.75MG;172.5MG/ /N88462/001/ /JAN/03,/1985/

/SULFABENZAMIDE;/SULFACETAMIDE;/SULFATHIAZOLE;/UREA/

/CREAM;/VAGINAL/
/GYNE-SULF/
/AT/ /G/AND/W/ /3.72;2.862;3.422;0.642/ /N88667/001/ /JUN/09,/1986/
/TRIPLE SULFA/
/AT/ /CLAY/PARK/ /3.72;2.862;3.422;0.642/ /N87285/001/ /NOV/15,/1982/
/AT/ /FOUGERA/ /3.72;2.862;3.422;0.642/ /N86424/001/
/AT/ /NMC/ /3.72;2.862;3.422;0.642/ /N87864/001/ /SEP/01,/1982/
/AT/ /PHARMADERM/ /3.72;2.862;3.422;0.642/ /N87887/001/ /JUL/23,/1982/
/VAGITIA/
/AT/ /LEMMON/ /3.72;2.862;3.422;0.642/ /N88821/001/ /NOV/09,/1987/

SULFAMETHIZOLE

TABLET; ORAL
/BROKLAG/
/AB/ /FOREST/PHARMS/ /500MG/ /N80273/001/
∂ FOREST PHARMS 500MG N80273 001

THIOSULFIL
/AB//+//WYETH/AYERST/ /500MG/ /N08565/004/
+ WYETH AYERST 500MG N08565 004

SULFAMETHOXAZOLE

TABLET; ORAL
/URODAK/
/AB/ /SHIONOGI/ /500MG/ /N87307/001/
∂ SHIONOGI 500MG N87307 001

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION
SULFAMETHOXAZOLE AND TRIMETHOPRIM
AP CETUS BEN VENUE 80MG/ML;16MG/ML N72383 001 APR 29, 1992
AP STERLING WINTHROP 80MG/ML;16MG/ML N73199 001 SEP 11, 1992

TABLET; ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM
AB EON LABS 400MG;80MG N18598 001 MAY 19, 1982

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

/AB/	/INTERPHARM/	/400MG;80MG/	/N71299/001/ /OCT/27,/1987/	
/AB/		/800MG;160MG/	/N71300/001/ /OCT/27,/1987/	
B*	INTERPHARM	400MG;80MG	N71299 001 OCT 27, 1987	
B*		800MG;160MG	N71300 001 OCT 27, 1987	
/AB/	/MARTEC/	/400MG;80MG/	/N72408/001/ /DEC/07,/1988/	
	@ MARTEC	400MG;80MG	N72408 001 DEC 07, 1988	
/B*/	/PHARM/BASICS/	/400MG;80MG/	/N70203/001/ /NOV/08,/1985/	
/B*/		/800MG;160MG/	/N70204/001/ /NOV/08,/1985/	
	@ PHARM BASICS	400MG;80MG	N70203 001 NOV 08, 1985	
	@	800MG;160MG	N70204 001 NOV 08, 1985	
/AB/	/VITARINE/	/400MG;80MG/	/N18598/001/ /MAY/19,/1982/	

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

AB	EON LABS	800MG;160MG	N18598 004 MAY 19, 1982
/AB/	/MARTEC/	/800MG;160MG/	/N72417/001/ /DEC/07,/1988/
	@ MARTEC	800MG;160MG	N72417 001 DEC 07, 1988
/AB/	/VITARINE/	/800MG;160MG/	/N18598/004/ /MAY/19,/1982/

SULFASALAZINE

TABLET; ORAL

SULFASALAZINE

@ EON LABS	500MG	N86184 001	>DLT>	
/@/VITARINE/	/500MG/	/N86184/001/	>ADD>	

SULFISOXAZOLE

TABLET; ORAL

/SULFALAR/

/AB/	/PARKE/DAVIS/	/500MG/	/N84955/001/
	@ PARKE DAVIS	500MG	N84955 001

SULFISOXAZOLE

TABLET; ORAL

SULFISOXAZOLE

/AB/	/WEST/WARD/	/500MG/	/N80379/001/
	@ WEST WARD	500MG	N80379 001

SULINDAC

TABLET; ORAL

SULINDAC

AB	LEMMON	150MG¤	N72972 001 FEB 28, 1992
AB		200MG¤	N72973 001 FEB 28, 1992

TALBUTAL

/TABLET;ORAL/ /LOTUSATE/ /STERLING/	/120MG/	/N09410/005/
@ STERLING	120MG	N09410 005

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

RBC-SCAN

CADEMA	N/A¤	N20063 001 JUN 11, 1992

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

CARDIOLITE

/DUPONT/	/N/A/	/N19785/001/ /DEC/21,/1990/	>DLT>
DUPONT MERCK	N/A	N19785 001 DEC 21, 1990	>ADD>

TEMAFLOXACIN HYDROCHLORIDE

TABLET; ORAL

OMNIFLOX

/*/	/ABBOTT/	/EQ 600MG BASE*/	/N20043 004/ JAN 30, 1992
		/EQ 400MG BASE*/	/N20043 003/ JAN 30, 1992
∂	ABBOTT	EQ 400MG BASE*	N20043 003 JAN 30, 1992
∂		EQ 600MG BASE*	N20043 004 JAN 30, 1992

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

/B*/	/PHARM BASICS/	/15MG/	/N70489 001/ JUL 07, 1986
/B*/		/30MG/	/N70490 001/ JUL 07, 1986
∂	PHARM BASICS	15MG	N70489 001 JUL 07, 1986
∂		30MG	N70490 001 JUL 07, 1986

TENIPOSIDE

INJECTABLE; INJECTION

VUMON

	BRISTOL MYERS SQUIBB 10MG/ML*	N20119 001 JUL 14, 1992

TERAZOSIN HYDROCHLORIDE

TABLET; ORAL

HYTRIN

+	ABBOTT	2MG	N19057 002 AUG 07, 1987
/*/		/10MG/	/N19057 004/ AUG 07, 1987
		/2MG/	/N19057 002/ AUG 07, 1987
		10MG	N19057 004 AUG 07, 1987

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELATESTRYL

AO	GYNEX	200MG/ML	N09165 003
∂		200MG/ML	N09165 001
/AO/	/SQUIBB/	/200MG/ML/	/N09165 003/
/*/		/200MG/ML/	/N09165 001/

TETRACYCLINE

SYRUP; ORAL

/BICYCLINE/

/AB/	/BARRE/	/EQ 125MG HCL/5ML/	/N60633 001/

TETRACYCLINE

AB	BARRE	EQ 125MG HCL/5ML	N60633 001

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

/CYCLOPAR/

/AB/	/PARKE/DAVIS/	/250MG/	/N61725 001/
/AB/		/250MG/	/N62175 001/
/AB/		/250MG/	/N62332 001/
/AB/		/500MG/	/N61725 002/
/AB/		/500MG/	/N62332 002/
∂	WARNER CHILCOTT	250MG	N61725 001
∂		250MG	N62175 001
∂		250MG	N62332 001
∂		500MG	N61725 002
∂		500MG	N62332 002

ROBITET

> DLT > /AB/	/ROBINS/	/250MG/	/N61734 001/
> DLT > /AB/		/500MG/	/N61734 002/
> ADD > AB	WYETH AYERST	250MG	N61734 001
> ADD > AB		500MG	N61734 002

TETRACYCLINE HCL

AB	EON LABS	250MG	N61471 001
∂		500MG	N61471 002 SEP 06, 1988
/AB/	/PARKE/DAVIS/	/250MG/	/N62300 001/
/AB/		/500MG/	/N62300 002/
/AB/	/VITARINE/	/250MG/	/N61471 001/
/*/		/500MG/	/N61471 002/ /SEP/06,/1988/
AB	WARNER CHILCOTT	250MG	N62300 001
AB		500MG	N62300 002

TETRACYCLINE HYDROCHLORIDE

/INJECTABLE;/INJECTION/
/ACHROMYCIN/
/AP/ /LEDERLE/ /100MG/VIAL/ /N50267/002/
/AP/ /100MG/VIAL/ /N50276/001/
/AP/ /250MG/VIAL/ /N50267/003/
/TETRACYN/
/AP/ /PFIZER/ /250MG/VIAL/ /N60285/003/
/3/ /100MG/VIAL/ /N60285/002/

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
SOMOPHYLLIN-CRT
/BC/ /ISONS/ /50MG/ /N87763/001/ /FEB/27,/1985/
/BC/ /100MG/ /N87194/001/
/BC/ /200MG/ /N88382/001/ /FEB/27,/1985/
/BC/ /250MG/ /N87193/001/
/BC/ /300MG/ /N88383/001/ /FEB/27,/1985/

BC GRAHAM LABS 50MG N87763 001 FEB 27, 1985
BC 100MG N87194 001
BC 200MG N88382 001 FEB 27, 1985
BC 250MG N87193 001
BC 300MG N88383 001 FEB 27, 1985

THEO-24
/BC/ /SEARLE/ /100MG/ /N87942/001/ /AUG/22,/1983/
/BC/ /200MG/ /N87943/001/ /AUG/22,/1983/
/BC/ /300MG/ /N87944/001/ /AUG/22,/1983/
/400MG¤/ /N81034/001/ /FEB/28,/1992/

BC WHITBY 100MG N87942 001 AUG 22, 1983
BC 200MG N87943 001 AUG 22, 1983
BC 300MG N87944 001 AUG 22, 1983
400MG¤ N81034 001 FEB 28, 1992

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
THEOPHYLLINE
∂ EON LABS 260MG N87462 001 MAY 11, 1982
/3/VITARINE/ /260MG/ /N87462/001/ /MAY/11,/1982/

INJECTABLE; INJECTION
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER
AP MCGAW 40MG/100ML¤ N19826 001 AUG 14, 1992
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER
AP MCGAW 80MG/100ML¤ N19826 002 AUG 14, 1992
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER
AP MCGAW 160MG/100ML¤ N19826 003 AUG 14, 1992
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER
AP MCGAW 200MG/100ML¤ N19826 004 AUG 14, 1992
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER
AP MCGAW 320MG/100ML¤ N19826 006 AUG 14, 1992
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER
AP MCGAW 400MG/100ML¤ N19826 005 AUG 14, 1992

TABLET, EXTENDED RELEASE; ORAL
T-PHYL
BC PURDUE FREDERICK 200MG N88253 001 AUG 17, 1983
/THEOCONTIN/
/BC/ /PURDUE/FREDERICK/ /200MG/ /N88253/001/ /AUG/17,/1983/

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
THIAMINE HCL
/AP/ /LUITPOLD/ /100MG/ML/ /N80667/001/
∂ LUITPOLD 100MG/ML N80667 001
/AP/ /PARKE/DAVIS/ /100MG/ML/ /N80770/001/
∂ PARKE DAVIS 100MG/ML N80770 001

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL
THIORIDAZINE HCL

/AB/	/PAR/	/150MG/	/N89764/001/ /FEB/09,/1988/
/AB/		/200MG/	/N89765/001/ /FEB/09,/1988/
	ə PAR	150MG	N89764 001 FEB 09, 1988
	ə	200MG	N89765 001 FEB 09, 1988

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL
THIOTHIXENE HCL INTENSOL

AA	ROXANE	EQ 5MG BASE/ML¤	N73494 001 JUN 30, 1992

TIMOLOL MALEATE

TABLET; ORAL
TIMOLOL MALEATE

/B*/	/PHARM/BASICS/	/5MG/	/N72001/001/ /JAN/10,/1989/
/B*/		/10MG/	/N72002/001/ /JAN/10,/1989/
/B*/		/20MG/	/N72003/001/ /JAN/10,/1989/
	ə PHARM BASICS	5MG	N72001 001 JAN 10, 1989
	ə	10MG	N72002 001 JAN 10, 1989
	ə	20MG	N72003 001 JAN 10, 1989

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION
TOBRAMYCIN SULFATE

AP	ABBOTT	EQ 40MG BASE/ML¤	N63116 001 MAY 18, 1992
AP	GENSIA	EQ 40MG BASE/ML¤	N63100 001 JAN 30, 1992

TOLAZAMIDE

TABLET; ORAL
TOLAZAMIDE

/AB/	/INTERPHARM/	/250MG/	/N71270/001/ /SEP/23,/1986/
/AB/		/500MG/	/N71271/001/ /SEP/23,/1986/
B*	INTERPHARM	250MG	N71270 001 SEP 23, 1986
B*		500MG	N71271 001 SEP 23, 1986
/B*/	/PHARM/BASICS/	/100MG/	/N71355/001/ /JAN/11,/1988/
/B*/		/250MG/	/N70168/001/ /APR/02,/1986/
/B*/		/500MG/	/N70169/001/ /APR/02,/1986/
	ə PHARM BASICS	100MG	N71355 001 JAN 11, 1988
	ə	250MG	N70168 001 APR 02, 1986
	ə	500MG	N70169 001 APR 02, 1986

TOLBUTAMIDE

TABLET; ORAL
TOLBUTAMIDE

AB	EON LABS	500MG	N12678 001
/AB/	/PARKE/DAVIS/	/500MG/	/N86047/001/
	ə PARKE DAVIS	500MG	N86047 001
/AB/	/VITARINE/	/500MG/	/N12678/001/

TOLMETIN SODIUM

CAPSULE; ORAL
TOLMETIN SODIUM

AB	BAKER CUMMINS	EQ 400MG BASE¤	N73392 001 JAN 24, 1992
AB	GENEVA	EQ 400MG BASE¤	N73462 001 APR 30, 1992
AB	LEMMON	EQ 400MG BASE¤	N73519 001 MAY 29, 1992
AB	PUREPAC	EQ 400MG BASE¤	N73308 001 JAN 24, 1992

TOLMETIN SODIUM

TABLET; ORAL

	TOLECTIN 600			
AB	+ JOHNSON RW	EQ 600MG BASE	N17628 002	
			MAR 08, 1989	
	TOLMETIN SODIUM			
AB	GENEVA	EQ 200MG BASE*	N73588 001	
			JUL 31, 1992	
AB	PUREPAC	EQ 600MG BASE*	N73527 001	
			JUN 30, 1992	

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

	TRAZODONE HCL			
/B*/	/PHARM/BASICS/	/50MG/	/N70491/001/	
			/APR/29,/1987/	
/B*/		/100MG/	/N70492/001/	
			/APR/29,/1987/	
	∂ PHARM BASICS	50MG	N70491 001	
			APR 29, 1987	
	∂	100MG	N70492 001	
			APR 29, 1987	

TRICHLORMETHIAZIDE

TABLET; ORAL

	TRICHLORMETHIAZIDE		
	∂ EON LABS	4MG	N86171 001
/∂/	/VITARINE/	/4MG/	/N86171/001/

TRIDIHEXETHYL CHLORIDE

/TABLET;/ORAL/			
	/PATHILON/		
	/LEDERLE/	/25MG/	/N09489/005/
	∂ LEDERLE	25MG	N09489 005

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

		SURMONTIL		
/AB/		/WYETH/AYERST/	/EQ 25MG BASE/	/N16792/001/
/AB/			/EQ 50MG BASE/	/N16792/002/
/AB//+/			/EQ 100MG BASE/	/N16792/003/
				/SEP/15,/1982/
	+	WYETH AYERST	EQ 100MG BASE	N16792 003
				SEP 15, 1982
			EQ 25MG BASE	N16792 001
			EQ 50MG BASE	N16792 002

/TRIMIPRAMINE/MALEATE;/

/B*/	/PHARM/BASICS/	/EQ/25MG/BASE/	/N71283/001/
			/DEC/08,/1987/
/B*/		/EQ/50MG/BASE/	/N71284/001/
			/DEC/08,/1987/
/B*/		/EQ/100MG/BASE/	/N71285/001/
			/DEC/08,/1987/
	TRIMIPRAMINE MALEATE		
	∂ EON LABS	EQ 25MG BASE	N71832 001
			SEP 10, 1987
	∂	EQ 50MG BASE	N71833 001
			SEP 10, 1987
	∂	EQ 100MG BASE	N71834 001
			SEP 10, 1987
	∂ PHARM BASICS	EQ 25MG BASE	N71283 001
			DEC 08, 1987
	∂	EQ 50MG BASE	N71284 001
			DEC 08, 1987
	∂	EQ 100MG BASE	N71285 001
			DEC 08, 1987
	TRIMIPRAMINE MALEATE		
/∂/	/VITARINE/	/EQ/25MG/BASE/	/N71832/001/
			/SEP/10,/1987/
/∂/		/EQ/50MG/BASE/	/N71833/001/
			/SEP/10,/1987/
/∂/		/EQ/100MG/BASE/	/N71834/001/
			/SEP/10,/1987/

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM; VAGINAL

	GYNE-SULF			
AT	G AND W	3.7%;2.86%;3.42%	N88607 001	
			JUN 09, 1986	
	SULTRIN			
AT	JOHNSON RW	3.7%;2.86%;3.42%	N05794 001	

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM; VAGINAL

TRIPLE SULFA

AT	CLAY PARK	3.7%;2.86%;3.42%	N87285 001	
			NOV 15, 1982	
AT	FOUGERA	3.7%;2.86%;3.42%	N86424 001	
AT	NMC	3.7%;2.86%;3.42%	N87864 001	
			SEP 01, 1982	

TRYSUL

AT	SAVAGE	3.7%;2.86%;3.42%	N87887 001	
			JUL 23, 1982	

VAGILIA

	∂ LEMMON	3.7%;2.86%;3.42%	N88821 001	
			NOV 09, 1987	

TABLET; VAGINAL

SULTRIN

	JOHNSON RW	184MG;143.75MG;172.5MG	N05794 002	

TRIPLE SULFA

	∂ FOUGERA	184MG;143.75MG;172.5MG	N88463 001	
			JAN 03, 1985	
	∂ PHARMADERM	184MG;143.75MG;172.5MG	N88462 001	
			JAN 03, 1985	

TRISULFAPYRIMIDINES

SUSPENSION; ORAL

/SULFALOID/

/AB/	/FOREST/PHARMS/	/500MG/5ML/	/N80100/001/
	∂ FOREST PHARMS	500MG/5ML	N80100 001

URACIL MUSTARD

CAPSULE; ORAL

URACIL MUSTARD

> ADD >	ROBERTS	1MG	N12892 001
> DLT >	/UPJOHN/	/1MG/	/N12892/001/

VALPROIC ACID

SYRUP; ORAL

VALPROIC ACID

AA	COPLEY	250MG/5ML¤	N73178 001
			AUG 25, 1992

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HCL

> ADD > AP	ABBOTT	EQ 500MG BASE/VIAL¤	N62931 001	
> ADD >			OCT 29, 1992	
> ADD > AP		EQ 1GM BASE/VIAL¤	N62933 001	
> ADD >			OCT 29, 1992	

VECURONIUM BROMIDE

INJECTABLE; INJECTION

NORCURON

	ORGANON	20MG/VIAL¤	N18776 003
			JAN 03, 1992

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VERELAN

+	ELAN	180MG¤	N19614 003	
			JAN 09, 1992	

TABLET; ORAL

VERAPAMIL HCL

/B*/	/CHELSEA/	/80MG/	/N70421/001/
			/SEP/17,/1986/
/B*/		/120MG/	/N70422/001/
			/SEP/17,/1986/
AB	GENEVA	40MG¤	N73168 001
			JUL 31, 1992
/AB/	/PARKE/DAVIS/	/80MG/	/N70340/001/
			/AUG/20,/1986/
/AB/		/120MG/	/N70341/001/
			/AUG/20,/1986/
	∂ PARKE DAVIS	80MG	N70340 001
			AUG 20, 1986
	∂	120MG	N70341 001
			AUG 20, 1986

TABLET, EXTENDED RELEASE; ORAL

ISOPTIN SR

AB	+ KNOLL	240MG	N19152 001	
			DEC 16, 1986	

VERAPAMIL HCL

AB	BAKER CUMMINS	240MG¤	N73568 001	
			JUL 31, 1992	

VINBLASTINE SULFATE

INJECTABLE; INJECTION

> DLT >		VELSAR			
> DLT >	AP	BULL	10MG/VIAL	N89565 001	
> DLT >				AUG 18, 1987	
		VINBLASTINE SULFATE			
> ADD >	AP	BULL	10MG/VIAL	N89565 001	
> ADD >				AUG 18, 1987	

VITAMIN A

CAPSULE; ORAL

		AQUASOL A		
AA		ASTRA	50,000 USP UNITS	N83080 001
			25,000 USP UNITS	N83080 002
AA		USV	50,000 USP UNITS	N83080 001
			25,000 USP UNITS	N83080 002

VITAMIN A PALMITATE

CAPSULE; ORAL

	VITAMIN A		
	∂ ELKINS SINN	EQ 50,000 UNITS BASE	N85479 001
∂	QUANTUM PHARMICS	EQ 50,000 UNITS BASE	N85479 001

WARFARIN SODIUM

TABLET; ORAL

		WARFARIN SODIUM		
B*		PHARM BASICS	2MG	N88719 001
				JUN 27, 1985
B*			2.5MG	N88720 001
				AUG 06, 1985
B*			5MG	N88721 001
				JUL 02, 1985
	∂	PHARM BASICS	2MG	N88719 001
				JUN 27, 1985
	∂		2.5MG	N88720 001
				AUG 06, 1985
	∂		5MG	N88721 001
				JUL 02, 1985

ZALCITABINE

TABLET; ORAL

	HIVID		
+	ROCHE	0.75MG	N20199 002
			JUN 19, 1992
		0.375MG	N20199 001
			JUN 19, 1992

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACEPHEN		
G AND W	120MG¤	N72218 001 MAR 27, 1992
	325MG¤	N72344 001 MAR 27, 1992
	650MG¤	N72237 001 MAR 27, 1992

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

MICROCOL		
JOHNSON AND JOHNSON	0.5%¤	N72292 001 JAN 28, 1992
STERI-STAT		
MATRIX MEDCL	4%	N70104 001 JUL 24, 1986
/MEDCL/SYSTEMS/	/4%/	/N70104/001/ /JUL/24,/1986/

CLEMASTINE FUMARATE

TABLET; ORAL

TAVIST-1		
SANDOZ	1.34MG¤	N17661 003 AUG 21, 1992

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TAVIST-D		
SANDOZ	1.34MG;75MG¤	N18298 002 AUG 21, 1992

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

/RESPORAL/		
/PIONEER/PHARMS/	/6MG;120MG/	/N89139/001/ /JUN/16,/1988/
∂ PIONEER PHARMS	6MG;120MG	N89139 001 JUN 16, 1988

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL

DIPHENHYDRAMINE HCL		
CUMBERLAND SWAN	12.5MG/5ML¤	N73611 001 AUG 20, 1992
SILPHEN		
SILARX	12.5MG/5ML¤	N72646 001 FEB 27, 1992

IBUPROFEN

TABLET; ORAL

IBUPROFEN		
TAG	200MG¤	N73141 001 MAY 29, 1992

INSULIN BIOSYNTHETIC HUMAN; INSULIN SUSP ISOPHANE BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION

HUMULIN 50/50		
LILLY	50 UNITS/ML;50 UNITS/ML¤	N20100 001 APR 29, 1992

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL

LOPERAMIDE HCL		
BARRE	1MG/5ML¤	N73187 001 SEP 15, 1992
PERRIGO	1MG/5ML¤	N73243 001 JAN 21, 1992
ROXANE	1MG/5ML¤	N73079 001 APR 30, 1992

> ADD >
> ADD >
> ADD >

TABLET; ORAL

LOPERAMIDE HCL		
PERRIGO	2MG¤	N74194 001 OCT 30, 1992

MICONAZOLE NITRATE

> ADD >
> ADD >
> ADD >

CREAM; VAGINAL

MICONAZOLE NITRATE		
COPLEY	2%¤	N74030 001 OCT 30, 1992

SODIUM CHLORIDE

AEROSOL, METERED; INHALATION

BRONCHO SALINE		
BLAIREX	0.9%	N19912 001 SEP 03, 1992

SODIUM MONOFLUOROPHOSPHATE

PASTE; DENTAL

EXTRA-STRENGTH AIM		
/CHESEBROUGH/PONDS/	/1.2%/	/N19518/001/ /JUN/03,/1987/
CHESEBROUGH PONDS	1.2%	N19518 001 JUN 03, 1987

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
LMD IN PLASTIC CONTAINER
ABBOTT LABS 10GM/100ML;0.9GM/100ML N72562
OCT 30, 1992

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
LMD IN PLASTIC CONTAINER
ABBOTT LABS 10GM/100ML;5GM/100ML N72563
OCT 30, 1992

DEXTRAN 75 6% INVERTED SUGAR 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
6% GENTRAN 75 AND 10% TRAVERT
TRAVENOL LABS 6GM/100ML;10GM/100ML; N08788
0.9GM/100ML

UROKINASE

INJECTABLE; INJECTION
BREOKINASE
STERLING DRUG 250,000 IU/VIAL N17873

ORPHAN DRUG PRODUCT DESIGNATIONS

SECTION 526 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT CONTAINS PROVISIONS WHEREBY FDA MAY DESIGNATE A SPONSOR'S DRUG, ANTIBIOTIC, OR BIOLOGICAL PRODUCT AS A "DESIGNATED ORPHAN DRUG." SECTION 527 OF THE ACT ESTABLISHES A PROCESS WHEREBY A SPONSOR MAY RECEIVE SEVEN YEARS OF EXCLUSIVE APPROVAL STATUS IF THAT SPONSOR IS THE FIRST TO ACHIEVE NEW DRUG, ANTIBIOTIC, OR BIOLOGICAL PRODUCT APPROVAL FOR A DESIGNATED ORPHAN DRUG FOR THE DESIGNATED INDICATION(S). THE EXCLUSIVE APPROVAL MAY BE REVOKED BY WRITTEN CONSENT OF THE SPONSOR OR BY FDA ACTION AFTER FINDING THAT THE SPONSOR HOLDING EXCLUSIVE APPROVAL CANNOT ASSURE THE AVAILABILITY OF SUFFICIENT QUANTITIES OF THE DRUG TO MEET THE NEEDS OF PATIENTS WITH THE DESIGNATED ORPHAN INDICATION(S).

WHEN A PRODUCT IS GRANTED ORPHAN DRUG DESIGNATION, IT WILL APPEAR IN THIS SECTION. ONCE A BIOLOGICAL OR DRUG PRODUCT IS LICENSED/APPROVED FOR MARKETING, IT WILL BE LISTED IN THIS SECTION AND ASTERISKED, AS APPROPRIATE, TO DENOTE MARKETING/EXCLUSIVE APPROVAL STATUS. IN ADDITION, THE EXCLUSIVITY EXPIRATION DATE WILL BE DISPLAYED FOLLOWING THE APPROVED DESIGNATED INDICATION(S).

THE FOLLOWING DRUGS AND BIOLOGICALS HAVE BEEN GRANTED ORPHAN DRUG DESIGNATION PURSUANT TO SECTION 526 OF THE FOOD, DRUG, AND COSMETIC ACT AS AMENDED BY THE ORPHAN DRUG ACT [PUBLIC LAW 97-414].

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS
[Approved for Marketing*]
[Exclusive Approval**]

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: AI-RSA TRADE: NOT ESTABLISHED	TREATMENT OF AUTOIMMUNE UVEITIS.	AUTOIMMUNE, INC
GENERIC: ALDESLEUKIN TRADE: PROLEUKIN*/**	TREATMENT OF PRIMARY IMMUNODEFICIENCY DISEASE ASSOCIATED WITH T-CELL DEFECTS.*/** [MAY 05, 1999]	CETUS
GENERIC: ANANAIN, COMOSAIN TRADE: VIANAIN	FOR THE ENZYMATIC DEBRIDEMENT OF SEVERE BURNS.	GENZYME CORPORATION
GENERIC: ANTIHEMOPHILIC FACTOR, HUMAN TRADE: HUMATE P	TREATMENT OF PATIENTS WITH VON WILLEBRAND'S DISEASE.	BEHRINGWERKE AKTIENGESELLSCHAFT
GENERIC: ANTITHROMBIN III TRADE: THROMBATE III*/**	USE AS REPLACEMENT THERAPY IN CONGENITAL DEFICIENCY OF ANTITHROMBIN-III FOR PREVENTION AND TREATMENT OF OF THROMBOSIS AND PULMONARY EMBOLI. [DEC 13, 1996]	CUTTER BIOLOGICAL

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: BOTULINUM TOXIN TYPE A TRADE: NOT ESTABLISHED	TREATMENT OF SYNKINETIC CLOSURE OF THE EYELID ASSOCIATED WITH VII CRANIAL NERVE ABERRANT REGENERATION.	BIOPURE CORPORATION
GENERIC: BOTULINUM TOXIN TYPE B TRADE: NOT ESTABLISHED	TREATMENT OF CERVICAL DYSTONIA.	ATHENA NEUROSCIENCES, INC
GENERIC: CILIARY NEUROTROPHIC FACTOR TRADE: NOT ESTABLISHED	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS.	ROGENERON PHARMACEUTICALS, INC
GENERIC: CILIARY NEUROTROPHIC FACTOR, RECOMBINANT HUMAN TRADE: NOT ESTABLISHED	TREATMENT OF SPINAL MUSCULAR ATROPHIES. TREATMENT OF MOTOR NEURON DISEASE (INCLUDING AMYOTROPHIC LATERAL SCLEROSIS, PROGRESSIVE MUSCULAR ATROPHY, PROGRESSIVE BULBAR PALSY, AND PRIMARY LATERAL SCLEROSIS).	SYNTEX-SYNERGEN NEUROSCIENCE
GENERIC: COAGULATION FACTOR IX TRADE: MONONINE*/**	REPLACEMENT TREATMENT AND PROPHYLAXIS OF THE HEMORRHAGIC COMPLICATIONS OF HEMOPHILIA B. [AUG 20, 1999]	ARMOUR PHARMACEUTICAL
GENERIC: CYSTIC FIBROSIS GENE THERAPY TRADE: NOT ESTABLISHED	TREATMENT OF CYSTIC FIBROSIS.	GENZYME CORPORATION
GENERIC: CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR TRADE: NOT ESTABLISHED	FOR CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN REPLACEMENT THERAPY IN CYSTIC FIBROSIS PATIENTS.	GENZYME CORPORATION
GENERIC: C1-ESTERASE INHIBITOR, HUMAN, PASTEURIZED TRADE: NOT ESTABLISHED	PREVENTION AND/OR TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA.	BEHRINGWERKE AKTIENGESELLSCHAFT

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: HERPES SIMPLEX VIRUS GENE TRADE: NOT ESTABLISHED	TREATMENT OF PRIMARY AND METASTATIC BRAIN TUMORS.	GENETIC THERAPY, INC
GENERIC: HIV NEUTRALIZING ANTIBODIES TRADE: IMMUPATH	TREATMENT OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS).	HEMACARE CORPORATION
GENERIC: HUMAN IMMUNODEFICIENCY VIRUS IMMUNE GLOBULIN TRADE: NOT ESTABLISHED	TREATMENT OF HIV-INFECTED PREGNANT WOMEN AND INFANTS OF HIV-INFECTED MOTHERS.	ABBOTT LABORATORIES
GENERIC: IMMUNE GLOBULIN INTRAVENOUS, HUMAN TRADE: IVEEGAM, IMMUNO	TREATMENT OF POLYMYOSITIS/DERMATOMYOSITIS.	IMMUNO CLINICAL RESEARCH CORPORATION
GENERIC: IMPORTED FIRE ANT VENOM, ALLERGENIC EXTRACT TRADE: NOT ESTABLISHED	FOR SKIN TESTING OF VICTIMS OF FIRE ANT STINGS TO CONFIRM FIRE ANT SENSITIVITY AND IF POSITIVE, FOR USE AS IMMUNOTHERAPY FOR THE PREVENTION OF IgE-MEDIATED ANAPHYLACTIC REACTIONS.	ALK LABORATORIES, INC
GENERIC: INTERFERON (RECOMBINANT HUMAN, BETA) TRADE: NOT ESTABLISHED	TREATMENT OF ACUTE NON-A, NON-B HEPATITIS.	BIOGEN, INC
GENERIC: INTERLEUKIN-1 RECEPTOR ANTAGONIST, HUMAN RECOMBINANT TRADE: ANTRIL	PREVENTION AND TREATMENT OF GRAFT VERSUS HOST DISEASE IN TRANSPLANT RECIPIENTS.	SYNERGEN, INC
GENERIC: PROTEIN C CONCENTRATE TRADE: PROTEIN C CONCENTRATE (HUMAN) VAPOR HEATED, IMMUNO	FOR REPLACEMENT THERAPY IN PATIENTS WITH CONGENITAL OR ACQUIRED PROTEIN C DEFICIENCY FOR THE PREVENTION AND TREATMENT OF WARFARIN-INDUCED SKIN NECROSIS DURING ORAL ANTICOAGULATION. FOR REPLACEMENT THERAPY IN CONGENITAL PROTEIN C DEFICIENCY FOR THE PREVENTION AND TREATMENT OF THROMBOSIS, PULMONARY EMBOLI, AND PURPURA FULMINANS.	IMMUNO CLINICAL RESEARCH CORPORATION

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: SARGRAMOSTIM TRADE: LEUKINE*/**	TREATMENT OF NEUTROPENIA ASSOCIATED WITH BONE MARROW TRANSPLANT, FOR THE PROMOTION OF EARLY ENGRAFTMENT, AND FOR THE TREATMENT OF GRAFT FAILURE AND DELAY OF ENGRAFTMENT.*/** [DEC 31, 1998] TREATMENT OF NEUTROPENIA ASSOCIATED WITH BONE MARROW TRANSPLANTS IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA, HODGKIN'S DISEASE AND ACUTE LYMPHOBLASTIC LEUKEMIA.*/** [MAR 05, 1998]	IMMUNEX
GENERIC: SECRETORY LEUKOCYTE PROTEASE INHIBITOR TRADE: NOT ESTABLISHED	TREATMENT OF BRONCHOPULMONARY DYSPLASIA.	SYNERGEN, INC
GENERIC: TECHNETIUM TC99M MURINE MONOCLONAL ANTIBODY (IGG2A) TO BCE TRADE: IMMURAID-LL-2[99mTc]	DIAGNOSTIC IMAGING IN THE EVALUATION OF THE EXTENT OF DISEASE IN PATIENTS WITH HISTOLOGICALLY CONFIRMED DIAGNOSIS OF NON-HODGKIN'S B-CELL LYMPHOMA, ACUTE B-CELL LYMPHOBLASTIC LEUKEMIA (IN CHILDREN AND ADULTS), AND CHRONIC B-CELL LYMPHOCYTIC LEUKEMIA.	IMMUNOMEDICS, INC

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS
[Approved for Marketing*]
[Exclusive Approval**]

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: ALLOPURINOL SODIUM TRADE: ZYLOPRIM FOR INJECTION	MANAGEMENT OF PATIENTS WITH LEUKEMIA, LYMPHOMA, AND SOLID TUMOR MALIGNANCIES WHO ARE RECEIVING CANCER THERAPY WHICH CAUSES ELEVATIONS OF SERUM AND URINARY URIC ACID LEVELS AND WHO CANNOT TOLERATE ORAL THERAPY.	BURROUGHS WELLCOME COMPANY
GENERIC: ANARITIDE ACETATE TRADE: AURICULIN	IMPROVEMENT OF EARLY RENAL ALLOGRAFT FUNCTION FOLLOWING RENAL TRANSPLANTATION. TREATMENT OF PATIENTS WITH ACUTE RENAL FAILURE.	SCIOS, INC
GENERIC: ARGININE BUTYRATE TRADE: NOT ESTABLISHED	TREATMENT OF BETA-HEMOGLOBINOPATHIES AND BETA-THALASSEMIA.	SUSAN P. PERRINE, M.D.
GENERIC: BACLOFEN (INTRATHECAL) TRADE: LIORESAL	TREATMENT OF INTRACTABLE SPASTICITY CAUSED BY SPINAL CORD INJURY, MULTIPLE SCLEROSIS, AND OTHER SPINAL DISEASES (INCLUDING SPINAL ISCHEMIA, SPINAL TUMOR, TRANSVERSE MYELITIS, CERVICAL SPONDYLOSIS, AND DEGENERATIVE MYELOPATHY.	MEDTRONIC, INC
GENERIC: BUTYRYLCHOLINESTERASE TRADE: NOT ESTABLISHED	FOR THE REDUCTION AND CLEARANCE OF TOXIC BLOOD LEVELS OF COCAINE ENCOUNTERED DURING A DRUG OVERDOSE. TREATMENT OF POST-SURGICAL APNEA.	PHARMAVENE, INCORPORATED
GENERIC: DAPSONE TRADE: DAPSONE	FOR THE COMBINATION TREATMENT OF PNEUMOCYSTIS CARINII PNEUMONIA IN CONJUNCTION WITH TRIMETHOPRIM.	JACOBUS PHARMACEUTICAL COMPANY
GENERIC: DIANEAL PD-2 PERITONEAL DIALYSIS SOLN WITH 1.1% AMINO ACIDS TRADE: NUTRINEAL PD-2 PERITONEAL DIALYSIS SOLN WITH 1.1% AMINO ACIDS	FOR USE AS A NUTRITIONAL SUPPLEMENT FOR THE TREATMENT OF MALNOURISHMENT IN PATIENTS UNDERGOING CONTINUOUS AMBULATORY PERITONEAL DIALYSIS.	BAXTER HEALTHCARE CORPORATION
GENERIC: DIAZEPAM VISCOUS SOLUTION FOR RECTAL ADMINISTRATION TRADE: DIASTAT	TREATMENT OF ACUTE REPETITIVE SEIZURES.	UPSHER SMITH LABORATORIES, INC
GENERIC: FIAU TRADE: NOT ESTABLISHED	ADJUNCTIVE TREATMENT OF CHRONIC ACTIVE HEPATITIS B.	OCLASSEN PHARMACEUTICALS, INC

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: HALOFANTRINE HCL TRADE: HALFAN*/**	TREATMENT OF MILD TO MODERATE ACUTE MALARIA CAUSED BY SUSCEPTIBLE STRAINS OF P. FALCIPARUM AND P. VIVAX. [JUL 24, 1999]	SMITHKLINE BEECHAM
GENERIC: HUMAN THYROID STIMULATING HORMONE (TSH) TRADE: THYROGEN	AS AN ADJUNCT IN THE DIAGNOSIS OF THYROID CANCER.	GENZYME CORPORATION
GENERIC: L-BACLOFEN TRADE: NEURALGON	TREATMENT OF INTRACTABLE SPASTICITY IN CHILDREN WITH CEREBRAL PALSY.	WTD, INC
GENERIC: L-THREONINE TRADE: NOT ESTABLISHED	TREATMENT OF SPASTICITY ASSOCIATED WITH FAMILIAL SPASTIC PARAPARESIS.	INTERNEURON PHARMACEUTICALS, INC
GENERIC: LEVOCARNITINE TRADE: CARNITOR*/**	GENETIC CARNITINE DEFICIENCY.* TREATMENT OF MANIFESTATIONS OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE (ESRD) WHO REQUIRE DIALYSIS. PREVENTION OF SECONDARY CARNITINE DEFICIENCY IN VALPROIC ACID TOXICITY. TREATMENT OF SECONDARY CARNITINE DEFICIENCY IN VALPROIC ACID TOXICITY.	SIGMA TAU
GENERIC: LIOTHYRONINE SODIUM TRADE: TRIOSTAT*/**	TREATMENT OF MYXEDEMA COMA/PRE-COMA. [DEC 31, 1998]	SMITHKLINE BEECHAM
GENERIC: LOXORIBINE TRADE: NOT ESTABLISHED	TREATMENT OF COMMON VARIABLE IMMUNODEFICIENCY.	R.W. JOHNSON RESEARCH INSTITUTE
GENERIC: MELPHALAN TRADE: ALKERAN FOR INJECTION	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA FOR WHOM ORAL THERAPY IS INAPPROPRIATE. FOR USE IN HYPERTHERMIC REGIONAL LIMB PERFUSION TO TREAT METASTATIC MELANOMA OF THE EXTREMITY.	BURROUGHS WELLCOME COMPANY
GENERIC: MINOCYCLINE HCL TRADE: MINOCIN	TREATMENT OF CHRONIC MALIGNANT PLEURAL EFFUSION.	LEDERLE LABORATORIES
GENERIC: OXALIPLATIN TRADE: NOT ESTABLISHED	TREATMENT OF OVARIAN CANCER.	AXION PHARMACEUTICALS

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: PAPAVERINE (TOPICAL GEL) TRADE: NOT ESTABLISHED	TREATMENT OF SEXUAL DYSFUNCTION IN SPINAL CORD INJURY PATIENTS.	PHARMEDIC COMPANY
GENERIC: PARA-AMINOSALICYLIC ACID TRADE: NOT ESTABLISHED	TREATMENT OF TUBERCULOSIS INFECTIONS.	JACOBUS PHARMACEUTICAL COMPANY
GENERIC: PILOCARPINE HCL TRADE: NOT ESTABLISHED	TREATMENT OF XEROSTOMIA AND KERATOCONJUNCTIVITIS SICCA IN SJOGREN'S SYNDROME PATIENTS.	MGI PHARMA, INC
GENERIC: POLYMERIC OXYGEN TRADE: NOT ESTABLISHED	TREATMENT OF SICKLE CELL ANEMIA.	CAPMED, USA
GENERIC: PPI-002 TRADE: NOT ESTABLISHED	TREATMENT OF MALIGNANT MESOTHELIOMA.	PLEXUS PHARMACEUTICALS, INC
GENERIC: SODIUM MONOMERCAPTOUNDECAHYDRO-CLOSODODECABORATE TRADE: BOROCELL	FOR USE IN BORON NEUTRON CAPTURE THERAPY IN THE TREATMENT OF GLIOBLASTOMA MULTIFORME.	NEUTRON TECHNOLOGY CORPORATION
GENERIC: SODIUM PHENYLBUTYRATE TRADE: NOT ESTABLISHED	TREATMENT OF SICKLING DISORDERS, WHICH INCLUDE S-S HEMOGLOBINOPATHY, S-C HEMOGLOBINOPATHY, AND S-THALASSEMIA HEMOGLOBINOPATHY.	JOHNS HOPKINS MEDICAL INSTITUTIONS
GENERIC: TENIPOSIDE TRADE: VUMON*/**	TREATMENT OF REFRACTORY CHILDHOOD ACUTE LYMPHOCYTIC LEUKEMIA (ALL). [JUL 14, 1999]	BRISTOL MYERS SQUIBB
GENERIC: ZALCITABINE TRADE: HIVID	TREATMENT OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS). [JUN 19, 1999]	ROCHE
GENERIC: 9-CIS RETINOIC ACID TRADE: NOT ESTABLISHED	TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA.	LIGAND PHARMACUETICALS, INC

DRUG PRODUCTS WHICH MUST DEMONSTRATE IN VIVO BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO OCTOBER 1992 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR IN VIVO BIOEQUIVALENCE STUDIES AND IN VITRO DISSOLUTION TESTING AVAILABLE FROM THE DIVISION OF BIOEQUIVALENCE, HFD-650, MPN-2 ROOM 279, 5600 FISHERS LANE, ROCKVILLE, MD 20857. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 12TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE
CARBIDOPA AND LEVODOPA (TABLET)	JUN 19, 1992	
CIMETIDINE (TABLET)	JUN 12, 1992	
CORTICOSTEROID *IN VITRO* AND *IN VIVO* INTERIM (TOPICAL)	JUL 01, 1992	
DIFLUNISAL (TABLET)	MAY 16, 1992	
DILTIAZEM HYDROCHLORIDE (TABLET)	MAY 16, 1992	
GEMFIBROZIL (CAPSULE AND TABLET)	JUN 23, 1989	JUN 15, 1992
METOPROLOL TARTRATE (TABLET)	JUN 12, 1992	
NADOLOL (TABLET)	MAY 16, 1992	
NAPROXEN (TABLET)	JUN 12, 1992	
NORTRIPTYLINE HYDROCHLORIDE (CAPSULE)	JUN 15, 1992	
PIROXICAM (CAPSULE)	JUN 15, 1992	
STATISTICAL PROCEDURE FOR BIOEQUIVALENCE STUDIES USING A STANDARD TWO-TREATMENT CROSSOVER DESIGN	JUL 01, 1992	
TERFENADINE (TABLET)	JUN 12, 1992	

ANDA SUITABILITY PETITIONS

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 4-62, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 12TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
ACETAMINOPHEN; CODEINE PHOSPHATE TABLET; ORAL	500MG 7.5MG	91 P-0514/ CP1	SOFTAN	NEW STRENGTH	APPROVED JUN 03, 1992
ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET; ORAL	660MG 10MG	91 P-0004/ CP1	KNOLL	NEW STRENGTH	APPROVED OCT 27, 1992
ALBUTEROL SULFATE CAPSULE, EXTENDED RELEASE; ORAL	EQ 4MG BASE	91 P-0348/ CP1	HAMER	NEW DOSAGE FORM	APPROVED MAR 17, 1992
CHLORZOXAZONE TABLET; ORAL	750MG	91 P-0153/ CP1	MIKART	NEW STRENGTH	APPROVED JUN 03, 1992
CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER INJECTABLE; INJECTION	EQ 90MG BASE/100ML EQ 120MG BASE/100ML EQ 180MG BASE/100ML EQ 240MG BASE/100ML EQ 360MG BASE/100ML EQ 480MG BASE/100ML	92 P-0337/ CP1	ABBOTT	NEW STRENGTH	APPROVED OCT 26, 1992
HYDROCORTISONE ACETATE AEROSOL; TOPICAL	2.5%	92 P-0101/ CP1	HOGAN & HARTSON	NEW DOSAGE FORM	APPROVED JUL 08, 1992
NALBUPHINE HYDROCHLORIDE INJECTABLE; INJECTION	10MG/ML (2ML/CONTAINER)	92 P-0224/CP	STERLING	NEW STRENGTH	APPROVED SEP 11, 1992

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
NITROGLYCERIN IN DEXTROSE 5% INJECTABLE; INJECTION	5MG/ML (50ML/CONTAINER)	91 P-0387/ CP1	ABBOTT	NEW STRENGTH	APPROVED FEB 18, 1992
NITROGLYCERIN IN DEXTROSE 5% INJECTABLE; INJECTION	10MG/ML (100ML/CONTAINER)	91 P-0387/ CP1	ABBOTT	NEW STRENGTH	APPROVED FEB 18, 1992
TAMOXIFEN CITRATE TABLET; ORAL	EQ 20MG BASE	92 P-0269/ CP1	KROSS	NEW STRENGTH	APPROVED OCT 26, 1992
TRIAZOLAM SOLUTION; ORAL	0.125MG/5ML	92 P-0048/ CP2	ROXANE	NEW DOSAGE FORM	APPROVED SEP 11, 1992

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
ETOPOSIDE INJECTABLE; INJECTION	20MG/ML (50ML/VIAL)	91 P-0076/ CP1	ADRIA	NEW STRENGTH	DENIED FEB 19, 1992

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 12TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES
NEW DOSING SCHEDULE

D-18	LOWER RECOMMENDED STARTING DOSE GUIDELINES

REFERENCES
NEW INDICATION

I-67	TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER
I-68	CENTRAL PRECOCIOUS PUBERTY
I-69	SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY
I-70	USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER
I-71	VARICELLA INFECTIONS (CHICKENPOX)
I-72	PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE
I-73	INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES
I-74	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-75	TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS
I-76	PREVENTION OF OSTEOPOROSIS
I-77	DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM
I-78	CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY
I-79	MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM
I-80	DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE
I-81	PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS

REFERENCES
PATENT USE CODE

U-57	OPHTHALMIC USE OF NORFLOXACIN
U-58	METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES
U-59	METHOD OF TREATING HYPERCHOLESTEROLEMIA

EXCLUSIVITY TERMS

REFERENCES
PATENT USE CODE

U-60	NASAL ADMINISTRATION OF BUTORPHANOL
U-61	CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD
U-62	CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY
U-63	ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE
U-64	TREATMENT OF VIRAL INFECTIONS
U-65	METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
U-66	TRIPHASIC REGIMEN
U-67	METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL
U-68	TREATMENT OF ACTINIC KERATOSIS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20232 001	ACETAMINOPHEN; FIORICET W/ CODEINE				NC	OCT 26, 1993
	18828 001	ACYCLOVIR; ZOVIRAX				I-71	FEB 26, 1995
	19909 001	ACYCLOVIR; ZOVIRAX				I-71	FEB 26, 1995
	20089 001	ACYCLOVIR; ZOVIRAX				I-71	FEB 26, 1995
	20089 002	ACYCLOVIR; ZOVIRAX				I-71	FEB 26, 1995
>ADD>	19729 001	AMCINONIDE; CYCLOCORT	4158055	JUN 12, 1996	U-19		
>DLT>	~~19729 001~~	~~AMCINONIDE; CYCLOCORT~~	~~4158055~~	~~JUN 12, 1996~~	~~U-34~~		
	19787 001	AMLODIPINE BESYLATE; NORVASC	4572909	FEB 25, 2003		NCE	JUL 31, 1997
	19787 002	AMLODIPINE BESYLATE; NORVASC	4572909	FEB 25, 2003		NCE	JUL 31, 1997
	19787 003	AMLODIPINE BESYLATE; NORVASC	4572909	FEB 25, 2003		NCE	JUL 31, 1997
>DLT>	~~18760 001~~	~~ATENOLOL; TENORETIC~~	~~3934032~~	~~JAN 20, 1993~~			
>DLT>	~~18760 002~~	~~ATENOLOL; TENORETIC~~	~~3934032~~	~~JAN 20, 1993~~			
	20075 001	BACLOFEN; LIORESAL				ODE	JUN 17, 1999
						NDF	JUN 17, 1995
	20075 002	BACLOFEN; LIORESAL				ODE	JUN 17, 1999
						NDF	JUN 17, 1995
	19851 001	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2002		NCE	JUN 25, 1996
	19851 002	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2002		NCE	JUN 25, 1996
	19851 003	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2002		NCE	JUN 25, 1996
	19851 004	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2002		NCE	JUN 25, 1996
	20033 001	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	OCT 18, 2002		NCE	JUN 25, 1996
						NC	MAY 19, 1995
	20033 002	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	OCT 18, 2002		NCE	JUN 25, 1996
						NC	MAY 19, 1995
	20033 003	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	OCT 18, 2002		NCE	JUN 25, 1996
						NC	MAY 19, 1995
	20033 004	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	OCT 18, 2002		NCE	JUN 25, 1996
						NC	MAY 19, 1995
	19001 001	BEPRIDIL HYDROCHLORIDE; BEPADIN	RE30577	JUN 08, 1995		NCE	DEC 28, 1995
	19001 002	BEPRIDIL HYDROCHLORIDE; BEPADIN	RE30577	JUN 08, 1995		NCE	DEC 28, 1995
	19001 003	BEPRIDIL HYDROCHLORIDE; BEPADIN	RE30577	JUN 08, 1995		NCE	DEC 28, 1995
	19002 001	BEPRIDIL HYDROCHLORIDE; VASCOR	RE30577	JUN 08, 1995		NCE	DEC 28, 1995
	19002 002	BEPRIDIL HYDROCHLORIDE; VASCOR	RE30577	JUN 08, 1995		NCE	DEC 28, 1995
	19002 003	BEPRIDIL HYDROCHLORIDE; VASCOR	RE30577	JUN 08, 1995		NCE	DEC 28, 1995
>ADD>	19807 001	BETAXOLOL HYDROCHLORIDE; KERLEDEX				NC	OCT 30, 1995
>ADD>	19807 002	BETAXOLOL HYDROCHLORIDE; KERLEDEX				NC	OCT 30, 1995

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19982 001	BISOPROLOL FUMARATE; ZEBETA	4258062	MAR 24, 1998	U-63	NCE	JUL 31, 1997
	19982 002	BISOPROLOL FUMARATE; ZEBETA	4258062	MAR 24, 1998	U-63	NCE	JUL 31, 1997
	19548 001	BITOLTEROL MESYLATE; TORNALATE	4336400	JUN 22, 1999	U-5		
			4138581	FEB 06, 1998		NDF	FEB 19, 1995
	19890 001	BUTORPHANOL TARTRATE; STADOL	4464378	AUG 07, 2001	U-60	NDF	DEC 12, 1994
	19847 001	CIPROFLOXACIN; CIPRO	4808583	FEB 28, 2006			
			4705789	NOV 10, 2004			
			4670444	OCT 01, 2002		NCE	OCT 22, 1992
	19857 001	CIPROFLOXACIN; CIPRO IN DEXTROSE 5%	4957922	SEP 18, 2007			
			4808583	FEB 28, 2006			
			4705789	NOV 10, 2004			
			4670444	OCT 01, 2002		NCE	OCT 22, 1992
	19858 001	CIPROFLOXACIN; CIPRO IN SODIUM CHLORIDE 0.9%	4957922	SEP 18, 2007			
			4808583	FEB 28, 2006			
			4705789	NOV 10, 2004			
			4670444	OCT 01, 2002		NCE	OCT 22, 1992
	19537 002	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	OCT 01, 2002	U-36	NCE	OCT 22, 1992
	19537 003	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	OCT 01, 2002	U-36	NCE	OCT 22, 1992
	19537 004	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	OCT 01, 2002	U-36	NCE	OCT 22, 1992
	19992 001	CIPROFLOXACIN HYDROCHLORIDE; CILOXAN	4670444	OCT 01, 2002		NDF	DEC 31, 1993
>ADD>	18713 001	CLOTRIMAZOLE; MYCELEX				I-81	SEP 29, 1995
	20118 001	DESFLURANE; SUPRANE	4762856	AUG 09, 2005	U-67	NCE	SEP 18, 1997
	20037 001	DICLOFENAC SODIUM; VOLTAREN	4960799	OCT 02, 2007		NDF	MAR 28, 1994
>ADD>	20154 002	DIDANOSINE; VIDEX				D-18	SEP 25, 1995
>ADD>	20154 003	DIDANOSINE; VIDEX				D-18	SEP 25, 1995
>ADD>	20154 004	DIDANOSINE; VIDEX				D-18	SEP 25, 1995
>ADD>	20154 005	DIDANOSINE; VIDEX				D-18	SEP 25, 1995
>ADD>	20155 003	DIDANOSINE; VIDEX				D-18	SEP 25, 1995
>ADD>	20155 004	DIDANOSINE; VIDEX				D-18	SEP 25, 1995
>ADD>	20155 005	DIDANOSINE; VIDEX				D-18	SEP 25, 1995
>ADD>	20155 006	DIDANOSINE; VIDEX				D-18	SEP 25, 1995
>ADD>	20156 001	DIDANOSINE; VIDEX				D-18	SEP 25, 1995
	20027 001	DILTIAZEM HYDROCHLORIDE; CARDIZEM				NCE	NOV 05, 1992
	20027 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM				NCE	NOV 05, 1992

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20062 001	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5002776	MAR 26, 2008		NCE	NOV 05, 1992
			4894240	JAN 16, 2007		NS	MAY 29, 1995
>ADD>						I-79	OCT 15, 1995
	20062 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5002776	MAR 26, 2008		NCE	NOV 05, 1992
			4894240	JAN 16, 2007		NP	DEC 27, 1994
>ADD>						I-79	OCT 15, 1995
	20062 003	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5002776	MAR 26, 2008		NCE	NOV 05, 1992
			4894240	JAN 16, 2007		NP	DEC 27, 1994
>ADD>						I-79	OCT 15, 1995
	20062 004	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5002776	MAR 26, 2008		NCE	NOV 05, 1992
			4894240	JAN 16, 2007		NP	DEC 27, 1994
>ADD>						I-79	OCT 15, 1995
	20092 001	DILTIAZEM HYDROCHLORIDE; DILACOR XR	4839177	JUN 13, 2006		NS	MAY 29, 1995
						NCE	NOV 05, 1992
	20092 002	DILTIAZEM HYDROCHLORIDE; DILACOR XR	4839177	JUN 13, 2006		NP	DEC 27, 1994
						NCE	NOV 05, 1992
	20092 003	DILTIAZEM HYDROCHLORIDE; DILACOR XR	4839177	JUN 13, 2006		NP	DEC 27, 1994
						NCE	NOV 05, 1992
	19946 001	DOXACURIUM CHLORIDE; NUROMAX	4701460	MAR 06, 2005		NCE	MAR 07, 1996
	84499 001	ESTRADIOL; ESTRACE				I-76	SEP 08, 1995
	84500 001	ESTRADIOL; ESTRACE				I-76	SEP 08, 1995
	19697 001	ETHINYL ESTRADIOL; ORTHO TRI-CYCLEN	4628051	OCT 01, 2002	U-66		
			4616006	OCT 07, 2003	U-66		
			4544554	JUL 23, 2002	U-66		
			4027019	MAY 31, 1996		NP	JUL 03, 1995
	19697 002	ETHINYL ESTRADIOL; ORTHO TRI-CYCLEN	4628051	OCT 01, 2002	U-66		
			4616006	OCT 07, 2003	U-66		
			4544554	JUL 23, 2002	U-66		
			4027019	MAY 31, 1996		NP	JUL 03, 1995
	19462 001	FAMOTIDINE; PEPCID	4283408	AUG 11, 2000		I-69	DEC 10, 1994
	19462 002	FAMOTIDINE; PEPCID	4283408	AUG 11, 2000		I-69	DEC 10, 1994
	19527 001	FAMOTIDINE; PEPCID	4283408	AUG 11, 2000		I-69	DEC 10, 1994
	19834 001	FELODIPINE; PLENDIL	4264611	APR 28, 1998		NCE	JUL 25, 1996
	19834 002	FELODIPINE; PLENDIL	4264611	APR 28, 1998		NCE	JUL 25, 1996
	20180 001	FINASTERIDE; PROSCAR	4760071	JUL 26, 2005			
			4377584	MAR 22, 2000		NCE	JUN 19, 1997
	20038 001	FLUDARABINE PHOSPHATE; FLUDARA	4357324	NOV 02, 2001		NCE	APR 18, 1996

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20101 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4626549	DEC 02, 2003			
		4194009	APR 19, 1994			
20068 001	FOSCARNET SODIUM; FOSCAVIR	4018895	APR 19, 1994	U-12		
		4771041	JUL 29, 1997			
		4665062	JUL 29, 1997			
19915 002	FOSINOPRIL SODIUM; MONOPRIL	4339445	JUL 29, 1997	U-64		
		4215113	JUL 29, 1997	U-64	NCE	SEP 27, 1996
19915 003	FOSINOPRIL SODIUM; MONOPRIL	4337201	JUN 29, 2001		NCE	MAY 16, 1996
19661 001	GANCICLOVIR SODIUM; CYTOVENE	4337201	JUN 29, 2001		NCE	MAY 16, 1996
20051 001	GLYBURIDE; GLYNASE	4507305	OCT 19, 1999	U-35	I-72	MAY 15, 1995
		4916163	APR 10, 2007			
		4735805	APR 05, 2005		NCE	MAY 01, 1994
		3507961	APR 21, 1992		NP	MAR 04, 1995
		3507954	APR 21, 1992			
		3454635	APR 21, 1992			
		3426067	APR 21, 1992			
20051 002	GLYBURIDE; GLYNASE	4916163	APR 10, 2007			
		4735805	APR 05, 2005		NCE	MAY 01, 1994
		3507961	APR 21, 1992		NP	MAR 04, 1995
		3507954	APR 21, 1992			
		3454635	APR 21, 1992			
		3426067	APR 21, 1992			
20055 001	GLYBURIDE; GLUBATE				NP	MAR 04, 1995
					NCE	MAY 01, 1994
20055 002	GLYBURIDE; GLUBATE				NP	MAR 04, 1995
					NCE	MAY 01, 1994
19967 001	HALOBETASOL PROPIONATE; ULTRAVATE				D-1	DEC 31, 1994
19968 001	HALOBETASOL PROPIONATE; ULTRAVATE				D-1	DEC 31, 1994
20250 001	HALOFANTRINE HYDROCHLORIDE; HALFAN				NCE	JUL 24, 1997
					ODE	JUL 24, 1999
19046 001	HYDROCHLOROTHIAZIDE; NORMOZIDE	4012444	MAR 15, 1994		NCE	AUG 01, 1994
19046 002	HYDROCHLOROTHIAZIDE; NORMOZIDE	4012444	MAR 15, 1994		NCE	AUG 01, 1994
19046 003	HYDROCHLOROTHIAZIDE; NORMOZIDE	4012444	MAR 15, 1994		NCE	AUG 01, 1994
19046 004	HYDROCHLOROTHIAZIDE; NORMOZIDE	4012444	MAR 15, 1994		NCE	AUG 01, 1994

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19174 001	HYDROCHLOROTHIAZIDE; TRANDATE HCT	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19174 002	HYDROCHLOROTHIAZIDE; TRANDATE HCT	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19174 003	HYDROCHLOROTHIAZIDE; TRANDATE HCT	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19174 004	HYDROCHLOROTHIAZIDE; TRANDATE HCT	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19261 001	HYDROXYAMPHETAMINE HYDROBROMIDE; PAREMYD				NC	JAN 30, 1995
	20100 001	INSULIN BIOSYNTHETIC HUMAN; HUMULIN 50/50				NP	APR 29, 1995
>ADD>	18735 007	IOPAMIDOL; ISOVUE-250				NS	JUL 06, 1995
>ADD>	19710 002	IOVERSOL; OPTIRAY 240				I-78	JUL 09, 1995
	19710 004	IOVERSOL; OPTIRAY 300	4396598	OCT 26, 2002	U-61	NS	JAN 22, 1995
	19710 005	IOVERSOL; OPTIRAY 350	4396598	OCT 26, 2002	U-62	NS	JAN 22, 1995
						I-74	JAN 22, 1995
	20083 001	ITRACONAZOLE; SPORANOX	4267179	MAY 12, 1998		NCE	SEP 11, 1997
	19645 001	KETOROLAC TROMETHAMINE; TORADOL	4089969	MAY 16, 1997	U-55	NDF	DEC 20, 1994
						NCE	NOV 30, 1994
	08107 001	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				I-70	DEC 12, 1994
	08107 002	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				I-70	DEC 12, 1994
	08107 004	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				I-70	DEC 12, 1994
	08107 005	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				I-70	DEC 12, 1994
	19732 001	LEUPROLIDE ACETATE; LUPRON DEPOT	4917893	MAR 24, 2004			
			4849228	JUL 18, 2006			
			4728721	MAR 01, 2005			
			4677191	JUN 30, 2004			
			4652441	MAR 24, 2004			
	20011 001	LEUPROLIDE ACETATE; LUPRON DEPOT	4917893	MAR 24, 2004			
			4849228	JUL 18, 2006			
			4728721	MAR 01, 2005			
			4677191	JUN 30, 2004			
			4652441	MAR 24, 2004			
	20105 001	LIOTHYRONINE SODIUM; TRIOSTAT				ODE	DEC 31, 1998
	20013 001	LOMEFLOXACIN HYDROCHLORIDE; MAXAQUIN	4528287	JUL 09, 2002	U-36	NCE	FEB 21, 1997
	19940 001	MASOPROCOL; ACTINEX	5008294	APR 15, 2008	U-68		
			4695590	SEP 22, 2004		NCE	SEP 04, 1997
>ADD>	20246 001	MEDROXYPROGESTERONE ACETATE; DEPO-PROVERA				NP	OCT 29, 1995
	19651 001	MESALAMINE; ASACOL				NCE	DEC 24, 1992
						NDF	JAN 31, 1995
	17659 001	METAPROTERENOL SULFATE; ALUPENT				I-67	NOV 14, 1994

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19962 001	METOPROLOL SUCCINATE; TOPROL XL	3998790	APR 08, 1992		NE	JAN 10, 1995
		3876802	APR 08, 1992			
19962 002	METOPROLOL SUCCINATE; TOPROL XL	3998790	APR 08, 1992		NE	JAN 10, 1995
		3876802	APR 08, 1992			
19962 003	METOPROLOL SUCCINATE; TOPROL XL	3998790	APR 08, 1992		NE	JAN 10, 1995
		3876802	APR 08, 1992			
20208 001	METRONIDAZOLE; METROGEL				NDF	AUG 17, 1995
20098 001	MIVACURIUM CHLORIDE; MIVACRON	4761418	AUG 02, 2005		NCE	JAN 22, 1997
20098 002	MIVACURIUM CHLORIDE; MIVACRON IN DEXTROSE 5%	4761418	AUG 02, 2005		NCE	JAN 22, 1997
19583 001	NABUMETONE; RELAFEN	4420639	DEC 13, 2000		NCE	DEC 24, 1996
		4061779	DEC 06, 1994	U-19		
19583 002	NABUMETONE; RELAFEN	4420639	DEC 13, 2000		NCE	DEC 24, 1996
		4061779	DEC 06, 1994	U-19		
19886 001	NAFARELIN ACETATE; SYNAREL				I-68	FEB 26, 1995
20109 001	NAFARELIN ACETATE; SYNAREL	4234571	NOV 18, 1997		NCE	FEB 13, 1995
					I-68	FEB 26, 1995
19734 001	NICARDIPINE HYDROCHLORIDE; CARDENE	3985758	OCT 12, 1995		NDF	JAN 30, 1995
					NCE	DEC 21, 1993
20005 001	NICARDIPINE HYDROCHLORIDE; CARDENE SR	3985758	OCT 12, 1995		NDF	FEB 21, 1995
					NCE	DEC 21, 1993
20005 002	NICARDIPINE HYDROCHLORIDE; CARDENE SR	3985758	OCT 12, 1995		NDF	FEB 21, 1995
					NCE	DEC 21, 1993
20005 003	NICARDIPINE HYDROCHLORIDE; CARDENE SR	3985758	OCT 12, 1995		NDF	FEB 21, 1995
					NCE	DEC 21, 1993
19983 001	NICOTINE; PROSTEP	4946853	AUG 07, 2007	U-56	NS	JAN 28, 1995
19983 002	NICOTINE; PROSTEP	4946853	AUG 07, 2007	U-56	NS	JAN 28, 1995
20076 001	NICOTINE; HABITROL	5016652	MAY 21, 2008		NDF	NOV 07, 1994
20076 002	NICOTINE; HABITROL	5016652	MAY 21, 2008		NDF	NOV 07, 1994
20076 003	NICOTINE; HABITROL	5016652	MAY 21, 2008		NDF	NOV 07, 1994
20150 001	NICOTINE; NICOTROL				NP	APR 22, 1995
20150 002	NICOTINE; NICOTROL				NP	APR 22, 1995
20150 003	NICOTINE; NICOTROL				NP	APR 22, 1995

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20165 001	NICOTINE; NICODERM	5004610	APR 02, 2008			
			4144317	SEP 09, 1992		NDF	NOV 07, 1994
	20165 002	NICOTINE; NICODERM	5004610	APR 02, 2008			
			4144317	SEP 09, 1992		NDF	NOV 07, 1994
	20165 003	NICOTINE; NICODERM	5004610	APR 02, 2008			
			4144317	SEP 09, 1992		NDF	NOV 07, 1994
	20066 001	NICOTINE POLACRILEX; NICORETTE DS				NP	JUN 08, 1995
	20064 001	NITROFURANTOIN; MACROBID	4798725	JAN 17, 2006			
			4772473	SEP 20, 2005		NDF	DEC 24, 1994
	19757 001	NORFLOXACIN; CHIBROXIN	4551456	NOV 05, 2002	U-57		
	20087 001	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	MAY 10, 2000		NCE	DEC 28, 1995
	20087 002	OFLOXACIN; FLOXIN	4382892	MAY 10, 2000		NCE	DEC 28, 1995
	20087 003	OFLOXACIN; FLOXIN	4382892	MAY 10, 2000		NCE	DEC 28, 1995
	20087 004	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	MAY 10, 2000		NCE	DEC 28, 1995
	20087 005	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	MAY 10, 2000		NCE	DEC 28, 1995
	19715 001	OLSALAZINE SODIUM; DIPENTUM	4559330	AUG 04, 2004	U-58	NCE	JUL 31, 1995
>ADD>	18841 004	OXAPROZIN; DAYPRO				NCE	OCT 29, 1997
	19828 001	OXICONAZOLE NITRATE; OXISTAT				NCE	DEC 30, 1993
>ADD>						I-77	SEP 30, 1995
	20209 001	OXICONAZOLE NITRATE; OXISTAT				NP	SEP 30, 1995
>ADD>						NCE	DEC 30, 1993
	19775 001	PRAZOSIN HYDROCHLORIDE; MINIPRESS XL	5082668	SEP 16, 2003			
			4783337	SEP 16, 2003			
			4765989	SEP 16, 2003			
			4612008	SEP 16, 2003			
			4327725	MAY 04, 1999			
			4092315	MAY 30, 1995		NDF	JAN 29, 1995
	19775 002	PRAZOSIN HYDROCHLORIDE; MINIPRESS XL	5082668	SEP 16, 2003			
			4783337	SEP 16, 2003			
			4765989	SEP 16, 2003			
			4612008	SEP 16, 2003			
			4327725	MAY 04, 1999			
			4092315	MAY 30, 1995		NDF	JAN 29, 1995
	19157 001	PREDNISOLONE SODIUM PHOSPHATE; PEDIAPRED	4448774	MAY 15, 2001			
	19627 001	PROPOFOL; DIPRIVAN	4798846	NOV 01, 1996		I-73	DEC 31, 1994
	18703 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	4521431	JUN 04, 2002		I-75	MAY 19, 1995
	18703 002	RANITIDINE HYDROCHLORIDE; ZANTAC 300	4521431	JUN 04, 2002		I-75	MAY 19, 1995

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19675 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4128658	DEC 05, 1995		I-75	MAY 19, 1995
	19766 001	SIMVASTATIN; ZOCOR	4444784	APR 24, 2001	U-59	NCE	DEC 23, 1997
	19766 002	SIMVASTATIN; ZOCOR	4444784	APR 24, 2001	U-59	NCE	DEC 23, 1997
	19766 003	SIMVASTATIN; ZOCOR	4444784	APR 24, 2001	U-59	NCE	DEC 23, 1997
	19766 004	SIMVASTATIN; ZOCOR	4444784	APR 24, 2001	U-59	NCE	DEC 23, 1997
	20166 001	SODIUM THIOSULFATE; SODIUM THIOSULFATE				NCE	FEB 14, 1997
>ADD>	19865 001	SOTALOL HYDROCHLORIDE; BETAPACE				NCE	OCT 30, 1997
>ADD>	19865 002	SOTALOL HYDROCHLORIDE; BETAPACE				NCE	OCT 30, 1997
>ADD>	19865 003	SOTALOL HYDROCHLORIDE; BETAPACE				NCE	OCT 30, 1997
	20063 001	TECHNETIUM TC-99M RED BLOOD CELL KIT; RBC-SCAN				NP	JUN 11, 1995
>ADD>	19785 001	TECHNETIUM TC-99M SESTAMIBI KIT; CARDIOLITE				I-80	SEP 09, 1995
	20043 003	TEMAFLOXACIN HYDROCHLORIDE; OMNIFLOX	4730000	MAR 08, 2005	U-36	NCE	JAN 30, 1997
	20043 004	TEMAFLOXACIN HYDROCHLORIDE; OMNIFLOX	4730000	MAR 08, 2005	U-36	NCE	JAN 30, 1997
	20119 001	TENIPOSIDE; VUMON				NCE	JUL 14, 1997
						ODE	JUL 14, 1999
	19614 003	VERAPAMIL HYDROCHLORIDE; VERELAN	4863742	SEP 05, 2006	U-3	NDF	MAY 29, 1993
	20199 001	ZALCITABINE; HIVID	5028595	JUL 02, 2008	U-65	NCE	JUN 19, 1997
			4879277	NOV 07, 2006	U-65	ODE	JUN 19, 1999
	20199 002	ZALCITABINE; HIVID	5028595	JUL 02, 2008	U-65	NCE	JUN 19, 1997
			4879277	NOV 07, 2006	U-65	ODE	JUN 19, 1999
	19655 001	ZIDOVUDINE; RETROVIR	4837208	FEB 09, 2005			
			4833130	FEB 09, 2005		I-47	MAY 02, 1993
			4828838	FEB 09, 2005		ODE	MAR 19, 1994
			4724232	FEB 09, 2005		NCE	MAR 19, 1992
	19910 001	ZIDOVUDINE; RETROVIR	4837208	FEB 09, 2005			
			4833130	FEB 09, 2005		ODE	MAR 19, 1994
			4818538	FEB 09, 2005		I-47	MAY 02, 1993
			4724232	FEB 09, 2005		NCE	MAR 19, 1992
	19951 001	ZIDOVUDINE; RETROVIR	4837208	FEB 09, 2005			
			4833130	FEB 09, 2005		NCE	MAR 19, 1992
			4818538	FEB 09, 2005			
			4724232	FEB 09, 2005		ODE	MAR 19, 1994

*U.S. Government Printing Office: 1992 — 342-345/60004

New 13th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

13TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 7023

Charge your order. It's easy! MasterCard VISA

☐ **Yes,** please send me the following indicated subscriptions:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $55.00 per year.

1. The total cost of my order is $_____. All prices include regular domestic postage and handling and are subject to change. International customers please add 25%.

Please Type or Print

2. _____
(Company or personal name)

_____
(Additional address/attention line)

_____
(Street address)

_____
(City, State, ZIP Code)

(_____) _____
(Daytime phone including area code)

3. **Please choose method of payment.**

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐☐ – ☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Credit card expiration date)

Thank you for your order!

_____
(Signature) (10/91)

4. **Mail To:** Superintendent of Documents, Government Printing Office, Washington, DC 20402-9371.
To **FAX** your charge order, call (202) 512-0019.
To charge your subscription call (202) 783-3238.